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QUILL ON SCALPEL
This section provides a medium through which Canadian
surgeons can declare themselves, briefly and informally, on
the day-to-day affairs of surgery.

Defunctioning Colostomy: an Outmoded Operation?
For many years primary resection
with anastomosis has been the treat
ment of choice for lesions causing
total obstruction of the right colon. It
has the attraction of removing the
lesion, anastomosing to collapsed,
albeit unprepared, colon using small
intestine that can be decompressed by
milking the liquid contents back or in
to the portion of bowel to be resected.
In marked contrast, surgeons have
been much less inclined to resect such
lesions in the left colon and to per
form primary anastomosis.
We were all influenced by the low
mortality (8%)‘ reported as early as
the 1940s when right transverse colos
tomy was performed for obstructing
left colonic lesions; previously, when
cecostomy had been used, the death
rate for large-bowel obstruction was
50%.2 After a totally diverting colosto
my and before definitive resection it
is possible to cleanse the colon com
pletely so that a wider resection can

be performed if carcinoma is the
cause of obstruction.
In our teaching, we have always
emphasized the hazardous nature of
large-bowel obstruction, which can be
a “closed loop” type with urgent need
for decompression. Modern textbooks
suggest right transverse colostomy3 as
the initial treatment for obstructing
lesions of the left colon, but if resec
tion is preferred primary anastomosis
is not recommended.4-5 A one-stage
procedure with primary anastomosis
has been proposed but with total ab
dominal colectomy and ileorectal
anastomosis in order to avoid using
distended colon in the anastomosis.5-7
A randomized prospective trial
comparing resection and immediate
anastomosis with traditional manage
ment in two or three stages has not
been done for obstructing lesions of
the left colon.
In this issue of the Journal (pages
167 and 168), Goodall and Park, in

The Canadian Journal of Surgery
1867 Alta Vista Dr.
Ottawa, Ont. K1G 3Y6
Tel.: (613)731-9331

a remarkable report on 40 patients
with totally obstructing left colonic
lesions, advise immediate resection
with colocolostomy. During the peri
od of the study, 1981 to 1986, 20
other patients with total obstruction
were treated at their hospital, by ei
ther the Hartmann procedure or anas
tomosis with protective colostomy. Of
the study group of 40 patients, 30 had
carcinoma, 9 diverticulitis and 1 vol
vulus as the cause for the obstruction.
In three patients perforations had oc
curred and in two an intraperitoneal
abscess existed at the time of surgery.
Two patients died — one, aged 84
years, of myocardial infarction, the
other, aged 89 years, of pneumonia —
a death rate of 5%. Morbidity was
acceptable and could probably have
been diminished even further, as the
authors state, by using delayed prima
ry wound closure.
This is not a randomized trial and
the authors do not tell us the fate of
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the 20 patients with left colonic ob
struction treated differently during
this same period. The results could
not have been much better. It is
gratifying to see these impressive re
sults, especially in the elderly who can
be overwhelmed by the necessities of
care of a colostomy.
In patients with cancer as the cause
of obstruction some might prefer a
two- or three-stage operation in order
to obtain a wider resection and possi
bly a better long-term survival. How
ever, obstructing cancers are usually
more advanced lesions. A prospective
trial supporting the concept that a
wider resection on prepared bowel
increases survival rate in this setting
has also not been done. One retro
spective study of primary versus
staged resection for obstructing left
colonic cancers reported 5-year sur
vival rates of 63% and 33% respective
ly.8 These differences are significant
but may indicate that the more favou
rable lesions with a better prognosis
were treated by primary resection.
In the report by Goodall and Park
the colonic anastomosis is protected
by aspirating the contents of the colon
at surgery and packing the proximal
opening with Gelfoam to prevent
fecal material from coming into con
tact with the anastomosis during the
initial phases of healing. In another
study,9 an intracolonic device, Coloshield (Deknatel, Lake Success, NY)
has been used for the same purpose in
28 patients with diverticulitis and

perforation who underwent one-stage
colectomy and colocolostomy. Of
these 28 patients, 18 had paracolic
abscesses and 10 generalized peritoni
tis at the time of surgery. There were
no anastomotic leaks and no deaths.
Should a transverse colostomy be
used to protect a left-sided anastomo
sis? There may be some argument for
this if the resection is elective, bowel
preparation was possible and the
anastomosis is technically difficult. It
is not rational to do a protective
colostomy after emergency resection
and anastomosis when the large bowel
proximal to the anastomosis and dis
tal to the colostomy is heavily con
taminated and likely to cause major
peritonitis if there is a disruption of
the anastomosis. Local drainage and
colostomy for perforated diverticulitis
are known to be associated with a
high death rate (10% to 48%).10-n
We must conclude that defunction
ing colostomy without resection is
now rarely indicated even in totally
obstructing and perforated left colonic
lesions.
L lo y d D. M a c L ean , m d , frcsc
Coeditor,
Canadian Journal of Surgery
Surgeon-in-Chief,
Royal Victoria Hospital,
687 Pine Ave. W,
Montreal, PQ
H3A 1A1
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Colonoscopy After Resection for Bowel Cancer — Is It
Already Too Late to Answer the Questions?
At the time of primary resection of a
colorectal carcinoma, the entire colon
should be examined carefully, even in
areas remote from the primary tu
mour, and all coexisting polyps and
synchronous cancers should be re
moved. At follow-up, the colon should
be routinely examined to treat meta
chronous cancers at an early stage and
to remove all polyps when they are
small, before cancer develops. This
should benefit the patient by reducing
140

the occurrence of second cancers and
the overall death rate. There are a
large number of “shoulds” in the
foregoing statements and the paper in
this issue of the Journal by Vasilevsky
and Gordon, entitled “Colonoscopy
in the follow-up of patients with colo
rectal carcinoma” (pages 188 to 190),
helps us to examine at least one of
these critically.
There appears to be increasing ac
ceptance by general surgeons of the

case management method described
above. It is an attractive concept that
the entire colon can be completely
“cleaned” of benign and malignant
masses at the time of primary resec
tion of a carcinoma and subsequently
kept “clean” by repeated colonos
copy, with obvious patient benefit.
There is no question that the more
often and the more rigorously the
colon is examined, the more lesions
will be discovered and diagnosed than
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would otherwise be possible, or that
the majority of these small lesions can
be removed endoscopically. The un
answered questions concern which
regimen of surveillance should be fol
lowed, which methods of colonic ex
amination should be used and to what
extent these programs benefit the pa
tients. As in so many areas of modern
medicine, the acceptance of regular
follow-up protocols has occurred far
ahead of the evidence for their bene
fits. Even when the answers to these
questions are clear, we still must an
swer the last (and most difficult) ques
tion in coming to a management deci
sion — that is, do the benefits out
weigh the costs?
Our understanding of the natural
history of colorectal polyps and their
relationship to carcinoma is at present
inadequate to permit a definite rec
ommendation on the desirable fre
quency of follow-up after primary re
section of colorectal cancer. The con
tribution by Vasilevsky and Gordon
does help us to assess the relative
benefits of colonoscopy as opposed to
radiology. All of their patients had
normal barium enema findings and
the subsequent findings at colonos
copy would, presumably, have been
missed until at least the time of the
next follow-up examination. In sum
mary, they found 2 anastomostic re
currences, 2 metachronous cancers
and 22 neoplastic polyps (of which 10
were greater than 1 cm in size) in
their 100 patients. The study design is
open to the criticism that only single
contrast barium enema examination
was performed, and their statement
that this is the examination most
commonly performed (rather than
double-contrast barium enema) is no
longer true for most major centres.
A pros and cons list may be drawn
up for colonoscopy versus barium
enema examination in postoperative
surveillance of the colorectum. Nei
ther method is an enjoyable experi
ence for the patient, but the compli
ance with suggested follow-up pro
grams is high. Complete colonoscopy,
a procedure described as “difficult” in
25% of cases by highly experienced
colonoscopists,1 was achieved in 94%
of the patients in the current series.
Barium enema study achieves about
the same level of completeness over
all.2 Colonoscopy and double-contrast
barium enema have about the same
rate of false-negative results (about
10%), but colonoscopy has no false
positive results.3 Colonoscopy can cer
tainly detect lesions smaller than can
be seen on double-contrast barium
enema examination, but, as the au
thors discuss in detail, the clinical

importance of small polyps is a major
question. Perforation is rare and
bleeding uncommon after colonos
copy and even more so after barium
enema. A major advantage of colonos
copy is its operative capability. If one
must choose between the two tech
niques, colonoscopy seems to have
the edge. Why not use colonoscopy
and double-contrast barium enema to
gether? This would raise the sensitiv
ity to near 100%.4 This question can
only be answered in relation to the
overall benefit-cost equation, which
is the key issue.
Cost-benefit analysis of an inter
vention is always difficult, because
different people will always take the
same data and come to totally differ
ent conclusions based on different
values. There is no doubt that too few
cancers are found on follow-up by
colonoscopy to justify the costs and
hazards of the intervention, but what
about the polyps? A rate of 25 polyps
in 100 patients would seem adequate
to justify the procedure, but this is
where we have the final missing link
in the chain. The evidence that colo
rectal polyps are associated with colo
rectal cancer is strong,5 but more evi
dence is desperately required on the
actual clinical benefit that may be
expected by removing them prophylactically. Unfortunately, the answer
to this question has been pre-empted
by many surgeons and gastroenterolo
gists who have adopted protocols that
have been advocated prematurely.
Not only is this question suitable for a
randomized prospective trial, but the
large number of patients that could be
collected in a comparative study in a
relatively short time would ensure a
valuable answer. There is an ideal
opportunity here for a collaborative
research protocol to be organized by a
Canadian general surgical organiza
tion such as the Canadian Association
of General Surgeons or the Canadian
Association of Clinical Surgeons. The
question is circumscribed, important
and answerable. The protocol would
require randomization of patients
after primary resection into two
groups, one managed on the basis of
subsequent signs and symptoms and
the other managed by regular colonos
copy in addition. Unfortunately, it
may already be too late for surgeons
and gastroenterologists to comply
with such a study because of en
trenched clinical behaviour. Compli
ance can be expected only if we ac
knowledge that we do not know the
answer to the question.
Large fees are generated by endos
copy and there is a medical-political
minefield here in terms of appropriate

VOLUME 31, NO. 3 M A Y 1988 / THE C AN AD IA N JO U R N A L OF SURGERY

and possible contraction of indica
tions for the procedures. Health econ
omists and government agencies
should recognize the need for research
funding on issues like this, and physi
cians should recognize the need for
adequate evaluation of protocols be
fore mass implementation — there we
have another couple of “shoulds” to
add to the list. Without proper evalu
ation we cannot even begin to address
the benefit versus cost issue; we don’t
even know whether we are causing net
harm to our patients regardless of the
dollars and resources aspects of cost.
We desperately need to know the
answer to these questions: does annu
al colonoscopic follow-up of patients
after primary resection of colorectal
cancer reduce mortality; if so, by how
much? It simply will not do to claim
that the answer is obvious because
polyps can be detected and removed
at colonoscopy. Any suggested proto
col for unpleasant, costly and poten
tially dangerous intervention such as
colonoscopy requires validation. We
often lament the progressive reduc
tion in bench surgical research, but
here is an example of the prime im
portance of evaluative research for
which the majority of surgeons are
most suited. To acknowledge igno
rance, however, is a prerequisite to
seeking the required knowledge. Let
us not dig the trenches around clinical
behaviour so deep that it becomes
completely impossible to evaluate it.
Let us not pretend that the answers to
the questions are so obvious that even
asking them is inappropriate.
C harles J. W r ig h t ,

mb , ch b . m sc ,

FRCSC, FRCS, FRCS(EDIN)
Member,
Editorial Board,
Canadian Journal o f Surgery
Department o f Surgery,
University H ospital,
University o f Saskatchewan,
Saskatoon, S ask.
S7N 0X0
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SURGEONS’ UPDATE
What's new in surgery is the subject of this column. The short items are designed to let readers know
who's doing what and why. Surgeons are interested in what other surgeons are doing in
research, education, practice and administration. Surgery is a vibrant specialty, and, as
its practitioners, you must be the source as well as the readers of this column.

Royal College Statement on Informed Consent
Complying with legal requirements
for obtaining a patient’s consent be
fore medical treatment does not en
sure that acceptable ethical standards
have been met, advises the Biomedi
cal Ethics Committee of the Royal
College of Physicians and Surgeons of
Canada, since “higher standards of
informed consent than those required
by law may be appropriate”. In a
recently released statement by the
Royal College, the principles of in
formed consent are discussed, guide
lines for procedures for obtaining a
patient’s consent provided and a set
of maxims outlined.
Because in our society so much
value is placed on the rights of the
individual, to entrust the physician
with absolute authority would not be
acceptable. Therefore, patients have

the right to make decisions concern
ing their medical care after receiving
sufficient information from their phy
sician. This, of course, applies only to
patients who are able to take the
responsibility and who wish to do so.
The Committee recommends proce
dures to follow in other instances: a
competent patient cannot make a de
cision or leaves it to the physician to
make a decision; a patient is incompe
tent (e.g., an infant, unconscious or
severely retarded); a patient is in
competent and it is an emergency
situation; a patient’s competence is
uncertain.
Copies of the statement are avail
able from the Communications Sec
tion of the Royal College of Physi
cians and Surgeons of Canada in Ot
tawa.

Task Force Formed to Analyse
Use of Health Care Services in
Ontario

One of the task force’s goals is to
identify the factors that influence
both how the health care system is
used and how demand on resources is
created, such as increasing requests
for services from patients, physician
behaviour, or the use of more sophis
ticated diagnostic and treatment
methods.
When these influencing factors
have been identified and documented,
the second goal of the task force can
be achieved — to formulate a series of
recommendations that will reinforce
“sound practices” and “modify any
behaviour that has resulted in inap
propriate use of the health care sys
tem in Ontario”.
The task force intends to achieve
its goals by the following means:
• Gathering and analysing data
provided by the Ministry, the OMA
and other sources, including research
literature.
• Using this information to identi
fy the factors that influence the use of

Ontario Health Minister Elinor Caplan and Ontario Medical Association
(OMA) President Hugh Scully an
nounced recently that the Ministry of
Health and the OMA have formed a
task force to study the use of medical
services in the province.
The task force has been formed to
look for answers to a worrying prob
lem — the rising cost of health care in
Ontario. Said Health Minister Caplan, “I have been concerned about
the demands on our health care sys
tem and the use of medical services
since I took over this portfolio.”

Contributions to this column are welcome.
Please send your material to: Miss Laurel
Williamson, Canadian Journal o f Surgery,
PO Box 8650, Ottawa, Ont. K1G 0G8.
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health resources, such as: physician
services in offices, hospitals and other
settings, technology, changing demo
graphics, legislation and the political
process, changing malpractice climate
and growing public education and
awareness.
• Initiating studies to determine
what resources and structures are
necessary to provide optimal health
care.
• Developing short- and long-term
plans designed to achieve efficient use
of medical services without compro
mising their quality.
The chairman of the nine-member
task force is former Deputy Minister
of Health Graham Scott. Quarterly
reports will be submitted to the Min
istry of Health and to the OMA, and
there will be an annual review of the
task force’s progress by the two bo
dies.

Princess Margaret Hospital’s
New Radiotherapy Unit
Approved

Toronto’s Princess Margaret Hospi
tal, the largest cancer treatment, re
search and teaching centre in Canada,
has received approval from Ontario’s
Ministry of Health to proceed with
plans for a new radiotherapy unit to
be housed in the basement of Mount
Sinai Hospital. Construction of the
unit will begin in April 1989 and is
the first step in the reconstruction of
the Princess Margaret Hospital, which
by 1995 should be situated at its new
location adjacent to Mount Sinai Hos
pital on University Avenue. There
will be 16 radiotherapy machines op
erating at the new hospital, including
the 4 in the Mount Sinai unit. The
Princess Margaret Hospital currently
operates nine radiotherapy machines.
Laurel Williamson
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HOW I DO IT
A section on surgical technique, supervised by Dr. N.M. Sheiner

P h il ip H. G ordon , md, frcsc , facs

Ivalon Sponge Wrap Operation
Numerous operations have been de
scribed for the many distressing
symptoms of rectal procidentia. In the
good-risk patient, the Ivalon (supplied
by Downs Surgical Canada Ltd.,
Cooksville, Ont.) wrap operation de
scribed by Wells' has been effective.
There are several variations of this
operation2-6 and the technique I have
found satisfactory is as follows.
Technique
With the patient in the supine posi
tion the bladder is catheterized and
the skin prepared with a suitable anti
septic. The abdomen is entered
through an infraumbilical transverse
incision. The table is tilted to the
Trendelenburg position to facilitate
packing the abdominal viscera into
the upper abdomen. Taking care to
protect the ureters, the surgeon incises
the peritoneum on each side of the
rectosigmoid, beginning about 5 cm
above the pelvic brim (Fig. 1). The
presacral space is entered at the level
of the sacral promontory and the
rectum is gently and fully mobilized
from the sacral hollow to the level of
the coccyx (Fig. 2), avoiding the pre
sacral nerves (Fig. 3). To permit ante
rior mobilization, the lateral peritone
al incisions are extended distally to
join each other in the deepest portion
of the cul-du-sac (Fig. 4). With the
rectum grasped in the left hand, a
plane of dissection is achieved with
the fingers of the right hand. Dissec
tion in this plane need not be exten-

sive as a deep cul-de-sac is a charac
teristic of most cases of complete
rectal procidentia, and the seminal
vesicles or vaginal vault is easily
reached. The lateral stalks, or at least
their upper portion on each side, are
divided between clamps and ligated
with an absorbable suture. If the rec
tum is not fully mobilized, redundant
rectum below the point of fixation
may cause the prolapse to recur.
Throughout the procedure, meticu
lous hemostasis is essential since he
matoma formation may predispose to
infection of the sponge.
A rectangular sheet of previously
sterilized Ivalon is then moistened in
normal saline to make it pliable.
Three sutures of a material such as
2-0 Prolene or 2-0 Vicryl on a non
cutting needle are then passed
through the Ivalon sponge, the presa
cral fascia and then back through the
Ivalon sponge (Fig. 5). The distal
suture should be placed as low as
possible, deep in the pelvis. The
sponge is then “railroaded” into the
pelvis and the sutures are tied (Fig. 6).
The mobilized rectum is drawn up
ward and placed in front of the Ivalon

From the Department o f Surgery, Sir Mor
timer B. Davis-Jewish General Hospital,
Montreal, PQ

sheet, the lateral ends of which are
folded to encompass approximately
three-quarters of the circumference of
the rectum. The residual gap is essen
tial to prevent constriction of the
lumen. Excess Ivalon is excised and a
series of three 3-0 Prolene or 3-0

Fig. 2a

Fig. 2b

Accepted for publication May 4, 1987
Reprint requests to: Dr. P.H. Gordon,
Department o f Surgery, Sir Mortimer B.
Davis-Jewish General Hospital, 3755 Cote
Ste-Catherine, Montreal, PQ H 3T1E2

FIG. 1 — Peritoneum incised on both
sides of rectosigmoid, beginning 5 cm above
pelvic brim.
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FIG. 2 — (a) Mobilization of rectum
accomplished by gentle manual dissection,
avoiding presacral plexus of veins, (b) Sa
gittal view. Dissection carried down toward
tip of coccyx, preserving mesorectum.
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Vicryl sutures is used on each side to
fasten the lateral limbs of the sponge
to the anterior aspect of the rectum
(Fig. 7).
The sponge is extraperitonealized
by closing the pelvic peritoneum with
continuous 3-0 chromic catgut (Fig.
8). No drains are used. Postoperatively, fluids are given intravenously until
ileus has resolved. Nasogastric suction
is usually not necessary. The Foley
catheter is removed on day 2. It is
essential to ensure that the patient
does not strain at defecation, so as
soon as oral feeding is tolerated, a
bulking agent in the form of a psylli
um seed preparation is given, supple
mented by Milk of Magnesia as neces
sary.

FIG. 3 — Lateral incisions joined in
anterior cul-de-sac. Presacral neural plexus
should be left intact.
FIG. 6 — Three polypropylene sutures
hold Ivalon immobile against presacral fas
cia.

All figures are reproduced by permission
from N yhus LM, Baker RJ: Mastery of
Surgery, Little, Boston 1984: 1045-1050.
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FIG. 4 — Blunt or sharp dissection frees
anterior rectal wall. Peritoneum of anterior
cul-de-sac is retracted superiorly.
FIG. 7 — Ivalon sheet applied to posteri
or three-quarters of circumference of rectum
and sutured in place with 3-0 polypropylene
sutures on each side.

FIG. 5 — Sheet of Ivalon sponge sewn to
presacral fascia with interrupted 2-0 poly
propylene suture material on round needle.
Rectum is retracted forward away from
sacrum.
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FIG. 8 — Operation completed by closing
pelvic peritoneum.
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Cyclosporin A Metabolites Suppress T-Cell Proliferation by
Concanavalin A and in a Mixed Lymphocyte Reaction
To ascertain if cyclosporine metabo
lites (CMs) have immunosuppressive
activity, bile, whole blood and urine
taken from patients after cholecystec
tomy and from a liver transplant recipi
ent on cyclosporin A (CsA) were as
sayed to determine their effect on Tcell proliferation induced by con
canavalin A (Con A) and in a two-way
mixed-lymphocyte response. Bile and
whole blood from the liver transplant
patient completely suppressed Con A
proliferation and the mixed lymphocyte
response (MLR) at dilutions at which
normal bile and whole blood have no
suppressive activity, but no such activ
ity was noted from the urine. The CMs
were separated into six peaks (frac
tions) by high-pressure liquid chroma
tography (HPLC). Metabolites were
identified by internal standards and
HPLC/mass spectrophometric analy
sis. Cyclosporine metabolite fractions
2 and 3 from bile and blood had im
munosuppressive activity similar to
parent CsA whereas fractions 5 and 6
demonstrated less but substantial im
munosuppressive activity. Fractions 2,
3 and 5 demonstrated an ability to

t
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inhibit two-way MLR similar to parent
CsA; the other metabolite fractions
were able to inhibit the MLR but to a
lesser extent.
These results demonstrate that a
number of CMs have immunosuppres
sive effects similar to those of the
parent compound, and this may ac
count for the lack of correlation be
tween whole blood CsA levels and
immunosuppressive activity.

metaboliques etaient capables d'inhiber la reponse des lymphocytes en cul
ture mixte mais a un degre moindre.
Ces resultats demontrent que cer
tains des metabolites de la cyclospor
ine possedent des effets immunosuppresseurs semblables a ceux du pro
duit pere et ceci peut expliquer le peu
de correlation observe entre les taux
de cyclosporine A dans le sang entier
et I'activite immunosuppressive.

Afin d'etablir si les metabolites de la
cyclosporine possedent une activite
immunosuppressive, la bile, le sang
entier et I'urine de patients qui eurent
a subir une cholecystectomie et ceux
d'un greffe du foie traite a la cyclospo
rine A ont ete doses d'apres leurs
effets sur la proliferation des lympho
cytes T provoquee par la conacavaline
A et sur la reponse bi-directionnelle de
lymphocytes en culture mixte. La bile
et le sang entier du greffe du foie ont
completement supprime la prolifera
tion provoquee par la conacavaline A
et la reponse des lymphocytes en cul
ture mixte a des dilutions auxquelles la
bile et le sang entier normaux n'exercent aucune activite immunosuppres
sive; toutefois, aucune activite n'a ete
decelee dans I'urine. Les metabolites
de la cyclosporine ont ete separes d'a
pres six pics d'elution (fractions) par
chromatographie liquide a haute per
formance (HPLC). Les metabolites ont
ete identifies a I'aide de standards
internes et par HPLC/spectrophotometrie de masse. Les fractions 2 et 3 de
la bile et du sang possedaient une
activite immunosuppressive semblable
a celle du produit pere, alors que les
fractions 5 et 6 demontraient une acti
vite moindre mais quand meme importante. Les fractions 2, 3 et 5 montraient une activite semblable a celle
de la cyclosporine A contre la reponse
bi-directionelle des lymphocytes en
culture mixte. Les autres fractions

Cyclosporin A (CsA) is a biologically
active product of the fungus Trichoderma polysporum.' It is a chemi
cally neutral, extremely hydrophobic,
cyclic polypeptide composed of 11
amino acids.2 Previous studies using
tritiated CsA demonstrated that the
molecule is rapidly and extensively
metabolized mainly through the mono
oxygenase cytochrome P450 system
in man and that the liver is the major
site of its elimination.3-4 Over 50% of
an intravenously administered dose of
CsA is excreted in bile, predominant
ly in metabolite form, and less than
0.1% is excreted as parent CsA.5 In
contrast, less than 6% of the adminis
tered dose excreted in the urine con
tains more than 99% cyclosporine me
tabolites (CMs).5 Recent studies have
shown that biogradation of CsA pro
duces a relatively small number of
metabolites, some of which have been
isolated from blood, bile and urine
from both experimental animals and
humans.5-8 Most are lipophilic, as in
dicated by their occurrence in the
ether phase of liquid extraction, al
though polar metabolites have been
described. The cyclic endecapeptide
structure of CsA is preserved in all
identified metabolites.3-5
Cyclosporin A is unique in that it is
not cytotoxic and is selective in its
immunosuppressive effects, having
particular influence on T-cell func-
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tion.9-12 Although the precise mecha
nism of action is controversial, it has
been suggested13-14 that the major im
munosuppressive property of CsA
stems from inhibitory effects on interleukin-2 (IL-2) receptor expression on
activated T cells. Others15-16 have de
scribed an inhibitory effect on DNA
synthesis due to selective blockage of
IL-2 production, rather than IL-2 re
ceptor generation. The immunosup
pressive effects of CsA on immune
cells in vitro can be measured by the
inhibition of T-lymphocyte prolifera
tive responses induced by mitogens
(e.g., concanavalin A [Con A], phy
tohemagglutinin [PHA]) and in a
mixed lymphocyte response (MLR).
Little is known about the effects of
CMs on immune responses. Maurer3
found that CMs had low immunosup
pressive effects when compared with
CsA. However, Fidelus and Fergu
son17 suggested that a second im
munosuppressive agent, other than
parent CsA, exists in plasma. More
recently Freed and colleagues18 have
reported that some purified CMs and
CMs isolated from the blood of renal
transplant patients have immunosup
pressive properties. Because of these
conflicting reports we undertook
studies to identify CMs in bile, blood
and urine from an orthotopic liver
transplant patient, to determine their
effects on Con A-induced prolifera
tion and on a MLR and to compare
their immunosuppressive activity
with that of the parent compound
(CsA).
Methods

Patients
Blood and urine were collected
from six, normal, healthy, control
patients after cholecystectomy and
from a patient who underwent or
thotopic liver transplantation for he
patocellular carcinoma. Bile was col
lected daily from the liver transplant
patient and those who had undergone
cholecystectomy. The former was oth
erwise healthy and receiving CsA in
travenously (7.5 mg/kg daily) and methylprednisolone (10 to 20 mg/d) to
control rejection. All samples were
collected daily and stored at -70°C
until assayed.
Cells
Peripheral blood mononuclear cells
(PBM) were collected from the venous
blood of healthy control subjects,
aseptically drawn into 50 ml conical
tubes containing 1.5 ml of 0.5 M
citrate buffer at pH 5.0. The blood
146

was centrifuged at 2200 g for 20
minutes and the plasma removed.
The cells were then diluted 4:1 with
RPMI 1640 medium (Flow Laborato
ries, Mississauga, Ont.) and centri
fuged over Ficoll Hypaque gradients
(1.074 g/L) at 2200 g for 12 minutes
at 22°C, as previously described.19
Mononuclear cells were removed at
the interface (less than 1% polymor
phonuclear cells), washed three times
with RPMI 1640 and resuspended at
a concentration of 2 X 106 PBM/ml in
RPMI 1640 which had been supple
mented with 10% fetal calf serum
(Flow Laboratories) and 4 mM gluta
mine (Gibco Scientific, Burlington,
Ont.).
Isolation of Cyclosporin A and
Cyclosporine Metabolites
One part bile (10 ml), blood (10 ml)
or urine (50 ml) was extracted with
two parts diethyl ether (Fisher Scien
tific Co., Toronto, Ont.) three times.
The ether extracts were combined and
evaporated to dryness under vacuum
at 45 °C. The residue was reconstitut
ed in 400 m1 of the solvent system,
acetonitrile:methanol:water (50:20:20)
and chromatographed by high-pres
sure liquid chromatography (HPLC).
Two methods of HPLC separation
were used. In the first, a 15-cm uBondapak/C18 column and model M-45
pump (Waters Associates, Milford,
Mass.) were used to separate CsA
from its metabolites. Of the reconsti
tuted residue 400 /A was subjected to
chromatography on the C l8 column
at 50°C with a flow rate of 1.5
ml/min. Cyclosporine metabolites and
CsA were collected in the first and
second 10 ml respectively. The pres
ence of metabolites and CsA was de
termined by radioimmunoassay20 and
the samples were dried under vacuum
at 45°C. In the second method, two
Beckman “ultrasphere-ocytl” 5-/tm re
versed phase columns (4.6 mm X 250
mm) were connected in tandem to
further separate CMs. Again 400 #tl of
the reconstituted residue was injected
and run at a flow rate of 1.0 ml/min
at 70°C, and 0.5-ml fractions were
collected. The presence of CMs was
determined again by radioimmunoas
say, and six fractions were pooled and
evaporated to dryness. In the Con A
proliferation assay, separate fractions
were redissolved in RPMI 1640 con
taining 0.1% Tween 20 (Sigma Chem
ical Co., St. Louis, Mo.).
Concentrations of fractions con
taining known CMs were calculated
by utilizing data on the cross-reactivi
ty of the different metabolites in the
Sandoz cyclosporine radioimmunoas

say as documented in the product
monograph (Table I).
Mitogenic Response to
Concanavalin A
The proliferative response of PBM
was assessed by culturing 4 X 105cells
with 5 ug/ml of Con A (Sigma Chemi
cal Co.) for 72 hours in 96 well
microtitre plates (Falcon 3040, Micro
test II, Becton-Dickinson, Lincoln
Park, NJ) at 37°C in a 5% carbon
dioxide atmosphere in 200 jitl of
RPMI 1640 supplemented with 10%
fetal calf serum and 4 mM glutamine.
Cells were cultured alone or with
increasing concentrations of CM or
CsA. One uCi of 3H-methyl thymidine
(3HTdR) (25 Ci/mmol) (Amersham
Corp., Toronto, Ont.) was added for
the final 18 hours of culture. Cells
were harvested onto fibreglass filters
with a minimash II cell harvester
(Microbiological Associates, Bethesda, Md). The uptake of 3HTdR was
quantitated by placing the filters in 5
ml of scintillation fluid consisting of
10 ml of Omnifluor (New England
Nuclear, Boston, Mass.) per 3.785 L
toluene (Aquasol II, New England
Nuclear) and by counting in a Beck
man scintillation counter (Beckman
Instruments Inc., Schiller Park, 111.).
The mean counts of stimulated cul
tures were corrected for uptake of
control unstimulated cultures.
Data Analysis
Data were statistically analysed
using the Student’s /-test, and a p
value of less than 0.05 was considered
significant.
Results

Isolation and Fractionation of
Cyclosporine Metabolites and
Cyclosporin A
Cyclosporines, identified by radiTable I— Relationship of Cyclosporin A (CsA)
and Cyclosporine Metabolites (CMs) in
Radioimmunoassay (RIA)

CsA/CM
CsA
CM1
CM8
CM9
CM10
CM 17
CM18

Concentrations True concentration
by RIA (/ug/ml)
(/xg/ml)
100
100
100
100
100
100
100

910
1000
1000
1000
1000
670
710

Cross-reactivity of CMs in the RIA to parent
CsA is described in the Sandimmune RIA kit
(Sandoz Pharmaceuticals, Dorval, PQ).
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oimmunoassay, were extracted from
blood, bile and urine of the liver
transplant patient and separated into
total CM and CsA fractions by HPLC
method 1. When the same fluids were
fractionated by method 2 and
analysed by radioimmunoassay, seven
peaks (fractions) of cyclosporines
were obtained, corresponding to the
six fractions of CMs and the parent
CsA (fraction 7) (Fig. 1).
Identification of CMs (7, 18 and
21) was accomplished by using inter
nal purified CM kindly provided by
G. Maurer, Sandoz, Basel, Switzer
land. Metabolites 1, 8, 9, 10 were
identified by HPLC/mass spectrometric analysis as previously described21
(Table II).
Utilizing the data from Table I,
true concentrations of parent CsA and
those fractions containing known
CMs were determined as shown in

Table II. Based on these data, the
concentration of total cyclosporines in
the bile of the liver transplant patient
was 27- and 128-fold greater than that
of blood and urine respectively. Con
centrations could not be established
for fractions 1 and 4, which did not
contain known CM.
Bile fractions 3 and 5 accounted for
80% of total cyclosporines, with CsA
accounting for less than 1% of the
total (Fig. 1A, Table II). Blood con
tained significantly (p = 0.007) lower
concentrations of CsA and CMs, but
in contrast to bile, parent CsA consti
tuted a substantially greater propor
tion of the total cyclosporines (3.5%).
Of the CMs in blood, 82% was local
ized to fractions 3 and 5, similar to
that seen in bile (Fig. IB, Table II).
Small amounts of CMs and CsA were
detected in urine; however, 90% of
the CMs were equally distributed in
fractions 2, 3 and 5, and parent CsA
was 1% of the total (Fig. 1C, Table II).
No cyclosporines, as measured by ra
dioimmunoassay, were detected in
bile, blood or urine extracted with
diethyl ether from control subjects.
Effect of Cyclosporine Metabolites and
Cyclosporin A on Concanavalin A
Proliferation
Marked stimulation of proliferative
activity in human PBM, as reflected
by 3HTdR uptake, in response to Con
A was noted. Maximum proliferation
(115 282 ± 12 840 cpm) was seen at 5
Mg/ml of Con A, as previously de
scribed.22 Bile, whole blood and urine
were assayed for their ability to inhib
it the Con A proliferative response.
Bile from controls significantly (p <
0.01) inhibited the Con A prolifera
tive response up to a 1:32 dilution
(Fig. 2A). In contrast, bile from the
liver transplant patient (to a 1:1024
dilution) completely suppressed the
Con A proliferative response, suggest
ing the presence of additional inhibi
tory compounds (Fig. 2A). Whole
blood from normal controls inhibited

Con A proliferation to a dilution of
1:64, whereas whole blood from the
liver transplant patient fully sup
pressed Con A proliferation to a dilu
tion of 1:1024 (Fig. 2B). In contrast,
no inhibitory activity was detected in
urine from either the controls or the
liver transplant patient (Fig. 2C).
Total CMs isolated from bile and
blood exhibited dose-dependent sup
pression of Con A proliferation. The
immunosuppressive activity of the
CM fraction was similar to that of the
parent CsA fraction in both fluids,
indicating that a substantial portion
of the immunosuppressive effect of
cyclosporine was related to CMs.
The six CM fractions obtained
from bile and blood by HPLC method
2 demonstrated dose-dependent inhi
bition of the Con A proliferative re
sponse (Figs. 3 and 4). However, dif
ferent CM fractions exhibited differ
ent degrees of suppressive activity.
Relative potency was expressed as the
concentration required for 50% inhi
bition of Con A-induced proliferation
(Table III). However, as fractions 1
and 4 did not contain known CMs,
their concentrations could not be es
tablished accurately; thus, relative po
tency could not be determined. By
this analysis fractions 2 (CMs 8 + 9)
and 3 (CM 10) from bile and blood
had similar potency to parent CsA. In
contrast, peaks 5 and 6 had substan
tially less (5- to 20-fold) immunosup
pressive activity (Table III). Fractions
1 and 4 had substantial immunosup
pressive activity; however, their con
centrations could not be established
because their structure is unknown.
Thus, relative potency could not be
determined.
Discussion

The fungal metabolite cyclosporin
A (CsA) is a powerful immunosup
pressant and is now the major drug
used to prevent rejection after organ
transplantation. There is evidence
that CsA is metabolized extensively

Table II— Cyclosporin A (CsA) and Cyclosporine Metabolites (CMs) in the Bile, Blood and Urine of
a Liver Transplant Patient

FIG. 1 — Isolation of cyclosporin A
(CsA) and cyclosporine metabolites (CMs)
from liver transplant patient. Cyclosporine
metabolites (fractions 1 to 6) and CsA
(fraction 7) were isolated from (A) 10 ml of
bile, (B) 20 ml of blood and (C) 50 ml of
urine and separated by high pressure liquid
chromatography (HPLC) method 2. Con
centrations of cyclosporines were deter
mined by radioimmunoassay and are ex
pressed as cyclosporine-relative equivalents
(ng/ml of HPLC effluent).

CsA/CM

Bile,

Total cyclosporines
Fractions
1 Unknownt
2 CMs 8, 9
3 CMs 9, 10
4 Unknownt
5 CMs 17, 1
6 CM 18
7 CsA

237 687

mq/L

—

33 520
93 600
—

97 695
1 2 2 12
660

Whole blood, Mg/L*

Urine, Mg/L

887

1860

—

86
200
—

528
43
31

—

570
700
—

500
70
20

‘ For comparison the blood level for CsA by radioimmunoassay was 880 Mg/L.
fA s these metabolites have not been identified, concentrations could not be assigned.
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by hydroxylation and N-demethylation,3-23 and the structure of the me
tabolites suggests the involvement of
the hepatic microsomal cytochrome
P-450-dependent mono-oxygenase
system.3-5-23 The liver appears to be
the major site of CsA metabolism as
well as the primary excretion site by
way of bile and thence fecal elimina
tion.8 Enterohepatic recirculation of
CsA has been suggested by the ap
pearance of two phases of CsA in
radioimmunoassay pharmacokinetic
profiles.17 It has been noted that upon
restoration of the integrity of the bili
ary system, CsA requirements are re
duced.24 This could be explained by
improved intestinal absorption of
CsA as well as reabsorption of CMs in

bile possessing immunologic activity.
Supportive of a role for CMs is a
recent report25 that bile contains pri
marily crossreactive metabolites with
low concentrations of parent CsA.
Several CMs have been identified
by chromatography. Two major oxi
dative metabolites, 17 and 18, have
been isolated from urine, bile and
blood, and both appear to express less
immunosuppressive activity than
CsA.3 Lensmeyer and Fields26 de

scribed the presence of a compound
in whole blood from a renal trans
plant patient on CsA which crossreacted in the Sandoz radioim
munoassay. It appeared to be local
ized to red blood cells, with very little
detected in plasma. Fidelus and Fer
guson17 also reported the presence in
the serum of renal allograft patients
who were on cyclosporine of a factor
that possessed potent immunosup
pressive activity. Freed and colLEG END
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FIG. 3 — Effect of CM and CsA extracted from bile of liver transplant patient on Con
A-induced proliferation. Cyclosporine metabolites (fractions 2, 3, 5 and 6) and CsA
(fraction 7) isolated from bile of liver transplant patient were assayed for their ability to
inhibit Con A-induced proliferation of PBM.
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FIG. 2 — Effects of bile, whole blood and
urine from normal control subject and liver
transplant patient on concanavalin A (Con
A)-induced proliferation of peripheral blood
mononuclear cells (PBM). Dilutions of (A)
bile, (B) w-hole blood and (C) urine from
normal control (crosses) and liver trans
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sayed for their ability to inhibit Con Ainduced proliferation of PBM.
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FIG. 4 — Effect of CsA and CM isolated from whole blood of liver transplant patient
on Con A-induced proliferation. Cyclosporine metabolites (fractions 2, 3, 5 and 6) and CsA
(fraction 7) were extracted from whole blood of liver transplant patient and assessed for
their ability to inhibit Con A-induced proliferation of PBM.
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leagues18 recently reported that puri
fied CMs 1, 17 and 21 have potent
immunosuppressive activity in vitro
and that CMs isolated from the blood
of a renal transplant patient also ex
hibited significant immunosuppres
sive activity.
Our present studies were undertak
en to document the presence by
HPLC and radioimmunoassay of
CMs in bile, blood and urine from a
patient who had undergone orthotop
ic liver transplantation and to deter
mine whether these metabolites pos
sessed immunosuppressive activity.
Bile and whole blood from the liver
transplant patient suppressed Con Ainduced proliferation in dilutions at
which normal bile and whole blood
had no such effects, suggesting the
presence of one or more inhibitory
factors. Diethyl ether-soluble factors
were isolated from bile, blood and
urine and analysed for the presence of
cyclosporines by radioimmunoassay.
Although they all contained cyclospo
rines, immunosuppressive activity
could be detected only in blood and
bile with bile having significantly (p <
0.008) more activity. High-pressure
liquid chromatography and radioim
munoassay of diethyl ether-soluble
material confirmed the presence of
CMs and CsA in all three body fluids,
with the highest concentrations in bile
as previously reported.8-25 Significant
(p = 0.002) immunosuppressive activ
ity was found in both fractions of
CMs and the parent CsA fraction.

This suggests that, in vivo, CMs exert
a marked immunosuppressive effect.
Separation of the metabolites by
HPLC method 2 yielded six CM frac
tions, two of which appeared to have
immunosuppressive activity, similar
to that of parent CsA. Two other
fractions, 1 and 4, were also potent
but cannot be assessed further until
their structure is known.
Freed and colleagues18 recently re
ported that CMs 1 and 17 had signifi
cant immunosuppressive activity, but
that CM 8 showed little activity in
both the Con A proliferation and
MLR assays. As CM fraction 2 in our
study showed significant immunosup
pressive activity and contained CMs 8
and 9, CM 9 would also appear to
inhibit both MLR and Con A prolifer
ation.
Our radioimmunoassay method of
assessing CMs does not allow for de
tection of those that are nonreactive
in the radioimmunoassay. The pres
ence of such metabolites will only be
confirmed using tracer techniques and
comparing these simultaneously to radioimmunoassasy-positive metabo
lites. Indeed Maurer and associates,5
using tracer techniques, identified 17
metabolites, all of which retained
their basic endecapeptide structure.
This suggests that each of the six CM
fractions we identified may indeed
contain many more distinct metabo
lites. It is apparent that CMs are
present in the blood of transplant
patients in much greater amounts

Table III— Relative Inhibition of Concanavalin A-Induced Proliferation by Cyclosporin A (CsA) and
Cyclosporine Metabolites (CMs)
Concentration of CMs for 50%
inhibition, ng/ml

Cyclosporine
fractions

Metabolite

1
2
3
4
5
6
7

Unknown*
8, 9
10
Unknown*
17, 1
18
CsA

Bile

Blood
—

—

100
300
—

2700
5000
270

250
100
—
1000
2000
160

•These metabolites have not been identified and thus concentrations cannot be assigned.
Table IV— Relative Inhibition of a Mixed Lymphocyte Response by Cyclosporin A (CsA) and
Cyclosporine Metabolites (CMs)
Concentration of CMs for 50%
Inhibition, ng/ml

Cyclosporine
fractions

Metabolite

1
2
3
4
5
6
7

Unknown*
8 ,9
10
Unknown*
17, 1
18
CsA

Bile
—

90
75
—

50
1000
50

Blood
—
180
70
—
50
500
30

•These metabolites have not been identified and thus concentrations cannot be assigned.
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than CsA, but this has not been ap
parent due to differences in reactivity
in the CsA radioimmunoassay.
We excluded methylprednisolone
as the immunosuppressive factor in
our transplant patient, both by failing
to detect it in diethyl ether-extracted
blood and bile, and by the fact that
immunosuppression of Con A prolif
eration could only be detected at
pharmacologic concentrations (1
Mg/ml).
The observation that urinary CMs
have no immunosuppressive activity,
while similar fractions from bile and
whole blood are strongly inhibitory, is
intriguing. Although the urinary CMs
are recovered from the HPLC column
in the same fractions as bile and
blood, they may not be identical in
chemical structure. Conjugation could
impair immunosuppressive activity,
and although conjugated metabolites
have not previously been detected,3-4
this does not exclude their presence in
this clinical setting. Finally, as previ
ously reported,3-8-25 only very small
amounts of CMs were recovered from
the urine of the transplant patient,
and in order to recover the CMs, large
volumes of urine (50 to 100 times the
volume of bile) needed to be extract
ed; this may result in recovery of
substances from the urine that could
interfere with the immunosuppressive
properties of the CMs.
Although in this study data from
only one allograft recipient are pre
sented, we have now isolated similar
CM fractions from the whole blood of
a renal allograft recipient that had
similar immunosuppressive activity,
but only when used at higher concen
trations (unpublished data). The vari
ability in immunosuppressive activity
may be related to differences in CsA
metabolism from patient to patient.
Furthermore, we have now demon
strated that three CM fractions isolat
ed from bile and two CM fractions
isolated from blood can inhibit a
mixed lymphocyte response similar to
that of parent CsA, adding strength to
the concept that CMs have potent
immunosuppressive properties (Table
IV). It is interesting that the im
munosuppressive activity of some
CMs differed in the two different
assays; however, this has been ob
served for other immunosuppressive
agents.
In summary, we report that bile
and blood from a liver transplant
patient contain CMs that have signifi
cant immunosuppressive activity, re
sults that may help to explain why
patients with similar blood levels of
CsA often exhibit different degrees of
immunosuppression. Furthermore, it
149

is conceivable that susceptibility to
nephrotoxicity may reflect different
patterns of CsA metabolism. Experi
ments are now under way to charac
terize these metabolites and deter
mine their effects in other in-vitro
and in-vivo immunologic assays.
These studies should improve our un
derstanding of the biologic behaviour
of CsA.
We thank Mr. Lai Sum Fung and Aniel
Menon for their technical assistance and
Charmaine Jaglal for typing.
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Prognostic Factors in Colorectal Carcinoma of Young
Adults
To determine why the prognosis for
colorectal cancer in young adults is
poor, survival and prognostic factors in
patients under 40 years of age were
compared with those in patients be
tween 40 and 50 years of age. In a
10-year period, 122 patients less than
50 years of age (88 between 4 0 and
50 years) presented at the Victoria
General Hospital in Halifax, NS, with
colorectal cancer. Their charts were
retrospectively reviewed. Follow-up
was obtained for all patients.
Of the 3 4 patients younger than 40
years, 71 % (24) were men compared
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with 38% (33) of older patients. Symp
toms, their duration and the location of
primary tumours were similar in the
tw o groups. Patients younger than 40
years presented with advanced lesions
(Dukes' stages C and D) in 67% of
cases compared with 52% of the older
group. Mucinous tumours were twice
as common in patients less than 40
years old (p = 0.036) and actuarial
survival rates were lower at all stages
for the same group.
The authors conclude that the poor
er prognosis in patients less than 40
years of age is not due to late symp
tom reporting or delay in diagnosis, but
to more aggressive disease.

Afin de determiner pourquoi le pronostic du carcinome recto-colique chez les
patients jeunes est mauvais, la survie
et les facteurs pronostiques des malades de moins de 40 ans ont ete com
pares a ceux de patients de 4 0 a 50
ans. Sur une periode de 10 ans, 122
patients de moins de 50 ans (dont 88
entre 40 et 50 ans) ont ete recus au

Victoria General Hospital de Halifax,
NE, souffrant de cancer recto-colique.
Les dossiers medicaux ont ete etudies
retrospectivement. Un suivi a pu etre
obtenu pourtous les patients.
Sur les 34 patients de moins de 40
ans, 71 % (24) etaient des hommes,
comparativement a 38% (33) pour les
patients plus ages. Les symptdmes et
leur duree, et la localisation des tumeurs primitives etaient les memes
dans les deux groupes. Les patients
ages de moins de 4 0 ans presentaient
des lesions avancees (stades C e t D a
la classification de Dukes) dans 67%
des cas, comparativement a 52% pour
les patients plus ages. Les tumeurs
mucineuses etaient deux fois plus
frequentes chez les patients de moins
de 40 ans (p = 0.0 3 6 ) et la survie
actuarielle etait plus faible a tous les
stades pour ce meme groupe.
Les auteurs concluent que le plus
sombre pronostic des patients de
moins de 4 0 ans n'est pas du a un
retard a signaler les symptomes ou a
un delai de diagnostic, mais piutot a
une maladie plus agressive.
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Colorectal carcinoma is most com
monly seen in older patients, the peak
incidence occurring in the seventh
decade of life.1 However, it has been
reported that in 8% of cases the pa
tient is younger than 40 years2 and in
1% younger than 30 years.3 There has
been a long-standing impression that
patients under 40 years old have a
poor prognosis.45 However, in recent
studies identical survival rates were
found for patients both under and
over 40 years of age,6-9 while others

W om en

M en

1

24

10

2

33

55

T o ta ls

57

65

Patients and Methods

We reviewed the charts of all pa
tients less than 40 years of age admit
ted to the Victoria General Hospital
in Halifax between Jan. 1, 1974 and
Dec. 31,1984 with colorectal carcino
ma.
The patients were divided into two

T a b le 1— S e x D is trib u tio n
G ro u p

confirmed a worse prognosis for the
younger group.10-13 We undertook a
retrospective study to determine if
patients less than 40 years of age have
a worse prognosis than those between
40 and 50 years, and also to compare
the two groups in terms of symptoms
and their duration, pathologic charac
teristics of the tumour and clinical
stage.

T a b le II - - P r e s e n t in g S y m p to m s a n d S ig n s *
G ro u p 1, n o. (%)

S y m p to m /s ig n

G ro u p 2 , no. (% )

A b d o m in a l pain

8 (2 4 )

R e cta l b le e ding

1 5 (4 4 )

3 6 (4 1 )

C h a n g e o f b o w e l h a b it

1 4 (4 1 )

3 4 (3 9)

O b s tru c tio n

5 (1 5 )

1 0 (1 1 )

A n e m ia

2

(6)

9 (1 0 )

W e ig h t loss

3

(9)

11 (1 3)

M a ss

1

(3)

7

M isce lla n e o u s

2

(6)

5

(6)

N one

2

(6)

4

(5)

3 5 (4 0)

(8)

Findings

• N o n e o f th e d iffe re n c e s w e re s ig n ific a n t.

T a b le III— D u ra tio n o f S y m p to m s *
D u ra tio n , m o

G ro u p 1, n o. ( % ) t

G ro u p 2 , no. (% ) $

1 0 (2 9 )

3 0 (34)

< 1

(6)

1 5 (1 7 )

11 (3 2 )

2 0 (23)

2

1 -3
4 -6

(6)

1 2 (1 4 )

7 -1 2

2

> 12

4 (1 2 )

4

(5)

U nknow n

3

3

(3)

(9)

* N o s ig n ific a n t d iffe re n c e s b e tw e e n th e g ro u p s .
| 2 w e re a s y m p to m a tic .
$ 4 w e re a s y m p to m a tic .

T a b le IV — L o c a tio n o f P rim a ry T u m o u r*
L o c a tio n

G ro u p 1, n o . (% )

C e cu m a n d a sc e n d in g c o lo n

5 (1 5 )

T ra n s v e rs e co lo n

1

D e s c e n d in g co lo n

4 (1 2 )

(3)

G ro u p 2 , no. (% )
1 5 (1 7 )
7

(8)

9 (1 0 )

S ig m o id

1 3 (3 8 )

3 3 (38)

R e ctu m

11 (3 2 )

2 9 (33)

U nknow n

1

(3)

0

(0)

* N o s ig n ific a n t d iffe re n c e s b e tw e e n th e g ro u p s .

T a b le V — D u k e s ' S ta g e *
S ta g e

groups: group 1, 34 patients who were
less than 40 years of age at the time of
diagnosis and group 2, 88 patients
aged 40 to 49 years. The two groups
were compared with respect to diag
nosis, duration of symptoms, present
ing symptoms, location of the primary
tumour, Dukes’ stage, pathological
findings and survival. The current
status of all patients was noted from
ongoing hospital charts or the files of
the Nova Scotia Tumour Registry, or
by contacting the attending physician.
The date and cause of death were
available for all who died. Follow-up
of living patients ranged from 15
months to 135 months (mean 44
months for group 1 and 47 months for
group 2). One pathologist (N.H.A.)
examined the 82 original specimens
available for review. The histologic
grade, depth of invasion, lymph-node
involvement and presence or absence
of mucin were assessed for each le
sion. A tumour was judged to be
mucinous if it met the criteria of
Symonds and Vickery.14 The x2 test
was used to assess apparent differ
ences, and actuarial survival rates
were calculated. A p value of less than
0.05 was considered significant.

G ro u p 1, n o. (% )

A - c o n fin e d to b o w e l w a ll

0

(0)

G ro u p 2 , n o. (% )
3

(3)

B - p e n e tra tin g se ro sa l s u rfa c e

11 (3 2 )

3 9 (4 4)

C - p o s itiv e n o d e s

1 4 (4 1 )

2 9 (3 3 )

9 (2 6 )

1 7 (1 9 )

D - d is ta n t m e ta s ta s e s
* N o s ig n ific a n t d iffe re n c e s b e tw e e n th e g ro u p s .
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The sex distribution of the 122
patients (Table I) was highly signifi
cant (p = 0.002).
Symptoms and signs of colorectal
carcinoma in the two groups were
similar (Table II). In both, abdominal
pain, rectal bleeding and change of
bowel habit were the most common
complaints. Table III shows the dura
tion of symptoms; in group 1, 74%
had been symptomatic for less than 6
months compared with 78% in group
2.
There was a predominance of leftsided primary tumours (Table IV) —
82% in group 1 and 81% in group 2
were distal to the splenic flexure. One
patient in group 1 had two synchro
nous primaries as did five patients in
group 2.
The Dukes’ staging was recorded at
the time of diagnosis for all patients
(Table V). No patients in group 1 but
three in group 2 had stage A lesions.
On the other hand, more advanced
disease (stages C and D) was seen in
group 1 (67%) than group 2 (52%),
although the difference was not sig
nificant (p = 0.18). Table VI shows
5-year survival rates for each Dukes’
stage; again, the differences were not
significant. Of 12 patients with rectal
tumours in group 1, 2 survived 5
years, compared with 14 of 31 in
151

group 2, an insignificant difference.
There was no difference in survival
between the groups for patients with
colonic tumours.
There was an overall similarity in
the histologic grading of the tumours.
Moderately differentiated lesions
were present in 70% of group 1 and
82% of group 2 patients; the remain
der were equally divided between
poorly and well-differentiated tu
mours. The incidence of predisposing
conditions was low — one group 1
patient with ulcerative colitis and an
other with polyposis coli and in group
2 two patients with polyposis coli.
With respect to actuarial survival
(Fig. 1), group 1 had a lower propor
tion surviving at all intervals, most
apparent in years 1 to 3. The number
surviving at each interval was inade
quate to prove statistical significance,
but we can infer a poorer prognosis
for younger patients from the consis
tently lower proportion surviving.
A review of the surgical specimens
showed general agreement with the
initial pathology reports. On re
examination of lymph nodes, five pa
tients initially classified as having
Dukes’ B lesions were found to have
Dukes’ C. Classifications of lesions as
mucinous or nonmucinous were not
changed as a result of specimen re
examination. When the initial slides
were not available, the findings on the
original pathology report were used.
In group 1 there were 13 mucinous
and 21 nonmucinous lesions, while
group 2 had 16 mucinous and 72
nonmucinous lesions (p = 0.036) (Ta
ble VII).
Although retrospective evaluation
of their overall health is difficult, the
fact that both groups of patients were
composed of relatively young people
(mean ages 32.3 and 46.5 years)
should limit the importance of this
factor. All patients who died of natu
ral causes did so as a result of colorec

tal carcinoma (one committed sui
cide).

have an extremely high percentage of
mucinous lesions.1-15
Two Scandinavian studies that re
viewed all cases of colorectal carcino
ma in Denmark8 and Sweden9 over
more than 20 years found that prog
nosis was not affected by age at pre
sentation; interestingly, there was no
difference in histologic type between
younger and older patients. The previ
ously cited study6 from Britain also
found no histologic difference in the
tumours of both groups. It is interest
ing that European studies show a
similar survival for younger and older
patients, while American studies tend
to reveal a poorer prognosis in youn
ger patients, especially when there is
an increased incidence of mucinous
tumours; our results reflect the Ameri
can pattern.
Fifteen percent of colorectal tu
mours produce large quantities of
mucin and are associated with a par
ticularly poor prognosis. The 5-year
survival for such patients is 34%,
compared with 53% for those with
nonmucinous lesions. The poor prog
nosis may relate to either an increased
water absorption by the mucus, en
couraging malignant cell dispersal, or
a mucopolysaccharide coating on the
cells interfering with immunologic
recognition of the malignant cells.14
Safford and colleagues7 found that
stage of the tumour at the time of
diagnosis, rather than patient age, was
the most accurate prognostic determi
nant. A report on United States mili
tary personnel found that patients
under 30 years of age with Dukes’ A
or B lesions had the same prognosis as
older patients, but those with stage C
lesions had a much poorer outlook.16
Patients in Hong Kong under 40 years
old17 were found to have a higher
number of Dukes’ C and D lesions. In

Discussion
There has been a long-standing im
pression that young patients with co
lorectal carcinoma have a poorer
prognosis than their older counter
parts as noted by Ezzo and col
leagues13 in 1958. A study in 19744
found that the 5-year survival for
those under age 35 was 17.5%. Sugarbaker and colleagues5 concluded that
age less than 30 years is associated
with a particularly poor prognosis. A
number of recent papers on the sub
ject do not agree with this conclusion;
a British study6 found that age 40
years was not synonymous with a
poor prognosis. Although they had a
higher incidence of more anaplastic
lesions, younger patients tolerated
emergency surgery better and overall
had an improved prognosis.
To limit the factor of better toler
ance we reviewed two groups close to
each other in age. Although the num
bers are too small to show significant
differences in actuarial survival, the
trend to a poorer prognosis is clear.
An interesting observation is that
mucin-secreting tumours were twice
as prevalent in the younger group;
38% of group 1 patients had mucin
ous tumours, compared with 18% of
group 2 (p = 0.036). Bedikian and
colleagues10 found an increased rate of
mucin-secreting tumours in patients
under 40 years of age. A study of 62
patients11 found that colorectal carci
noma was a more virulent disease in
patients under the age of 40 years,
with a higher incidence of poorly
differentiated lesions and mucinsecreting tumours. Adolescents with
far advanced colorectal carcinoma

T a b le V I— F iv e-Y e a r S u rv iv a l B y D u k e s ' S tage*
S ta g e

G ro u p 1, n o . /to t a l (%)

G ro u p 2 , n o ./to ta l (%)

A

0

B

5 /7

(7 1 )

1 7 /3 0

(5 7 )

C

3 /1 2 (2 5 )

1 1 /2 5

(4 4 )

D

0 /8

0 /1 7

(0)

O ve ra ll

(0 )

(0 )

8 / 2 7 (3 0 )

3 /3

(1 0 0 )

3 1 / 7 5 t (4 1 )

‘ D a ta n o t y e t a vaila b le o n a la rg e e no u g h n u m b e r to p ro v e s ta tis tic a l s ig n ific a n c e .
f N o . fo llo w e d up fo r 5 y e a rs .

T a b le V II— M u c in o u s T u m o u rs
T y p e o f tu m o u r

FIG. 1 — Actuarial survival.------ =
under 40 years of age (group 1), — = 40 to
50 years of age (group 2).
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G ro u p 1, n o . (% )

G ro u p 2 , n o . (%)

M u c in o u s *

13

(3 8 )

16

(1 8 )

N o n m u c in o u s

21

(6 2 )

72

(8 2 )

T o ta ls

3 4 (1 0 0 )

8 8 (1 0 0 )

• D iffe re n c e is s ig n ific a n t (p = 0 .0 3 6 ) .
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our study, advanced lesions were seen
more commonly in younger patients,
but the difference was not significant.
The histologic grade of the tumour in
both age groups was similar.
The majority opinion is that the
poor prognosis in younger patients is
due to late reporting o f symptoms and
failure o f physicians to investigate
their complaints thoroughly.1015 Simstein and associates,12 in their review
of military personnel with colorectal
carcinoma, found no evidence of a
delay in diagnosis. Other investiga
tors10 have reported an average of 3
months between onset o f symptoms
and diagnosis. Rosato and col
leagues18 noted a greater interval be
tween onset o f symptoms and diagno
sis in the young, but this did not lead
to a poorer prognosis. Moreover, it
has been established that there is no
correlation between a delay in treat
ment and survival from colorectal
carcinoma. Associated disorders such
as ulcerative colitis, familial polyposis
and familial nonpolyposis syndromes
have been suggested as contributing
factors in colorectal cancer, but re
views to date report a very small
number of patients with these culpa
ble conditions present simultaneously.
An interesting and unexpected
finding in our study was that colorec
tal carcinoma in those under 40 years
of age was much commoner in men.

Most reports do not indicate this
difference; some in fact show higher
numbers o f women,20 while in others
there is essentially no difference.2-6
The one study that had a much higher
number o f men was that of US Army
personnel.7
Conclusions
Patients under 40 years of age with
colorectal carcinoma have a poorer
prognosis than those aged 40 to 50
years, due to a tendency toward ag
gressive tumours that present as ad
vanced lesions and to a larger number
of mucinous tumours in these pa
tients.
We thank Dr. D. Rathbone for assis
tance with the chart review and Dr. P. Roy
for assistance with the statistical analysis.
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Profound Hypothermia and Circulatory Arrest in Excision
of Renal Cell Carcinoma Invading the Vena Cava
Two patients with renal cell carcinoma
invading the inferior vena cava to the
level of the right atrium underwent
complete excision of their renal tu
mours. Clearance of the caval exten
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pulmonary bypass, profound hypo
thermia and circulatory arrest. The use
of these techniques visually improved
the operative field without extending
operating time. Profound hypothermia
and circulatory arrest do not increase
postoperative morbidity or mortality
and offer the best opportunity for cure.

arret circulatoire. L'emploi de ces
techniques a permis de degager le
champ operatoire sans prolonger la
duree de I'intervention. L'hypothermie
profonde et I'arret circulatoire n'augmentent pas la morbidite et la mortalite postoperatoires et ameliorent les
chances d'obtenir une guerison com
plete.

Deux patients porteurs de carcinomes
des cellules renales envahissant la
veine cave inferieure au niveau de
I'oreillette droite, ont subi une excision
complete de la tumeur renale. Le nettoyage de I'extension cave a ete reali
se grace a une circulation extracorporelle, une hypothermie profonde et un

Renal cell carcinoma is an aggressive,
locally invasive tumour that tends to
invade the renal veins and subse
quently the inferior vena cava.1-5 The
best opportunity for cure is offered by
complete removal of the renal mass
and its local extension.3-15 It is a
formidable undertaking for a surgeon
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to embark on excision of a renal mass
with extension into the inferior vena
cava reaching to the heart. We recent
ly experienced two such cases and
found the technique o f profound hy
pothermia and circulatory arrest to be
a safe and useful adjunct, facilitating
resection of the intravascular compo
nent.
Case Reports
Case 1
Routine urinalysis in a 67-year-old
woman in June 1986 revealed microscopic
hematuria. A subsequent intravenous pyelogram demonstrated a right renal mass
and inferior vena cavography a tumour
obstruction to the level of the diaphragm.
Computed tomography and echocardiogra
phy confirmed the presence of a thrombus
extending from the right renal vein to the
right atrial-caval junction (Fig. 1). There
was no evidence of metastases on physical
examination, chest x-ray film or computed
tomography of the chest and abdomen.
This patient gave a history of long
standing hypertension, treated with pro
pranolol, hydrochlorthiazide and prazosin.
She had undergone a hysterectomy and a
cholecystectomy without complications.
The only abnormal findings on physical
examination were palpable right flank full
ness and a blood pressure of 205/100 mm
Hg. There was no clinical evidence of
caval obstruction. On admission her hemo
globin level was 9.62 mmol/L, leukocyte
count 6.9 X 109/L, blood urea nitrogen
level 5.35 mmol/L (urea) and serum creati
nine value of 88.4 /umol/L (all within
normal limits). An SMA-12 biochemical
analysis was normal. Urinalysis showed
microscopic hematuria.
Just before operation, intravenous, radi
al artery and pulmonary artery catheters
were inserted. General endotracheal anes
thesia was induced using isoflurane, fentanyl citrate and pancuronium bromide.
A small roll was placed under the right
flank and the patient’s skin prepared with
Betadine solution. A two-team approach
was used, the urology team performing a
right subcostal incision and the thoracic
team a median sternotomy.
The right renal artery was ligated and
the renal veins were isolated. The renal
mass was widely dissected, removing the
kidney within Gerota’s fascia and dividing
the ureter well away from the mass. Re
gional lymph nodes and the right adrenal
gland were also taken en bloc.
After renal dissection, the patient was
fully heparinized and cannulated for car
diopulmonary bypass, using an aortic arch
cannula, a superior vena caval cannula and
a right femoral cannula. Sodium pentothal,
1.5 g intravenously, was administered over
a period of 8 minutes. Cardiopulmonary
bypass was begun using a membrane oxy
genator and roller pump, and the pa
tient’s body temperature was lowered to
18°C as her head was packed in ice. The
aorta was cross-clamped and cold blood
cardioplegia was given at 20-minute inter
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vals to protect the myocardium. When the
cooling process was completed, the pa
tient’s blood was diverted into the pump
oxygenator and the inferior vena cava and
right atrium were opened widely.
The tumour was carefully and complete
ly removed from within the inferior vena
cava. Its entire length from the renal veins
to the right atrium could easily be visual
ized by this approach. After excision of the
caval mass, the vein was liberally irrigated
with sterile water.
After cavotomy closure, cardiopulmo
nary bypass was reinstituted and the pa
tient gradually rewarmed. During this peri
od, hemostasis was assured in the bed of
the excised renal tumour. Once the patient
was weaned from cardiopulmonary bypass
and the heparin effect reversed with prot
amine sulfate, the wounds were closed
routinely and she was moved to the inten
sive care unit.
The total bypass time was 74 minutes
with 40 minutes of aortic cross-clamp
time. The time of circulatory arrest, how
ever, was only 25 minutes.
The patient had no neurologic sequelae.
She required eight units of packed red cells
and four units of fresh frozen plasma
during the postoperative period.
When she was discharged home on post
operative day 9 she had normal renal
function and a hemoglobin level of 6.95
mmol/L. She was still well 22 months later.

ery), myocardial infarction and arthritis of
her knees. She was an obese woman with
evidence of peripheral arterial disease and
varicose veins. On admission she had a
hemoglobin level of 7.88 mmol/L, leuko
cyte count of 5.4 X 109/L, blood urea
nitrogen level 5.0 mmol/L (urea) and a
serum creatinine value of 79.6 /tmol/L.
She underwent resection of a right renal
cell carcinoma, using the method described
in Case 1, except that we found it neces
sary to cannulate only the right atrium for
venous access.
Adherence of the tumour thrombus
made it necessary to resect 8 cm of inferior
vena cava, which was reconstructed using
a pericardial patch.7 The total bypass time
was 68 minutes with 49 minutes of circula
tory arrest.
Postoperatively, the patient had no
major complications; she required 12 units
of packed red cells and 2 of fresh frozen
plasma and she had anorexia secondary to
a prolonged ileus. She was depressed for
several days, but there was no detectable
neurologic deficit.
The patient was discharged home on
postoperative day 12 with a hemoglobin
level of 5.8 mmol/L and normal renal
indices. She was placed on a 3-month
course of Coumadin to prevent thrombosis
of the inferior vena caval patch graft and
was still well 16 months postoperatively.

Discussion
Case 2
A 72-year-old woman was seen by her
family physician for nonspecific chest and
abdominal pains. There was no history of
hematuria. She had lost 2.3 kg in weight
over the preceding 2 months while dieting.
She was taking guanethidine, ranitidine
and chlorothiazide.
Abdominal ultrasonography revealed a
right renal mass. Intravenous pyelography
and computed tomography (Fig. 2) of the
abdomen demonstrated a right renal tu
mour (7 cm in diameter) with extension
into the right renal vein and inferior vena
cava. Bone scanning and computed tomog
raphy of the chest gave normal results.
Echocardiography showed the tip of a
caval thrombus close to the right atrium.
Her medical history included hyperten
sion, cholecystectomy, stroke (with recov-

Invasion of the inferior vena cava
by renal cell carcinoma is reported to
occur in 4% to 10% o f patients.1-15
Tumour extension to the right atrium
is less common.4-7-9-11 Several tech
niques have been described for re
moving renal tumours that involve
the renal veins and inferior vena ca
va,10-14 but when the tumour throm
bus extends to or above the dia
phragm, the problems are much grea
ter.4-915 Intraoperative hazards in
clude tumour embolization into the
right heart or lungs, massive bleeding
or incomplete clearance o f the throm
bus. Cardiopulmonary bypass, pro
found hypothermia and circulatory
arrest provide a clear, dry operative

FIG. 1 — Case 1. Preoperative abdomi
nal computed tomogram demonstrating
large right renal mass extending into inferi
or vena cava.

FIG. 2 — Case 2. Preoperative abdomi
nal computed tomogram showing tumour
thrombus within enlarged inferior vena
cava.
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field with excellent visualization of
the entire suprarenal inferior vena
cava, maximizing the opportunity for
complete tumour resection.6
One potential hazard associated
with this technique is the effect of
cardiopulmonary bypass and pro
found hypothermia on hemostasis.16
With the aid o f packed red cells and
specific clotting factors, we have not
found bleeding to be a problem using
this method. It is also possible that
the routine postoperative use of des
mopressin could further reduce peri
operative blood loss.17 There is con
cern that circulatory arrest may cause
a serious neurologic deficit. The
“safe” time limit for circulatory arrest
is controversial,1819 but it would seem
that the time should be kept under 40
minutes whenever possible. Whether
certain anesthetic and pharmacologic
maneuvers can be employed to pro
tect the brain during circulatory arrest
is unclear at present. As Hickey and
Anderson20 have noted, “the inci
dence of significant neurologic seque
lae using modern techniques is diffi
cult to distinguish from the incidence
o f cardiopulmonary bypass-related
neurologic complications”.
The use o f pentothal, 15 to 30
mg/kg, with profound hypothermia
has been shown to produce an isoelec
tric electroencephalogram, thereby de
creasing cerebral oxygen consumption
to 50% of that at normothermia.21'22
To optimize cerebral protection, both
patients received 20 mg/kg o f pento
thal 10 minutes before circulatory ar
rest. Potential side effects from the
pentothal, such as prolonged sedation
and myocardial depression, were not
evident. Both patients remained hemodynamically stable during the
rapid pentothal administration; nei
ther required vasopressors at the end
o f cardiopulmonary bypass and both
were extubated the morning after sur
gery.

Renal cell carcinoma is an aggres
sive lesion in which surgical extirpa
tion remains the only treatment.16
Poor prognostic features of this dis
ease include invasion of the peri
nephric fat, lymph-node involvement
and histologic evidence of spindle-cell
formation.23’24 Until recently, it was
believed that inferior vena caval in
volvement conferred a poor progno
sis, a view strengthened by the staging
system o f Robson and associates,25
which defines renal vein and inferior
vena caval involvement as a stage III
lesion. Other studies have indicated
that caval involvement may not be as
serious as lymph-node invasion, and
that survival of a patient with caval
involvement alone may approximate
that o f a patient with a stage I le
sion.23'24
These data reflect the aggressive
nature o f this disease, yet a carefully
planned, well-executed operation of
fers the best opportunity for cure or
palliation. We believe that the addi
tion of cardiopulmonary bypass, pro
found hypothermia and circulatory
arrest significantly increases the ease
o f the operative procedure with ac
ceptable morbidity.
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CANADIAN SOCIETY FOR VASCULAR SURGERY
Symposium on Mesenteric Ischemia
W.G. J amieson, md , frcs, frcsc, facs

1. Acute Intestinal Ischemia
Massive acute intestinal ischemia, an
intra-abdominal catastrophe, is associ
ated with a high death rate. Only with
early diagnosis and prompt aggressive
management can this rate be reduced.
The key to diagnosis is suspicion
followed by intelligent interpretation of
physical findings, awareness of the
importance of elevated leukocyte
count and inorganic phosphate levels
and of acidosis, and more liberal use of
superior mesenteric angiography in
cases of possible intestinal ischemia.
A "golden period" exists in which the
bowel may be revascularized without
tissue loss, so the aim should be to
make the diagnosis more often during
this period and to restore intestinal
blood flow promptly.

L'ischemie massive intestinale aigue,
veritable catastrophe intra-abdominale, est reliee a une mortalite elevee.
Seuls un diagnostic precoce et une
intervention agressive rapide permettent de reduire ce taux.
La clef du diagnostic tient dans sa
presomption, puis dans ('interpretation
intelligente de I'examen physique,
dans la reconnaissance de ('importan
ce d'un compte leucocytaire eieve, des
taux de phosphate inorganique et
d'une acidose, et dans une utilisation

plus repandue de I'angiographie
mesenterique superieure dans tous les
cas d'ischemie intestinale possible. II
existe un "intervalle privilegie" au
cours duquel I'intestin peut etre revascularise sans qu'il y ait de perte tissulaire. On doit done tendre a faire le
diagnostic durant cette periode et a
retablir la circulation sanguine intesti
nale promptement.

Acute mesenteric ischemia has been
the bete noire of acute abdominal
conditions. The impending intraperitoneal catastrophe is out of
keeping with the patient’s often vague
complaints, the paucity of physical
findings and the lack of diagnostic
help from routine laboratory investi
gations and plain abdominal x-ray
films.
The subject I shall discuss is mas
sive acute intestinal ischemia; I shall
not consider small areas of necrosis,
ischemic colitis, necrotizing enteroco
litis of children, celiac or inferior
mesenteric artery problems.
Etiology

There are three possible causes of
acute mesenteric ischemia: embolism,
thrombosis and nonocclusive mesen
teric insufficiency.
An embolus to the superior mesen
From the Division o f Vascular Surgery,
teric artery accounts for 25% to 30%
Victoria Hospital, London, Ont.
of cases of acute intestinal ischemia.1
Most (90% to 95%) emboli arise from
Presented as part of a symposium on mes
enteric ischemia at the 9th annual meeting the heart, usually because of atrial
of the Canadian Society for Vascular Sur
fibrillation, but also from mural
gery, held in conjunction with the 56th
thrombus in the left ventricle. Other
annual meeting of the Royal College of
sources of emboli may be atheroscle
Physicians ana Surgeons of Canada, Win
rotic plaques and vegetation or
nipeg, Man., Sept. 12, 1987
thrombi on valves. The embolus
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lodges in the superior mesenteric ar
tery a few centimetres from its origin
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and usually spares the middle colic
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artery and proximal jejunal branches,
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giving a classic distribution of isch
emia at the time of laparotomy.
Thrombosis of the superior mesen
teric artery, usually associated with
aortic atherosclerosis, occurs at the
origin of the vessel and involves all
branches of the superior mesenteric
artery, including the middle colic and
early jejunal branches. The gut be
comes ischemic from the duodenum
to the middle of the transverse colon.
Nonocclusive mesenteric insuffi
ciency is the term used for cases with
no mechanical blockage of the superi
or mesenteric artery. In the majority
of such patients a major contributing
factor, such as cardiac failure or ar
rhythmia, digitalis abuse, hemoconcentration following diuretic therapy
and other systemic debilitating diseas
es, leads to a reduction in cardiac
output and subsequently in mesenter
ic flow. The true frequency of this
problem remains unknown because
the underlying cause is often correct
ed with return of blood flow and
function of the gut.
Diagnosis

The key to early diagnosis is suspi
cion, especially during the first few
hours when the findings are only
vague abdominal pain with diffuse
tenderness, anorexia and abdominal
fullness.
The classic picture of obvious car
diac disease, sudden severe abdomi
nal pain and spontaneous defecation
is usually not present. I believe the
onset often is insidious and early
diagnosis is most difficult.
Help may be obtained from a triad
of laboratory observations.
• The leukocyte count is usually
grossly elevated.2
• Metabolic acidosis is usually
present; our group likes to call this
“inappropriate acidosis” as the pa157

tient has no other obvious cause of
the acid-base upset and early on is not
as ill as the acidosis would indicate.3
• We have shown that the level of
serum inorganic phosphate is substan
tially elevated in peripheral blood, at
a time when prompt restoration of
mesenteric blood flow is gut-sparing.
In 20 of our cases the finding of an
elevated serum phosphate level has
been an accurate reflection of gut
ischemia.46
I recommend that if there is any
chance of intestinal ischemia, the
serum phosphate level, leukocyte
count and pH should be measured. If
these are abnormal, the patient should
quickly undergo superior mesenteric
artery angiography and appropriate
action should be taken.
With nonocclusive mesenteric in
sufficiency suspicion again is the key.
A patient with a deteriorating cardiac
problem and vague abdominal com
plaints whose abdomen feels “doughy”
should undergo the same laboratory
investigations followed by angiogra
phy. If the supenor mesenteric artery
spasm is not treated, the cardiac prob
lem is magnified and often irrevers
ible.
Treatment

Superior Mesenteric Artery Embolus
Embolectomy and resection of the
necrotic bowel should be performed
promptly. Attention to the source of
the embolus and elimination of the
cause is mandatory. Metabolic acido
sis, if present, should be corrected. As
soon as the diagnosis is made, heparin
should be given systemically to help
prevent a second embolus from dis
lodging and to stop propagation of the
clot within the superior mesenteric
artery.
Some7 believe that the angiographic
catheter should be left in the superior
mesenteric artery and used to infuse
papaverine (60 mg/h) because spasm
is associated with the embolus and its
extraction.
The superior mesenteric artery is
found at the base of the mesentery as
it courses over the third part of the
duodenum. The embolus is removed
using a small Fogarty catheter, the
artery is irrigated distally with hepari
nized saline and the arteriotomy is
closed. Obviously necrotic bowel
should be resected and the viability of
the remaining bowel examined.
Doppler probes are available8 and flu
orescein dye tests have been helpful.8
We use observation and Doppler ex
amination.
Areas of bowel that are of question
158

able viability should be examined at a
“second look” operation 24 hours
after the first.9 There are no tests to
determine small areas of necrotic
bowel and too much is at stake to
adopt a “wait and see” attitude.
Superior Mesenteric Artery
Thrombosis
Ischemic bowel extending from
proximal jejunum to the splenic flex
ure is diagnostic of superior mesenter
ic artery thrombosis.
The same urgency is required for
this condition as for embolism — that
is, prompt surgery; I have had no
experience with fibrinolytic agents.
After the artery has been isolated, it
is opened at a soft spot. Removal of
the thrombus with a Fogarty catheter
may be attempted, but often it is to
no avail. I believe that a simple by
pass (aorta-superior mesenteric artery
or iliac artery-superior mesenteric ar
tery) using vein or synthetic material
is the operation of choice. Aortic su
perior mesenteric endarterectomy,
distal superior mesenteric artery-iliac
artery anastomosis and axial aortasuperior mesenteric artery grafting
have all been done with good results.
As with the superior mesenteric artery
embolus, the bowel is observed, re
sected if necessary and a second look
laparotomy done, if indicated.
Nonocclusive Mesenteric Ischemia

• An elevated serum inorganic
phosphate level in peripheral blood
may be an early key to diagnosis in
the patient with minimal abdominal
findings.
• Superior mesenteric angiography
should be used liberally if there is any
possibility of acute intestinal isch
emia.

Comment

Early diagnosis is mandatory for
successful management of mesenteric
ischemia.
A number of points should be em
phasized.
• The condition, if treated early,
will give excellent results with no loss
of bowel.
• Visible peritonitis with mesen
teric ischemia usually indicates ne
crotic bowel.
• The leukocyte count is usually
elevated.
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2. Chronic Mesenteric Ischemia
Although chronic mesenteric ischemia
is an infrequent, even rare, condition
and a busy vascular surgeon may en
counter only one such patient in a
year, the associated morbidity and
mortality are high, especially if the
condition is not recognized. General
and vascular surgeons must bear in
mind the triad of postprandial pain,
weight loss and diarrhea. Patients
with mesenteric ischemia are at high
risk and generally have diffuse periph
eral vascular disease. Although sur
gery is hazardous, successful repair
can result in long-term survival with
out morbidity. The author favours
antegrade supraceliac bypass grafting
over infrarenal grafting which is tech
nically more difficult.

L'ischemie mesenterique chronique
est peu frequente, voire rare. Un chirurgien vasculaire occupe peut n'en
recontrer qu'un seul cas annuellement.
Neanmoins, la morbidite et la mortalite
qui y sont rattachees sont elevees,
surtout quand I'affection n'est pas rapidement reconnue. Les chirurgiens
vasculaires et generaux doivent garder
a I'esprit la triade: douleur post-prandiale, perte de poids et diarrhee. Les
patients qui souffrent d'ischemie
mesenterique sont des sujets a risque
et ils ont generaiement une vasculopathie peripherique disseminee. Meme si
la chirurgie est risquee, une reparation
reussie peut resulter en une survie
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Chronic mesenteric ischemia is un
common, but the associated morbidi
ty and mortality are high. It is a
manifestation of atherosclerotic occlu
sive disease, usually involving a com
bination of two or three of the follow
ing: the celiac axis and superior and
inferior mesenteric arteries. Rarely,
fibromuscular disease in the young or
Buerger’s disease in the adult may be
causative, and very occasionally pa
tients will have symptoms with single
artery involvement (usually the supe
rior mesenteric artery). Interestingly,
women are affected more frequently
than men. The atherosclerotic lesion
usually involves the proximal cen
timetre of the vessel and may be
considered an extension of adjacent
aortic atheroma. Although atheroscler
otic involvement of the aortic ori
fices of the visceral vessels is com
mon, the functional effects of singleand even double-vessel lesions are
limited, due to the excellent potential
collateral pathways that exist between
the celiac axis and the superior mes
enteric artery (pancreatoduodenal ar
teries), and the superior mesenteric
and inferior mesenteric arteries (the
arc of Riolan and marginal artery of
Drummond). Usually all three vessels
are involved in the symptomatic pa
tient. The ensuing ischemia results in
postprandial pain and often malab
sorption, both of which may lead to
weight loss. Malabsorption may lead
to diarrhea which is often fatty. The
end result, as noted by Dunphy,1 is
often gut infarction and death.
Clinical Presentation and Diagnosis
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Pain is virtually universal in pa
tients with chronic mesenteric isch
emia. It usually develops 10 to 30
minutes after eating. It may be steady
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or colicky, is usually periumbilical
and often varies in duration with the
type and amount of food ingested.
The patient learns to avoid large
meals and may experience sitophobia,
resulting in weight loss which may be
massive and mimic carcinomatosis.
In extreme cases, abdominal pain may
be virtually continuous, analogous to
rest pain in the extremity, and the
clinical picture can merge into one of
acute mesenteric ischemia. Although
diarrhea is the classic form of bowel
disturbance, it occurs in only 50% of
patients. Constipation may also occur.
Physical findings are few. Weight
loss is usually marked. Generalized
atherosclerotic occlusive disease is
frequent and an epigastric bruit is
usually present.
The correct diagnosis is generally
not made until the patient has had
symptoms for many months. General
abdominal x-ray films are of little
value. Assessment of gut function
with xylose uptake and fecal fat mea
surements is useful if the findings are
positive, but they are frequently nor
mal. Diagnosis depends on the clini
cal picture and awareness and is con
firmed by angiography. Although
frontal aortography usually demon
strates collateral channels, lateral
views are essential to delineate the
proximal celiac and superior mesen
teric lesions.
Treatment
Treatment is by surgical reconstruc
tion. Although we have had short
term success in one instance of bal
loon angioplasty of the superior mes
enteric artery, there is no reason to
expect that the outcome of angioplas
ty of stenoses at the origins of the
visceral vessels will differ from the
rather dismal results seen in similar
lesions of the renal arteries.
Reconstructive techniques have
been many and varied. Local short
endarterectomy and patching through
an anterior transabdominal approach
can be applied to any of the visceral
vessels and has stood the test of time.
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Thromboendarterectomy of the supe
rior mesenteric artery can be accom
plished either above, through the gastrohepatic ligament, or below,
through the ligament of Treitz. The
retroperitoneal “ trap door” approach
recommended by Stoney and associ
ates2 affords an excellent repair,
which can include the renal arteries
when necessary, but demands a high
level o f technical expertise and famil
iarity with the anatomy involved. It is
not for the occasional operator.
Because of its relative simplicity,

the bypass graft remains the choice of
most surgeons. Here the major choice
lies between an infrarenal or supraceliac location for the origin of the
graft. In our experience, and that of
others,3the long retrograde infrarenal
graft taken through the mesentery to
the middle o f the superior mesenteric
artery, whether vein or prosthesis, is
difficult to position and is susceptible
to both early and late occlusion, often
with disastrous results. A short retro
grade infrarenal graft to the proximal
superior mesenteric artery, where pos

sible, is more durable. This may be
technically more difficult, particularly
in the patient who has previously
undergone aortic surgery. Our proce
dure of choice is the antegrade supraceliac graft that can be brought
down either in front or behind the
pancreas to the middle of the superior
mesenteric artery. In the very thin
patient with a mobile pancreas it is
possible to retract the pancreas inferiorly and accomplish the entire repair
through the divided gastrohepatic lig
ament. This is a durable procedure,

An emerging
IN THE MANAGEMENT

f

probably because of the axial orientation of the graft. If the celiac axis is
involved as well as the superior mes>•
enteric artery, the proximal anasto
mosis may be placed across the celiac
'
axis as a patch angioplasty. This tech4 ^
nique is equally applicable to the
previously reconstructed aorta, and
A
the aorta at the supraceliac level is
}
usually free of atheroma. If a suiA
praceliac graft is to be combined with
infrarenal aortic surgery, the visceral
A >
repair should be done as the initial
step.
*
t___________
K*

4

Symptoms of mesenteric ischemia
may be difficult to identify in the
abdomen postoperatively, and for this
reason angiography is mandatory if
there is any concern in the first few
days after surgical repair. In any
event, angiographic assessment of the
visceral vessels should be obtained
before the patient is discharged from
hospital.
Successful reconstruction is associ
ated with alleviation of symptoms
and the patient’s return to his usual
weight. As with other reconstructions,

late occlusion can occur, and later
abdominal symptoms should be ag
gressively investigated to forestall po
tential gut infarction.
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3. Colonic Ischemia After Aortic Reconstruction
Colonic ischemia after aortic recon
struction is rare, but when it occurs in
its worst form it carries a 50% death
rate. The etiology and pathogenesis of
this condition demonstrate that in
many instances it may be prevented.
Early recognition, particularly of the
transmural ischemic injury, is essen
tial.
Numerous techniques used during
surgery for assessing the adequacy of
colonic perfusion have been evaluated
and found to be cumbersome and inac
curate in terms of predicting colonic
ischemia. Recent experience with the
use of the pulse oximeter appears
promising in identifying patients with
inadequate colonic perfusion who may
then be candidates for reimplantation
of the inferior mesenteric artery.

L'ischemie colique consecutive a une
reconstruction de I'aorte est rare. Toutefois, lorsqu'elle survient, elle entraine, dans sa forme la plus grave,
une mortalite de 50%. L'etiologie et la
pathogenese de cette affection
demontrent que dans plusieurs cas elle
pourrait etre prevenue. Son identifica
tion precoce est essentielle. particulierement lorsqu'on est en presence
d'une lesion ischemique transmurale.
On a evalue plusieurs techniques
utilisees en salle d'operation pour etablir la capacite de perfusion colique.
Ces techniques sont souvent lourdes
et elles manquent de precision pour
predire l'ischemie colique. L'utilisation
recente de I'oxymetre a impulsion
parait prometteuse pour identifier les
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patients souffrant d'une perfusion
colique insatisfaisante qui pourraient
etre candidats a une reimplantation de
I'artere mesenterique inferieure.

Colonic ischemia after aortic proce
dures is mainly iatrogenic. In its worst
form, ischemic colitis complicating
aortic surgery carries a 50% mortality.
It is apparent, however, that vascular
surgeons now have the techniques to
recognize the potential for this condi
tion and to avoid it completely.
Historical Perspective
Only 2 years after Dubost and col
leagues1 resected the first aortic aneu
rysm in 1952, Moore2 reported the
first case of ischemic colitis after aor
tic reconstruction. Since then, numer
ous case reports and series have been
published.3-6
These series provide evidence of
marked differences in the incidence of
this condition.36 In retrospective
studies, an occurrence rate of 2% has
been found, usually associated with
an unfavourable outcome; in prospec
tive series, the frequency was from 7%
to 35% mainly because of better diag
nosis through colonoscopy in the
postoperative period. In 75% of cases
the condition is associated with liga
tion of the inferior mesenteric artery
during aneurysm resection; the other
25% occur during aortoiliac recon
struction for claudication.
A 12% incidence of ischemic colitis
is associated with ruptured abdominal
aortic aneurysm in retrospective
studies. However, routine postopera
tive colonoscopy will reveal demon
strable mucosal changes in 60%.. The
death rate for elective aortic proce
dures has declined to approximately
2% and a similar incidence of clinical
ly overt ischemic colitis would not be
considered high. However, for the
number of aortic procedures that are
done in Canada, for example, 2%
represents a sizable number of pa
tients and 50% of them will die of
complications associated with isch
emic colitis.

Johnstone and Scobie,7 reporting
on the Canadian Society for Vascular
Surgery Multicentre Study of Aneu
rysmectomy, demonstrated one of the
lowest rates of this complication ever
recorded — 0.6% in 666 patients —
but the series excluded patients with
ruptured aneurysms. In this series the
inferior mesenteric artery was reim
planted in 4.8% of patients and car
ried a greatly increased incidence of
hemorrhage postoperatively. Twelve
percent of patients had complete ex
clusion of the hypogastric vessels, and
in this group the frequency of both
diarrhea alone and ischemic colitis
was markedly increased.
In the four patients who had isch
emic colitis, wound infection, paralyt
ic ileus and renal dysfunction were
also common, as might be expected.
Two died, giving a death rate that was
consistent with those of other pub
lished series.
Etiology
Although most documented cases of
ischemic colitis are associated with
ligation of the inferior mesenteric ar
tery during the aortic procedure, asso
ciated factors contribute significant
ly.3-6 Arrthymias affecting cardiac
output, aortic clamp time, colonic
distension, hypogastric exclusion, hy
povolemia and retractor injuries have
all been cited as contributing causes.34
As well, operative measures will
prevent complications. Improper liga
tion of the inferior mesenteric artery
distal to its first bifurcation could be
prevented by transfixion within the
sac of the aneurysm. Limiting manip
ulation of the aneurysm may prevent
trash colon and trash foot. Also, if it
is considered necessary to evacuate
the retroperitoneal hematoma from
the mesentery, it should be done from
the lateral aspect rather than through
the sigmoid mesentery. Hypogastric
flow should be preserved whenever
possible and this is feasible in 90% of
cases.
To avoid unnecessary reconstruc
tion of the inferior mesenteric artery,
particularly when the hypogastric ves-
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sels are not going to be reperfused,
measurement of colonic perfusion by
one of several techniques should be
considered.
Anatomical Considerations

If the principal cause of ischemic
colitis is ligation of the inferior mes
enteric artery and the problem is fail
ure to recognize this dominant vessel,
the solution must lie in attempting to
predict the patient who requires re
construction of the hemodynamically
important inferior mesenteric artery
at the time the initial aortic procedure
is performed.
Collateralization between the supe
rior mesenteric artery, its midcolic
branch and the hypogastric arteries
through the middle and inferior rectal
arteries and the superior rectal branch
of the inferior mesenteric artery is
well known. The origin of the inferior
mesenteric artery and its first branch,

FIG. 1 — Barium enema demonstrating
stricture resulting from type B ischemic
insult.

3 to 4 cm from the aorta, can vary,
and the presence of a particularly
large abdominal aortic aneurysm can
shorten this distance considerably. Li
gation in this event can readily in
clude the superior rectal branch or the
ascending branch of the inferior mes
enteric artery which together form
part of a meandering mesenteric ves
sel. Many pseudonyms have been at
tached to this vessel, perhaps explain
ing the confusion related to the true
functional anatomy of the region.
Potentially present in 60% of the
general population, the meandering
mesenteric vessel is identified in 30%
of angiograms performed for occlu
sion or aneurysmal disease and is a
cardinal sign, the implications of
which the surgeon must not overlook.

may result in an unnecessary laparot
omy at best or an unnecessary colonic
resection with all its attendant risks at
worst.
Intervention too late in a patient
with a type C lesion is associated with
" 90% mortality. One can argue
strongly in favour of routine colonos
copy in the postoperative period.
Even performed at the bedside, it has
been shown to be sensitive in identify
ing early mucosal changes. The diag
nosis can be ruled out in a sick patient
if colonoscopy performed to the level
of the descending colon demonstrates
a normal appearance.
Barium enemas in the presence of
ischemic colitis are fraught with the
danger of perforation and subsequent
peritonitis and are to be condemned.

Classification

Prevention

Experience has taught us to differ
entiate three clinicopathological types
of ischemic insult, each characterized
by different prognostic features.
Type A is associated with a con
tained, generally mild, mucosal injury
from which the patient should recover
normally. This is the most common
type and the one most likely to be
seen during colonoscopy done after
aortic reconstruction.
Type B (Fig. 1) indicates an isch
emic insult to mucosa and underlying
muscularis; the latter lesion may pro
duce long-term problems with insidi
ous diarrhea and possibly stricture
formation.
Type C represents the transmural
ischemic injury, usually producing
fairly obvious signs within a short
time. Clinical signs, however, may be
masked in the early postoperative pe
riod, delaying the diagnosis and re
sulting in increased mortality. Overt
sepsis, gangrene of the colon and per
foration are anticipated sequelae.

The key to prevention lies in recog
nizing the basic vascular abnormality.
This can be achieved by identifying
preoperatively patients most at risk
for ischemic colitis and confirming
during surgery any altered blood flow
to the colon.

Clinical Recognition

FIG. 2 — Aortogram demonstrating me
andering mesenteric vessel after aortic re
construction.

Acute clinical awareness of isch
emic colitis contributes to an early
diagnosis, but with a frequency of
only 2% this is not always easy to
achieve, many cases not being detec
ted as soon as they could be.
Early after aortic surgery, patients
may exhibit pain, guarding, febrile
episodes, oliguria and leukocytosis,
features that are also typical of isch
emic colitis.
Although bloody diarrhea is recog
nized as pathognomonic of this condi
tion, it may not become evident for
several days after the initiating insult.
The decision to intervene surgically is
never easy. Intervention too early
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Angiography

It is important that vascular radiol
ogists place their catheters high
enough in the aorta to demonstrate
patency of the superior mesenteric
artery. If this vessel is not demon
strated angiographically,5 one cannot
be certain about its complicity in the
blood supply of the colon.
If a meandering mesenteric vessel
is demonstrated (Fig. 2), it may indi
cate obstruction of either the celiac or
superior mesenteric artery. If, howev
er, it appears on the superior mesen
teric artery injection, the risk of pro
ducing ischemic colitis by ligating the
origin of the inferior mesenteric ar
tery is minimal, unless ligation occurs
too far distally, which might happen
in association with a particularly large
aneurysm. Although angiography is
standard for assessing aortoiliac dis
ease, it is not for aneurysmal disease.
In fact, we may be moving away from
not only standard angiography but
also intravenous and intra-arterial
digital subtraction angiography. In
our efforts to reduce risk factors we
have become more selective in our
use of contrast studies,5 using them
only when we are concerned about
aneurysmal involvement of the renal
arteries, associated renovascular hy
pertension and claudication. Howev
er, this may prevent us from obtain
ing important information about vis
ceral blood flow.
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When digital subtraction angiogra
phy is used, it will seldom provide
adequate information regarding flow
in the mesenteric arteries.
The accepted standard in many
centres is now computed tomography,
but magnetic resonance imaging is
starting to play a similar role. Al
though either approach adds to the
surgeon’s knowledge of specific anato
my pertinent to the aneurysm, both
fail to provide information about vis
ceral flow. Duplex scanning of the
superior mesenteric artery in conjunc
tion with computed tomography or
magnetic resonance imaging may cor
rect this shortfall.
Assessing Perfusion of the Colon

It seems clear that prevention lies
in recognizing the potential for isch
emic colitis in the individual patient
and that the ability to predict clinical
ly the adequacy of colonic perfusion is
unreliable. Current techniques for as
sessing perfusion in the operating
room tend to be time-consuming,
cumbersome, subject to equipment
and human error and, thus, unreli
able.
Isotope scanning,8 although relia
ble, is cumbersome in the operating
room. It could be more informative in
the recovery period in questionable
cases. Surface temperature determina
tions and dye injection are generally
considered unreliable. Measurements
of stump pressure and the inferior
mesenteric artery systolic ratio have
been found helpful59 and are good
predictors of adequate colonic perfu
sion when the stump pressure exceeds
40 mm Hg or when the ratio exceeds
0.4:1.
These measurements can be diffi
cult to obtain, however, particularly
in aneurysmal disease where the in
ferior mesenteric artery at its origin is
occluded in 45% of cases.
Mucosal pH measurement with in
traluminal balloon catheters in the
colon, as described by Fiddian-Green
and associates,10 is a sensitive and
reliable means of assessing and pre
venting ischemic colitis. However, it
is also cumbersome and is unlikely to
be available outside tertiary or quater
nary care hospitals.
Thus, we need instrumentation that
is sensitive, reliable, inexpensive, not
time-consuming and readily available
in regional hospitals where aneurysm
surgery is usually carried out.
The pulse oximeter is standard
equipment for the anesthetist in any
hospital likely to undertake aortic sur
gery. It accurately measures pulsatility
and oxygen saturation and, although
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normally attached to an appendage
such as finger or nose, it readily
adapts to the surface of the colon or
small bowel.
Once the pulse oximeter is calibrat
ed by the anesthetist at the start of
surgery, movement of it between the
finger and colonic surface back to the
digit will not change its accuracy.
Under normal circumstances of ade
quate perfusion, the recordings made
by the anesthetist should mimic those
obtained from the colon or small bow
el. The oximeter probe is placed in a
sterile sleeve and is passed into the
operative field to be attached to the
segment of bowel in question. Arterial
pulsatility and transcolonic oxygen
saturation can be measured before
and after aortic reconstruction or dur
ing temporary clamping of the inferi
or mesenteric artery or iliac vessels.
Ouriel and colleagues11 described
their findings using this technique in
30 consecutive patients who under
went aortic reconstruction. In two
patients who demonstrated loss of
pulsatility with unmeasurable transco
lonic oxygen saturation but without
signs at surgery of impaired perfusion
in the colon, classic evidence of mu
cosal ischemic changes was seen on
colonoscopy and clinical signs of mild
colitis were noted in the postoperative
period. This test, although carried out
in a small group of patients, appeared
to be accurate in predicting viability
of the colon and the need for revascu
larization of the patent inferior mes
enteric artery.
Protocol for Identifying the Potentially
Ischemic Colon

If one could reliably identify the
subset of patients who, depending on
inferior mesenteric artery blood flow,
are clearly at particularly high risk for
ischemic colitis, selective inferior
mesenteric artery revascularization
could be performed and adequate co
lonic perfusion restored in this group
of patients.
The following protocol is suggested.
• Preoperative ultrasonography,
which generally has routinely been
done, should be followed by comput
ed tomography or magnetic resonance
imaging in the case of an aortic aneu
rysm, with angiography being added
in selected cases. Angiography clearly
is obtained in all cases of aortoiliac
disease but must in addition show
details of the superior mesenteric ar
tery.
• Patients with aneurysms who do
not undergo angiography should have
duplex scanning of the origin of the
superior mesenteric artery.

At the time of aortic reconstruction
when the possibility of colonic isch
emia is present, several options are
available but are not necessarily
equally desirable.
• First, one may proceed with
reimplantation of the inferior mesen
teric artery. This increases the operat
ing time and adds the risk of anasto
motic complications. It is an ap
proach that I do not believe is justi
fied as a routine add-on procedure.
My belief has been confirmed by the
Canadian Aneurysm Study.12
• Second, one may ignore the pos
sibility of colonic ischemia and pro
ceed with aortic reconstruction. If the
colon is not going to be assessed and
monitored during surgery, colonos
copy should be carried out routinely
in the postoperative period.
• Third, my own preference is to
either measure inferior mesenteric
stump pressure or use the pulse oxi
meter to assess perfusion. If colonic
perfusion is adequate, the primary
aortic procedure may be performed. If
the hypoperfusion of the colon is
confirmed, the inferior mesenteric ar
tery should be reconstructed using
one of several well-established methods.4’6'9
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Methyldopa Hypersensitivity Can Mimic
Acute Toxic Enterocolitis
The most widely known hypersensitiv
ity reaction of methyldopa, a drug
commonly used in the treatment of
hypertension, is seroconversion to a
positive result of a direct Coombs' test
that may lead to a hemolytic anemia.
The authors report a case of an infre
quently noted, but serious, hypersensi
tivity reaction to methyldopa, mani
festing primarily as acute toxic entero
colitis. A 63-year-old woman was ad
mitted to hospital and underwent ag
gressive and prolonged investigation of
enterocolitis. Withdrawal of methyl
dopa gave immediate relief of intesti
nal problems. Rechallenge precipitated
a return of symptoms within 14 hours.
It is recommended that periodic blood
counts and liver function tests be done
on patients treated with methyldopa
for hypertension. If any abnormalities
are noted the drug should be discontin
ued.
La reaction d'hypersensibilite le mieux
connu de la methyldopa, un medica
ment couramment utilise dans le traitem ent de I'hypertension systolique,
est I'induction d'un test direct de
Coombs positif, resultat qui peut conduire a une anemie hemolytique. Les
auteurs signalent le cas d'une reaction
d'hypersensibilite a la methyldopa,
reaction rarement observee mais
serieuse qui se manifeste principalement par une enterocolite toxique aigue. Une femme de 63 ans, fut hospitalisee pour des examens pousses et
prolonges des causes de I'enterocolite.
L'arret de la methyldopa a entrafne un
soulagement immediat des problemes
intestinaux. Une nouvelle exposition a
precipite le retour des symptomes en
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moins de 14 heures. II est recommande de soumettre les patients traites a
la methyldopa pour hypertension a des
numerations cellulaires et a des epreuves fonctionnelles hepatiques periodiques. Si des anomalies sont observees, la medication doit etre interrompue.

C urrent management regimens for ar
terial hypertension may include the
use o f methyldopa, alone or in combi
nation with other antihypertensive
m edications. The most commonly re
ported hypersensitivity reaction asso
ciated with this drug is seroconver
sion, giving a positive direct Coombs’
test result in 20% o f patients, which
may lead to hemolytic anemia in
0.02% o f cases.1
M ethyldopa may rarely cause hy
persensitivity reactions such as fever,
hepatitis, colitis, pancreatitis and
m yocarditis,1 reactions that are infre
quently noted in standard references
and hence can be overlooked. As a
result, patients may undergo extensive
and unwarranted clinical investiga
tions. We report a case of methyldopa
hypersensitivity.
Case Report
A 63-year-old woman was admitted to
the general surgical service of the Toronto
General Hospital with a provisional diag
nosis of acute enterocolitis. She had been
receiving antihypertensive (nadolol) and
thyroid supplement (L-thyroxine) medica
tions until 1 month before admission with
no adverse effects. Because of an upper
respiratory tract infection, erythromycin
ethylsuccinate was prescribed. Bronchospasm became an increasing problem, ne
cessitating sustained-release theophylline
(200 mg twice daily) and methyldopa (250
mg twice daily) and withdrawal of the
nadolol. The patient’s respiratory symp
toms resolved and the theophylline was
discontinued. Two weeks after the first
dose of methyldopa, she experienced diar
rhea, vomiting, undulating fever, chills and
debilitating headaches. These symptoms
persisted for 10 days and she returned to
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the hospital. On readmission her vital
signs were within normal limits, except for
mild pyrexia (38°C orally). There was
generalized abdominal tenderness but no
other evident abnormalities. Notable labo
ratory findings included eosinophilia 0.17
X 109/L (normal 0.01 to 0.06 X 109/L) and
an increased alkaline phosphatase level of
118 U/L (normal less than 80 U/L). Stan
dard abdominal x-ray films revealed a
large amount of air scattered throughout
the intestinal tract, compatible with a diag
nosis of paralytic ileus. Appropriate stool
cultures grew no important pathogens. In
particular there was no Clostridium diffi
cile toxin. Proctosigmoidoscopy, abdomi
nal ultrasonography and barium c~enia
examinations gave normal results. In hos
pital, the patient continued to have undu
lating fever with a body temperature
reaching 40°C, chills, persistent vomiting
and diarrhea. Because of a transient drop
in her blood pressure, below 100 mm Hg
systolic, methyldopa was withheld. For the
first time since admission her chills and
fever abated. The methyldopa was discon
tinued with subsequent resolution of the
nausea and diarrhea. After 5 days the
patient enjoyed good health. We were sus
picious of a drug reaction so a test dose
(250 mg) of methyldopa was administered
to the patient, with a return of acute
nausea, chills, fever and abdominal dis
comfort within 14 hours. She was dis
charged, free of symptoms, on hospital day
14.

Discussion
Fever with m ethyldopa has been
reported to occur in approxim ately
3% o f patients receiving the drug.1 It
usually develops within the first 3
weeks o f therapy, and in some cases is
associated with eosinophilia and ab
norm al results o f one or m ore liver
function tests (e.g., serum alkaline
phosphatase, serum transam inases, bi
lirubin and prothrom bin tim e).2 Our
patient dem onstrated fever and liver
function abnorm alities in addition to
a pronounced eosinophilia.
There are reports o f m ethyldopa
causing colitis and prolonged diar
rhea, but fever has not been noted in
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these cases.3-4 An extensive review5
from the Swedish Adverse Reaction
Reporting Program in 1978 summa
rized reactions to methyldopa report
ed over a 10-year period. In this
review, 159 patients had a fever; of
these, 13 had moderately elevated
serum transaminase levels, 8 skin
manifestations, 4 gastrointestinal
complaints and 2 had eosinophilia.
Gastrointestinal symptoms were re
ported in another 17 patients, diar
rhea being the most common com
plaint. The onset of fever within 3
weeks of drug administration was also
noted. The temperatures were high
and returned to normal within a cou
ple of days of discontinuing methyl
dopa therapy. Several patients under
went provocative tests and fever de
veloped within 12 hours of drug ad
ministration.5 Our patient demon
strated a combination of these clinical
events. She was also challenged with
the drug and her symptoms recurred
within 14 hours.
The occurrence of serious adverse
reactions with methyldopa is low, but
they may cause serious morbidity,
unwarranted investigations and result
in hospitalization. Rapid recovery
after drug withdrawal is the rule, al

though deaths have been reported due
to severe hemolysis or liver failure.
When methyldopa is used to treat
hypertension, periodic blood counts
and liver function testing are manda
tory. If jaundice or abnormalities of
liver function are noted, the drug
should be discontinued. The onset of
fever and enterocolitis within 3 weeks
of initiation of methyldopa therapy
should alert the physician to the pos
sibility of an adverse drug reaction.
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SESAP V Question
112. Overwhelming sepsis after splenectomy has been recognized since 1952.
Which of the following statements about this phenomenon is NOT true?
(A) Progression from onset to death may occur in a matter of hours

* T

(B) Most fatal episodes occur less than two years after splenectomy

W A

(C) Pneumococci have been isolated in approximately 50% of the fatal
cases.
(D) Patients who have had their spleen removed for hematologic
disease have a greater risk for overwhelming sepsis than those who
have splenectomy for trauma
(E) Postsplenectomy sepsis has not been reported in patients with
splenosis or accessory spleens
For the critique of Item 112 see page 194.
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(Reproduced by permission from S PS A P V Syllabus; Surgical Education and
Self-Assessment Program No. 5. For enrolment in the Surgical Education and
Self-Assessment Program No. 5, please apply to the American College of
Surgeons, 55 East Erie St., Chicago, IL 60611.)
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Primary Resection and Anastomosis of Lesions
Obstructing the Left Colon
It is becoming apparent that primary
resection and anastomosis of the left
colon for colonic obstruction is a feasi
ble operation.
This paper reviews 7 5 0 colonic re
sections at the Queen Elizabeth Hospi
tal of Montreal, of which 4 0 were
performed on unprepared bowel in pa
tients with obstructed left colonic le
sions.
The pre- and postoperative hospital
stay was greatly reduced. The death
rate was 5% and complication rate
40%. Follow-up results suggest this
procedure is safe and that an adequate
cancer operation can be carried out. It
should be stressed that not all ob
structing left colonic lesions can be
treated with a one-stage procedure
and that the Hartmann procedure or a
protective colostomy can always be
used if the situation warrants it.

Dans les cas d'obstruction colique, il
semble maintenant possible de pratiquer une resection primaire et une
anastomose du colon gauche.
Cet article passe en revue 750
resections coliques qui ont ete pratiquees a I'Hopital Reine Elizabeth de
Montreal. De ce nombre, 40 cas ont
ete effectues sur des intestins non
prepares, chez des patients souffrant
d'une obstruction colique gauche.
Le sejour hospitalier pre et postoperatoire a ete grandement reduit.
La mortalite fut de 5% et le taux de

From the Department o f Surgery, Queen
Elizabeth Hospital and McGill University,
Montreal, PQ
* Associate Professor of surgery, McGill
University
t Assistant Professor of surgery, McGill
University
Accepted for publication Dec. 21, 1987
Reprint requests to: Dr. R.G. Goodall,
Queen Elizabeth Hospital, 2100 Marlowe
Ave., Montreal, PQ H4A 3L6

complications de 40%. Les controles
ulterieurs indiquent que cette inter
vention est sure et qu'elle perm et de
realiser une chirurgie anticancereuse
satisfaisante. On doit souligner qu'une
intervention en un seul temps ne peut
pas etre realisee dans tous les cas
d'obstruction colique gauche et qu'une
operation de Hartmann ou une colostomie de protection peuvent toujours
etre utilisees quand la situation
I'exige.

The treatment of left colonic lesions
by a staged procedure is tedious and
time-consuming. Moreover, the 5-year
survival rate1 is very low (16%).
Treatment by extended right hemico
lectomy,2 subtotal colectomy or total
colectomy3-4 is radical, the procedures
requiring considerable skill and resec
tion of a great deal of normal colon in
most cases. The argument that the
terminal ileum has a richer blood
supply than the colon may be true,
but results still show that a considera
ble number of leaks occur. Fielding
and Wells5 reported that patients with
primary resection had a higher 5-year
survival than those with staged resec
tions.
In the 6 years 1981 to 1986, 750
colonic resections were performed at
the Queen Elizabeth Hospital in Mon
treal. Of these, 40 were emergency
primary resections with anastomosis
for obstruction or ruptures of the left
colon. It should be noted that not
every case was treated this way; in 12
cases the Hartmann procedure6 was
used and in 8 others a protective
colostomy was performed when the
anastomosis or some other condition
made this seem more prudent.
Indications and Contraindications
We believe that all patients with
obstructive lesions of the left colon
should be considered possible candi
dates for primary resection and anas
tomosis with the following exceptions:
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• Those with systemic disease.
(a) Severe medical disease that
would not allow a further 45 minutes
of surgery.
(b) Prolonged steroid therapy.
(c) Inflammatory bowel disease.
• Those with local problems in the
pelvis and sigmoid colon that pre
clude mobilization of the rectum and
sigmoid.
(a) Diffuse metastases in pelvis.
(b) Phlegmonous diverticulitis.
(c) Previous radiotherapy.
(d) Ischemic changes of bowel.
(e) Necrotic sigmoid volvulus.
Patients
This series consisted of 40 patients
(26 women, 14 men) between the ages
of 34 and 93 years (average 67.9
years) (Table I).
Of the 40 patients, 30 had carcino
ma, 9 diverticulitis and 1 necrotic
volvulus of the sigmoid. In three cases
there were associated perforations and
in two an abscess was present. The
stages of the 30 carcinomas were 14
Dukes’ B, 8 Dukes’ C and 8 Dukes’
D.
Preoperative Assessment
In addition to nasogastric suction
and intravenous therapy, appropriate
preoperative x-ray films were ob
tained and laboratory investigations
carried out. The lower rectum was
emptied by gentle enemas and the
colon assessed either using a flexible
sigmoidoscope or by colonoscopy to
confirm the level of the lesion and to
obtain a biopsy if possible. Barium
Table 1— A ge o f th e 4 0 Patients in th e S tu d y
A ge, yr

No.

3 0 41 51 61 71 81 -

40
50
60
70
80
90

91 -

10 0

1
5
8
12
9
4

1

I
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enema examination was done only if
the diagnosis could not be made by
colonoscopy. Most patients were
taken to the operating room within 48
hours of admission.
Many antibiotics were used perioperatively in the early cases, including
combinations of gentamicin, clin
damycin, Flagyl and tobramycin. The
last 16 patients were given cefoxitin
(2 g intravenously on call to the oper
ating room and then postoperatively
every 6 hours for 5 days) and this has
proved satisfactory.
Operative Technique
Under general anesthesia, the pa
tient is placed in a modified lithoto
my position and the rectum examined
to make sure it is clean and empty. If
fluid is present a rectal tube is put in
place.
The appropriate segment of colon
containing the lesion is mobilized.
The colon distal to the tumour is then
transected and a swab placed in the
lumen to prevent leakage. A large
rectal tube is inserted through a dou
ble pursestring suture placed in the
proximal distended colon close to the
tumour and attached to suction. Copi
ous amounts of normal saline are
used to empty the proximal bowel as
much as possible. The distended
colon above the tumour is milked
proximally with the fingers. When the
resection area is empty, pressure is
applied by the thumb and index finger
to occlude the fragile bowel. A clamp
is then placed across the colon just
proximal to the double pursestring
suture holding the rectal tube. The
anterior surface of the colon is opened
proximal to the clamp and Gelfoam
rapidly packed into the lumen to
avoid any spillage. We have found
this most effective in keeping the
anastomotic area clean. The decom
pressed proximal lumen is then anas
tomosed to the distal lumen. If any
doubt exists as to the integrity of the
anastomosis, the peritoneal cavity can
be flooded with saline and the rectum
distended with air using a bulb sy
ringe. The Gelfoam will obstruct the
lumen proximal to the anastomosis to
Table II— C o m p lic a tio n s
C o m p lic a tio n

N o.

U r in a r y o b s tru c tio n or in fe c tio n

4

W o u n d in fe c tio n

3

A te le c ta s is or p n e u m o n ia

3

S m a ll-b o w e l o b s tru c tio n

2

W o u n d d eh iscen ce

1

M y o c a rd ia l in fa rc tio n

1

D e e p -v e in th ro m b o s is

1

R e n a l failure

1
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allow good assessment of any air leak.
The Gelfoam passes with the first
bowel movement. Before abdominal
closure, the peritoneal cavity is irri
gated with large quantities of normal
saline until clean. The abdomen is
usually closed without drainage but if
a Hemovac drain is necessary it is
removed within 48 hours. Skin clo
sure depends upon the extent of con
tamination, but usually it is wise to
leave the skin open, with sutures
placed ready for closure later. A single
gauze pad soaked in 3% saline is
placed in the open wound.
In 20 patients whose wound was
closed primarily, 3 had wound infec
tions. In 20 others the wound was left
open and closed 5 days postoperative
ly with no infection.
The mean operating time was 109
minutes.
Postoperative Care
All patients were managed by naso
gastric suction, intravenous adminis
tration of fluids, sedation and Foley
catheterization. They were kept in the
intensive care unit on average for 48
hours. Antibiotic coverage with cefox
itin, 2 g intravenously every 6 hours
for 5 days, gave excellent results. The
wound was cleansed with 3% saline
three times daily, and moist gauze
was left in the open wound. Patients
were mobilized as rapidly as possible.
The Foley catheter on average was
removed between day 2 and day 5,
depending on the patient’s condition.
Wound closure was usually on day
5 and the patient was discharged
home on day 7 or 8 if there were no
complications. The mean postopera
tive stay in our series was 14.6 days.
Extent of Resection
Of our 40 patients 6 underwent left
hemicolectomy, 26 sigmoid resection,
6 rectosigmoid resection (below 18
cm) and 2 subtotal colectomy. One
subtotal colectomy was for a synchro
nous carcinoma of the cecum and
obstructing sigmoid lesion. On sig
moidoscopy, this patient was noted to
have a polyp in the rectum, and we
thought subtotal colectomy was the
appropriate treatment. The second
case was an obstructing carcinoma of
the sigmoid with perforation of the
cecum.
Complications (Table II)
There were two deaths. An
84-year-old man suffered a myocardi
al infarction on postoperative day 7,
followed by renal failure, and he died

on day 11. The second was a weak,
senile, 89-year-old man who had ne
crotic volvulus of the sigmoid. A
wound infection, dehiscence and
pneumonia developed and he died
when treatment was withdrawn at his
family’s request.
Of the other complications, the
four cases of urinary obstruction or
infection probably occurred because
the Foley catheter was withdrawn too
soon in these elderly men. The two
patients with small-bowel obstruction
both required surgery. Of note is that
five of the complications occurred in
the two patients who died.
Comments
Disparate diameter of bowel lumen
was not a problem in our series as the
lumen rapidly returns to reasonable
dimensions following decompression
and irrigation of the bowel. Necrotic
sigmoid volvulus is associated with a
very poor result in our hands and
requires further assessment.
From our study it would seem that
in patients with lesions obstructing
the left colon, resection with primary
anastomosis can be performed with a
reasonable death rate of 5%. Many of
these patients are elderly and would
have a hard time enduring two or
three procedures. The morbidity of
40% could be lowered by leaving all
wounds open. Cefoxitin is satisfactory
for controlling sepsis. Gelfoam
packed in the proximal lumen will
avoid spillage in the obstructed colon
after decompression by irrigation.
The Gelfoam passes through the anas
tomosis with little problem. However,
not all cases of left colonic obstruc
tion are suitable for a one-stage opera
tion, and the Hartmann procedure or
a protective colostomy are still some
times indicated.
References
1. O hman U: Prognosis in patients with obstructing
colorectal carcinoma. Am J Surg 1982; 143: 742-747
2. Morgan w p , J enkins n , Lewis p , et al: Manage
ment of obstructing carcinoma of the left colon by
extended right hemicolectomy. Am J Surg 1985; 149:
327-329
3. G lass RL, Smith LE, Cochran RC: Subtotal colec
tomy for obstructing carcinoma of the left colon. Am J
Surg 1983; 145: 335-336
4. hughes ES, Mc D ermott f t , P olglase a l , et al:
Total and subtotal colectomy for colonic obstruction.
Dis Colon Rectum 1985; 28: 162-163
5. FIELDING LP, Wells BW: Survival after primary and
after staged resection for large bowel obstruction
caused by cancer. Br J Surg 1974; 61: 16-18
6. Marien B: The Hartmann procedure. Can J Surg
1987; 30: 30-31

VOLUME 31, NO. 3 MAY 1988 /THE CANADIAN JOURNAL OF SURGERY

cost effective
prophylactic
alternative

in contaminated
or potentially
contaminated
gastro-intestinal
surgery
Claforan .. was superior
in preventing infectious
morbidity and side effects
and reduced hospital
drug costs compared
directly with multidose
regimens of cefazolin
or cefoxitin (p value not
statistically significant)
Dr. R.N. Jones
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Action
In vitro studies indicate that the bacterial action of CLAFORAN (cefotaxime sodium)
a semi-synthetic cephalosporin antibiotic, results from inhibition of cell wall
synthesis.
Indications and Clinical Uses
Treatm ent: CLAFORAN (cefotaxime sodium) may be indicated for the treatment
of infections caused by susceptible strains of the designated micro organisms
in the diseases listed below.
Lower respiratory tract in fe c tio n s : pneumonia and lung abscess caused by
Streptococcus pneumoniae (formerly Dipiococcus pneumoniae), other streptococci
(excluding enterocci, e.g. S. faecalis), Straphylococcus aureus (penicillinase and
non-penicillinase producing), Escherichia coli, Hemophilus influenzae, (including
ampicillin resistant strains) and unspecified Klebsiella species.
U rinary tract in fe c tio n s: caused by Escherichia coli, unspecified Klebsiella
species (including K. pneumoniae), Proteus mirabilis, indole positive Proteus, Serratia marcescens and Staphylococcus epidermidis. Also, uncomplicated gonor
rhea caused by N. gonorrhoeae including penicillin resistant strains.
Bacteremia / S e p tice m ia : caused by Escherichia coli, unspecified Klebsiella
strains and Serratia marcescens.
Skin in fe c tio n s : caused by Staphylococcus aureus (penicillinase and non
penicillinase producing, S. epidermidis, Group A streptococci, Escherichia coli,
Proteus mirabilis and indole positive Proteus.
Intra-abdominal infections: caused by Escherichia coli, and unspecified Kleb
siella species.
Gynecological infe c tio n s: including pelvic inflammatory disease, endometritis
and pelvic cellulitis caused by E. coli, Group A streptococci and Staphylococcus
epidermidis, anaerobic bacteria including unspecified Peptococcus and Peptostreptococcus strains and some strains of Bacterotdes fragilis. In several cases, although
clinical cures were achieved, bacteriological follow-up was not available.
Clinical experience with CLAFORAN in anaerobic infections is limited. CLAFORAN
has been used with some success in wound and intra-abdominal infections against
some strains of unidentified Bacteroides and anaerobic cocci.
CLAFORAN has been shown to be active against some strains of Pseudomonas.
In the treatment of infections encountered in immunosuppressed and granulo
cytopenic patients, results of therapy with CLAFORAN have not been impressive.
CLAFORAN should not be considered in the treatment of enterococcal infections,
i.e. Streptococcus faecalis.
Specimens for bacteriologic culture should be obtained prior to therapy in order
to isolate and identify the causative organisms and to determine their suscep
tibilities to CLAFORAN. Therapy may be instituted before results of susceptibility
studies are known; antibiotic treatment should be re evaluated once these results
become available.
Prophylactic U s e : The administration of CLAFORAN periopeiatively (pieoperatively, intraoperatively and postoperatively) may reduce the incidence of certain infec
tions in patients undergoing elective surgical procedures (eg. abdominal or vaginal
hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified
as contaminated or potentially contaminated.
In patients undergoing caesarian section who are considered to be at increased
risk of infection, intraoperative (after clamping the umbilical cord) and postoperative
use of CLAFORAN may also reduce the incidence of certain postoperative infections
Effective use for elective surgery depends on the time of administration (see Dosage
and Administration).
For patients undergoing gastrointestinal surgery, preoperative bowel preparation
by mechanical cleansing as well as with a non absorbable antibiotic (eg. neomycin)
is recommended.
If there are signs of infection, specimens for culture should be obtained for iden
tification of the causative organism so that appropriate therapy may be instituted.
Contraindications
CLAFORAN is contraindicated in patients who have shown hypersensitivity to
cefotaxime sodium, the cephalosporin or the penicillin groups of antibiotics.
Warnings
Before therapy with CLAFORAN is instituted, it must be carefully determined whether
the patient has had previous hypersensitivity reactions to cefotaxime,
cephalosporins, penicillins or other drugs. CLAFORAN should be given with caution
to patients with Type 1 hypersensitivity reactions to penicillin. Antibiotics, including
CLAFORAN should be administered with caution to any patient who has
demonstrated some form of allergy, particularly to drugs. If an allergic reaction
to CLAFORAN occurs, the drug should be discontinued and the patient treated
with the usual agents (e.g. epinephrine, antihistamine, pressor-amines or
corticosteroids).
Pseudomembranous colitis has been reported with the use of cephalosporins
(and other broad spectrum antibiotics); therefore, it is important to consider its
diagnosis in patients who develop diarrhea during the administration of CLAFORAN.
This colitis can range from mild to life-threatening in severity.
Treatment with broad spectrum antibiotics, such as CLAFORAN, alters the nor
mal flora of the colon and may permit overgrowth of Clostridium difficile or other
Clostridia. It has been established that a toxin produced by Clostridium difficile
is one primary cause of antibiotic-associated colitis.
Mild cases of colitis may respond to discontinuation of CLAFORAN and replace
ment with a suitable specific antibiotic. Moderate to severe cases should be manag
ed with fluid, electrolyte and protein supplementation as indicated. When the colitis
is not relieved by discontinuance of CLAFORAN administration or when it is severe,
an antibiotic specifically effective in antibiotic-associated pseudomembranous colitis
(e.g. vancomycin) or other suitable therapy may be indicated. Other possible causes
of colitis should also be considered (see Adverse Reactions).
Precautions
CLAFORAN (cefotaxime sodium) should be prescribed with caution in individuals
with a history of lower gastrointestinal disease particularly colitis.
The safety of CLAFORAN in pregnancy has not been established. Consequently,
use of the drug in pregnant women requires that the likely benefit from the drug
be weighed against the possible risk to the mother and fetus.
Use of CLAFORAN in women of child-bearing potential requires that the anticipated
benefits be weighed against the possible risks.
Cefotaxime is excreted in human milk in low concentrations. Caution should be
exercised when the drug is administered to nursing mothers.
Prolonged use of CLAFORAN may result in the overgrowth of nonsusceptible
organisms. Constant evaluation of the patient’s condition is essential. If super

infection occurs, therapy should be discontinued and appropriate measures taken.
Although CLAFORAN rarely produces alterations in kidney function, evaluation
of renal status is recommended, especially in severely ill patients receiving high
doses.
Patients with markedly impaired renal function should be placed on the special
dosage schedule recommended under Dosage and Administration, because nor
mal dosage in these individuals is likely to produce excessive and prolonged serum
antibiotic concentrations.
Positive direct Coomb’s test is known to develop in individuals during treatment
with the cephalosporin group of antibiotics, including cefotaxime sodium.
In laboratory tests a false positive reaction to glucose may occur with reducing
substances but not with the use of specific glucose oxidase methods.
Adverse Reactions
The most frequent adverse reactions with their frequency of occurrence are:
Hypersensitivity (1.8%): Rash, pruritus, fever. Local (5%): Injection site inflam
mation with intravenous administration. Pain, induration and tenderness after in
tramuscular injection. Gastrointestinal (1.7%): Colitis, diarrhea, nausea and
vomiting. Symptoms of pseudomembranous colitis can appear during or after
CLAFORAN treatment. H em ic and Lymphatic System ( < 1%): Mild, reversi
ble leukopenia, granulocytopenia and thrombocytopenia have been reported. Some
patients developed positive direct Coomb’s test during treatment with CLAFORAN.
Genitourinary System ( < 1%): Moniliasis, vaginitis. Liver ( < 1%): Transient
elevations in SGOT, SGPT, serum LDH and serum alkaline phosphatase levels
have been reported. Kidney ( < 1%): Increased serum creatinine and BUN have
occasionally been observed. Central Nervous System (0.2%): Headache.
Symptoms and Treatment of Overdosage
Since no case of overdosage has been reported to date with CLAFORAN, no
specific information on symptoms or treatment is available. Treatment of over
dosage should be symptomatic.
Dosage and Administration
CLAFORAN (cefotaxime sodium) may be administered intramuscularly or in
travenously after reconstitution (see Table with recommended mode of reconstitution
according to route of administration).

large muscle such as the upper outer quadrant of the buttock (i.e gluteus maximus); aspiration is necessary to avoid inadvertent injection into a blood vessel.
Intravenous: The intravenous route is preferable for patients with bacteremia,
bacterial septicemia, or other severe or life-threatening infections, or for patients
who may be poor risks because of lowered resistance resulting from such
debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure,
or malignancy, particularly if shock is present or impending.
For bolus administration a solution containing 1 or 2 g of CLAFORAN can be
injected over a period of 3 to 5 minutes Using an infusion system, it may also
be given over a longer period of time through the tubing system by which the
patient may be receiving other intravenous solutions Butterfly* or scalp vein type
needles are preferred for this type of infusion. However, during infusion of the
solution containing CLAFORAN, it is advisable to discontinue temporarily the ad
ministration of other solutions at the same site.
Reg’d TM of Abbott Laboratories.
Reconstitution
For Intram uscular U se : CLAFORAN should be reconstituted with Sterile Water
for Injection or Bacteriostatic Water for Injection in accordance with the volumes
recommended in the following table.
Reconstitution Table

Intramuscular

Guidelines for Dosage of CLAFORAN (cefotaxime sodium)
Daily Dose
Type of Infection
Uncomplicated
Gonorrhea
Uncomplicated
infections
Moderately
severe to severe
infections
Very severe
infections (e.g.
septicemia)
Life-threatening
infections

(g)

Frequency and Route

1

1 g IM (single dose)

2

1 g every 12 hours
IM or IV
1-2 g every
8 hours IM or IV

3-6

6-8

up to 12

2g every
6-8 hours IV
2g every
4 hours IV

To prevent postoperative infection in contaminated or potentially contaminated
surgery, recommended doses are as follows.
(a) 1g IM or IV administered V2 to 1V2 hours prior to the initial surgical incision
to ensure that adequate antibiotic levels are present in the serum and tissues
at the start of surgery
(b) 1 g IM or IV administered IV 2 to 2 hours following the first dose; for lengthy
operative procedures, additional intraoperative doses may be administered, if
necessary, at appropriate intervals (1 1/ 2 to 2 hours) during surgery
(c) 1 g IM or IV administered within 2 hours following completion of surgery
The total cumulative prophylactic dose should not exceed 6 g in a 12 hour period.
Caesarian Section Patients
The first dose of 1g is administered IV as soon as the umbilical cord is clamped.
The second and third doses should be given as 1 g IM or IV at 6 and 12 hours
after the first dose.
Neonates, Infants, and Children
The following dosage schedule is recommended:
Neonates:
0-1 week of age
50 mg / kg IV q 12 h
1-4 weeks of age
50 mg / kg IV q 8 h
Infants and children (1 month to 12 years): For body weights less than 50 kg,
the recommended daily dose is 50 to 100 mg / kg IM or IV of body weight divid
ed into 4 to 6 equal doses, or up to 180 m g/kg/day for severe infections.
For body weights 50 kg or more, the usual adult dosage should be used.
The maximum daily dosage should not exceed 12 grams.
Administration of CLAFORAN should be continued for a minimum of 48 to 72
hours after the patient defervesces or after evidence of bacterial eradication has
been obtained; a minimum of 10 days of treatment is recommended for infec
tions caused by Group A beta-hemolytic streptococci in order to guard against
the risk of rheumatic fever or glomerulonephritis; frequent bacteriologic and clinical
appraisal is necessary during therapy of chronic urinary tract infections and may
be required for several months after therapy has been completed; persistent in
fections may require prolonged treatment. Doses less than those recommended
should not be employed.
Dosage for Patients with Impaired Renal Function
In patients with estimated creatinine clearance of less than 20 mL / min / 1.73m2
the dose of CLAFORAN should be halved (see Precautions).
If serum creatinine values alone are available, the following formula (based on
sex, weight, and age of the patient) may be used to convert these values into
creatinine clearance.
M ales: Weight (kg) x (140 - age) Females: 0.85 x above value
72 x serum creatinine
Administration
Intram uscular: CLAFORAN should be injected well within the body of a relatively

Approximate
Available
Vol. (mL)

Approx. Average
Concentration
(mg/mL)

2
3
5

2.2
3.4
6.0

230
300
330

500 mg vial
1 g vial
2 g vial

'shake to dissolve.
For direct intravenous injection (bolus) and / or continuous intravenous
in fu s io n ; 500 mg, 1 and 2 g vials should be reconstituted with at least 10 mL
of Sterile Water for Injection. Reconstituted solution may be further diluted with
50 to 1000 mL of the fluids recommended for IV infusion.
Reconstitution Table

Dosage
Adults
The dosage of CLAFORAN should be determined by susceptibility of the causative
organisms, severity of the infection and condition of the patient.

Volume to be
Added to
Vial (m L)'

Intravenous
500 mg vial10
1 g vial
2 g vial

Volume to be
Added to
Vial (mL)'

Approximate
Available
Vol. (mL)

Approx. Average
Concentration
(mg/mL)

1 0 .2

50
10.4
11.0

95
180

10
10

'shake to dissolve.
Solutions fo r IV In fu s io n : CLAFORAN is compatible with the following infu
sion fluids:
- Sterile Water for Injection
- 0.9% NaCI injection
- 5% dextrose injection
- 0.9% NaCI and 5% dextrose injection
- 0.45% NaCI and 5% dextrose injection
- 0.2% NaCI and 5% dextrose injection
- Sodium Lactate injection
- 5% dextrose and 0.15% KCI injection
- Plasma-Lyte 56 Electrolyte Solution in 5% dextrose injection
- Ringer's injection
- Lactated Ringer's solution
- Lactated Ringer’s with 5% dextrose injection
CLAFORAN is also compatible with lignocaine 1%.
A solution of 1 g of CLAFORAN in 14 mL of Sterile Water for Injection is isotonic.
Stability of Solution
S to ra g e : Solutions of CLAFORAN range from light yellow to amber, depending
on concentration and the diluent used. The solutions tend to darken depending
on storage conditions and should be protected from elevated temperatures and
excessive light.
"Reg'd TM of Baxter-Travenol Laboratories.
CLAFORAN reconstituted in the original vial as described under Reconstitution
maintains satisfactory potency for 24 hours at room temperature (25°C) and for
48 hours under refrigeration (0-5°C). Only freshly prepared reconstituted solu
tions may be further diluted with 50 to 1000 mL of the recommended infusion
fluids in Viaflex" intravenous bags. Such solutions maintain satisfactory poten
cy for 24 hours at room temperature (25°C) and for 72 hours under refrigeration
(0-5°C). Any unused solutions should be discarded.
CLAFORAN reconstituted with 1% lignocaine maintains satisfactory potency for
up to 24 hours at room temperature and 48 hours under refrigeration (reference
to lignocaine restrictions is advisable).
CLAFORAN solutions exhibit maximum stability in the pH 5-7 range.
Special In s tru c tio n s : Parenteral drug products should be inspected visually
for particulate matter and discoloration prior to administration. Solutions of
CLAFORAN range from light yellow to amber, depending on concentration and
diluent used. The dry powder as well as solutions tend to darken, depending
on storage conditions.
Inco m patibilities: Solutions of CLAFORAN must not be admixed with
aminoglycoside solutions. If CLAFORAN and aminoglycosides are to be ad
ministered to the same patient, they must be administered separately and not
as a mixed injection.
Solutions of CLAFORAN should not be prepared with diluents having a pH above
7.5 such as Sodium Bicarbonate Injection.
Availability
Claforan (cefotaxime sodium) is supplied as a sterile, white to pale yellow powder,
in vials containing 500 mg, 1.0 and 2.0 g of cefotaxime sodium (expressed as
acid on a dry basis).
S to ra g e : CLAFORAN in the dry state should be stored at room temperature,
protected from light and heat.
Product monograph available on request
Reference
Jones R.N. et a l.: Antibiotic Prophylaxis of 1036 Patients Undergoing Elective
Surgical Procedures. The American Journal of Surgery, 1987; 153 : 341-346.
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Treatment of Experimental Peritonitis With Intraperitoneal
Povidone-Iodine Solution
Intraperitoneal lavage with povidoneiodine solution has been reported by
some to be beneficial in the treatment
of peritonitis and by others to cause
local and toxic side effects. In this
study, 200 white mice, divided into
four groups of 50, were subjected to
bacterial peritonitis. The first group
had no treatment; peritoneal lavage
was carried out using povidone-iodine
solution in the second group and a
0.9% sodium chloride solution in the
third. In the fourth group, antibiotics
(clindamycin and gentamicin) were in
stilled intraperitoneally without perito
neal lavage. The povidone-iodine solu
tion had no beneficial effect, the death
rate after 1 week (76%) being similar
to that in the control group (78%) and
much higher than that in mice treated
with sodium chloride lavage (38%) and
antibiotics without lavage (1 6%). A
second series of experiments was,
therefore, carried out to investigate
the toxic effect of povidone-iodine so
lution intraperitoneally on mice with
out peritonitis; the solution was found
to be toxic.
II a ete rapporte par certains que le lav
age intraperitoneal a la povidone-iode
pouvait etre utile dans le traitement de
la peritonite alors que d'autres ont
signale des reactions locales et des
reactions indesirables toxiques.
Dans cette etude, on a provoque une
peritonite bacterienne chez 2 0 0 souris
blanches reparties en quatre groupes
de 50. Le premier groupe n'a recu
aucun traitement; le second groupe a
ete soumis a un lavage de plevre a la
povidone-iode, alors que le troisieme
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groupe recevait un lavage au chlorure
de sodium a 0.9%. Chez le quatrieme
groupe, des antibiotiques (clindamycine et gentamicine) ont ete instilles
dans la cavite peritoneale, mais il n'y a
pas eu de lavage de plevre. La solution
de povidone-iode n'a exerce aucun
effet benefique, la mortalite apres 1
semaine (76%) etant similaire a cede
du groupe temoin (78%) et beaucoup
plus elevee que chez les souris ayant
recu un lavage au chlorure de sodium
(38%) ou des antibiotiques sans lavage
(16%). Une deuxieme serie d'experiences a done ete demarree pour
etudier la toxicite de la povidone-iode
en lavage intraperitoneal chez des
souris qui n'avaient pas de peritonite.
La solution s'est averee toxique.

Peritonitis is responsible for approxi
mately 50% of the deaths from septic
shock. As a treatment for peritonitis,
lavage of the peritoneal cavity with
antiseptic and antibacterial solutions
gives good results.1'2 No clear benefit
has been documented from lavage
with povidone-iodine solution.1-11 Re
cently, this solution has been used
preoperatively in elective colonic sur
gery,35 in the treatment of fungal12
and other infections of the skin13 and
in the treatment of burns,14 and has
been found useful.
We carried out a two-stage experi
ment, first to find out if povidoneiodine solution was of benefit as a
lavage fluid in the treatment of perito
nitis and second to study its toxicity
in this context.
Materials and Methods

With the exception of group 4, each
animal was anesthetized with ether
and subjected to laparotomy 6 hours
after bacterial injection.
Group 1. Only peritoneal biop
sies and cultures were performed.
Group 2. —- In addition to biopsies
and cultures the peritoneal cavities
were lavaged with povidone-iodine di
luted to 1 in 20 with Ringer’s lactate
solution. After lavage, fluid was again
taken from the peritoneal cavity for
culture.
Group 3. The same procedures as
in group 2 were followed using sodi
um chloride (0.9%) as the lavage solu
tion.
Group 4. No laparotomy was
performed on these 50 mice. They
were treated with 40 mg/kg clin
damycin and 8 mg/kg gentamicin di
vided into two equal doses over 24
hours.
The mice were followed up for 2
weeks. When one died, its peritoneal
cavity was cultured and biopsies were
taken from the liver, mesentery and
small intestine. All biopsies were ex
amined under the light microscope.
Stage 2
Twenty healthy mice were subject
ed to laparotomy and their peritoneal
cavities lavaged with the povidoneiodine solution. As a control group,
another 20 mice were subjected to
laparotomy but not lavaged. Iodide
concentrations in the blood, liver and
peritoneum were measured on post
operative days 1 and 2 with a potenti
ometer.
Statistical Analysis
The x2 test was used to calculate
statistical differences; p values less
than 0.05 were considered significant.
—

—

—

Stage 1
Two hundred white mice of both
sexes (mean weight 35 g) were injec
ted intraperitoneally with 0.2 ml of
Findings
Escherichia coli solution.
They were divided into four groups
of 50 each: group 1 control, group 2 Stage 1
povidone-iodine lavage, group 3 sodi
In the mice subjected to laparotomy
um chloride lavage, group 4 antibiot
E. coli was identified in all cultures
ics but no lavage.
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FIG. 1 — M ortality in mice with perito
nitis after 2 weeks. N S = sodium chloride,
PVI = povidone-iodine.

taken and in addition to reactionary
ascites the viscera and peritoneum
were hyperemic.
Necrosis and inflammation (rich in
neutrophils, poor in lymphocytes)
were seen in peritoneal biopsies (Fig.
1).

At the end of 1 week, the death
rates in groups 1 to 4 were 78%, 76%,
38% and 16% respectively. Similar
results were noted at the end of week
2 (Fig. 2). The povidone-iodine solu
tion had no positive effect whereas
sodium chloride solution and antibi
otics did. Also, the death rate for
group 2 mice was higher than that of
the group 1 control. The difference
between these two groups was not
significant, but the difference between
group 1 and other groups was.
Cultures from the peritoneal cavi
ties of mice that died grew E. coli and
the liver, small bowel and mesenteric
biopsies showed inflammatory cells
(Figs. 3 to 5).
Stage 2
The death rates in the lavage group
were 40% on day 1 and 45% on day 2
compared with only 10% for both
days in the control group (p < 0.05)
and did not change during a 1-week
observation period.
At the end of day 1 iodine values
had increased twofold in blood and
approximately sevenfold in the liver
and peritoneum of mice lavaged with
the povidone-iodine solution. These
values returned to normal by the end
of day 2 (Fig. 6).
Discussion

Identification of the source and
170

FIG. 3 — Inflammatory cell infiltration in liver (hematoxylin and eosin, X 100).

type of bacterial and chemical con
tamination is of prime importance
in the treatment of peritonitis.1 The
systemic administration of antibiot
ics, fluid and electrolytes, decompres
sion of the gastrointestinal system and
peritoneal lavage with antibiotics and
antibacterial agents are also recom
mended.1'26'11
The use of the povidone-iodine so
lution as a peritoneal lavage fluid is
still debatable; some recommend it,
others condemn its use because of its
local and toxic side effects.1 7'15-18
Gilmore and colleagues2’56 reported
that povidone-iodine solution yielded
good results with no toxicity in both
their clinical and experimental
studies. Other reports noted that la
vage with povidone-iodine decreased
the number of deaths, reduced wound
infection and had no side effects,
especially in the treatment of fecal
and purulent peritonitis.79'12 It is still
used in the treatment of burn pa
tients.14
McAvinchey and colleagues19 in

their study using peritoneal irrigation
in the treatment of peritonitis in rats
found the death rates were 90%, 60%
and 0% in the povidone-iodine, con
trol and metronidazole plus amikacin
sulfate groups respectively. In the first
stage of our study, at the end of week
1 the death rates were 78% in the
povidone-iodine group, 76% in the
control group, 38% in the sodium
chloride and 16% in the antibiotic
groups. One week later these rates
were 82%, 76%, 48% and 30% respec
tively. Consequently, it can be said
that the povidone-iodine solution had
no beneficial effect in our study.
Ahrenholz1 found that povidoneiodine lavage caused chemical burns
in the peritoneal cavity and had a
toxic effect not only on bacteria but
also on peritoneal cells.
Lineaweaver and colleagues20 inves
tigated the effects of 1% povidoneiodine, 0.25% acetic acid, 3% hydro
gen peroxide and 9.5% sodium hypo
chlorite on wound healing. They
found that all these solutions exerted
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FIG. 6 — Iodide concentrations (ng/ml)
in blood (-----------), peritoneum (—•—•—)
and liver ( ° — ° — °).
FIG. 4 — Inflammatory cells in intestine (hematoxylin and eosin, X 40).

FIG. 5 — Inflammatory cell infiltration in mesentery (hematoxylin and eosin, X 100).

toxic effects on fibroblasts (povidone- povidone-iodine solution as a perito
iodine caused a 25% to 30% cell neal lavage fluid, found that the blood
death).
iodide concentrations showed a nine
Mathews and colleagues18 investi fold increase in 24 hours.
In our experiment the death rates
gated various concentrations of povi
done-iodine in the treatment of fecal were high in mice with or without
peritonitis in rats, using 0.1%, 0.5%, peritonitis, when they were treated
1.0% and 5.0% solutions and reported with the povidone-iodine solution.
death rates of 66%, 22%, 78% and We believe this was due to toxic side
100% respectively. They also found an effects; the maximal iodide concentra
83% death rate with normal saline tions in the various tissues during the
solution. These findings are compara first 2 days, when death rates were the
ble to ours. They also stated that as highest, supports this view.
the number of abdominal lavages with
From our findings in this experi
iodine solution increased, so did the ment, we conclude that povidonenumber of deaths.
iodine solution is not recommended
In the second stage of our study, in the treatment of bacterial peritoni
mice lavaged with povidone-iodine tis because of its toxicity and associat
solution displayed a twofold iodide ed high death rates.
concentration in the blood and a seven
fold increase in the peritoneum and
the liver on postoperative day 1.
We thank Sedat Torel for his assistance
Sindelar and colleagues,8 using the in the English translation of this paper.
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Multiorgan Failure in Critically III Patients
Of 1136 patients admitted consecu
tively to tw o medical-surgical inten
sive care units, 100 were found to
have multiorgan failure, defined as fail
ure of more than two organ systems.
The average duration of stay in the
intensive care units was 13.4 days.
The overall death rate was 78% com
pared with 12.8% for patients without
multiorgan failure. The most common
initiating illnesses or insults were sep
sis, surgery, accidental trauma and
cardiogenic shock. Of potential risk
factors studied, shock, sepsis, surgery,
pre-existing organ disease and age
over 65 years were the most common.
Although sepsis occurred before or
during the course of multiorgan failure
in 7 8 patients, in only 34 was sepsis
judged to be the prime insult leading
to muitiorgan failure. Surgery during
the course of multiorgan failure had
neither an adverse nor beneficial effect
on outcome. The mean number of
organ systems failing was 4 .36 for
survivors and 5.03 for nonsurvivors.
The most common systems to fail
w ere central nervous, cardiovascular
and respiratory.

Sur 1136 hospitalisations consecutives a deux unites de soins intensifs
medico-chirurgicaux, 100 patients
souffraient d'une defaillance plurifonctionneile definie comme I'insuffisance
de plus de deux organes. La duree
moyenne du sejour aux soins intensifs
a ete de 1 3 .4 jours. La mortalite globale fut de 78% comparativement a
1 2.8% pour les patients qui n'etaient
pas atteints de defaillance plurifonctionnelle. Les maladies ou lesions causales les plus frequentes etaient la
sepsie, la chirurgie, les traumatismes
et le choc cardiogenique. Parmi les
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facteurs de risque etudies, le choc, la
sepsie, la chirurgie, une maladie organique preexistante et un age superieur
a 65 ans ont ete le plus souvent retrouves. Meme si une sepsie est survenue avant ou durant une defaillance
plurifonctionnelle chez 78 patients, on
juge qu'elle fut la principale cause de
cette defaillance dans seulement 34
cas. La chirurgie pendant une periode
de defaillance plurifonctionnelle paraft
n'avoir eu ni influence benefique, ni
effet indesirable sur I'issue. Le nombre
moyen d'organes defaillants fut de
4 .3 6 pour les survivants et de 5.03
pour ceux qui sont decedes. Les systemes les plus souvent touches ont ete
les systemes nerveux central, cardiovasculaire et respiratoire.

Many patients with serious illnesses,
previously the cause of death, are now
cured by modern intensive care tech
niques. The course of critical illness is
frequently dictated by the multiorgan
failure syndrome (MOFS), which may
be defined as dysfunction of more
than two organ systems.1 It is associ
ated with a high death rate, indicating
that current methods of treatment are
inadequate.
Previous studies2^6 have identified
risk factors that influence the devel
opment and outcome of MOFS after a
common insult, such as sepsis. This
report examines a group of patients
with multiorgan failure after a variety
of insults, to determine its prevalence,
initiating factors and prognostic sig
nificance in critically ill patients in
medical-surgical intensive care units,
whether there are causative factors,
such as sepsis, that are common to all
patients with multiorgan failure and
whether appropriate surgical interven
tion affected survival.
Patients and Methods

The charts of all patients admitted
over a 1-year period to the combined
medical-surgical intensive care units
at University and Victoria hospitals,

London Ont., were reviewed. Those
with failure oi more than two organ
systems are the subject of this study.
The patients were divided into
“surgery” and “no surgery” groups.
All patients in the surgery group had a
surgical procedure under general anes
thesia either immediately before or
during MOFS. The “no surgery”
group had no operative procedure
either before or during MOFS.
The criteria for organ failure are in
agreement with those used in other
studies.1-5’7
Pulmonary failure was defined by:
a fall in arterial oxygen tension to less
than 50 mm Hg on room air, the need
for mechanical ventilation for longer
than 48 hours because of hypoxemia
or hypoventilation, or radiologic evi
dence of pulmonary edema with a
pulmonary capillary wedge pressure
of less than 18 mm Hg.
Cardiovascular failure was defined
by a cardiac index of less than 2.5
L/min-m-2 with normal or elevated
filling pressures, or dependence on
inotropic drugs to maintain adequate
tissue perfusion as assessed by clinical
criteria.
Renal failure was indicated by a
serum creatinine level of more than
176.8 /imol/L, or double the previous
level if pre-existing renal impairment
was present, or a creatinine clearance
of less than 0.5 ml/s or urine output
less than 30 ml/h over 24 hours,
despite adequate hydration.
Liver failure was defined as a rise
in the serum bilirubin level of more
than 68.4 ^mol/L or the aspartate
aminotransferase to more than twice
the normal level in the absence of
duct obstruction, hemolysis or hepati
tis of viral or toxic etiology.
The criteria for failure of the hemo
poietic system were a platelet count of
less than 50 X 109/L in the absence of
previously documented autoimmune
thrombocytopenia, disseminated in
travascular coagulation documented
by fibrinogen levels of less than 2.0
g/L, fibrin-fibrinogen degradation
products greater than 10 /ug/ml or
positive protamine sulfate test, or a
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equivalent for 5 days or longer, che
motherapy within 1 year, radiothera
py within 1 year, lymphoma or im
mune deficiency syndrome.3
Shock was defined by a systolic
blood pressure of less than 80 mm Hg
for longer than 30 minutes.
Sepsis was indicated by: the pres
ence of appropriate organisms on cul
ture supported by clinical signs of
fever, leukocytosis and physical or
radiologic findings, including findings
at laparotomy (abscess, necrotic bow
el, perforation of a hollow viscus and
peritonitis). Pre-existing organ dys
function was indicated by angina pec
toris, previous myocardial infarction,
congestive heart failure, chronic ob
structive lung disease, chronic renal
failure or biopsy proven cirrhosis.
Mean values of variables were com
pared by unpaired /-tests. Differences
were considered significant at a p
value of < 0.05.

clinical bleeding diathesis as indicated
by spontaneous bleeding from mu
cous membranes or bleeding from
puncture sites.
Gastrointestinal failure was defined
by a patient’s inability to tolerate
enteral feeding in the absence of me
chanical obstruction and excluding an
initial 5-day period after abdominal
surgery, acalculous cholecystitis, pan
creatitis in the absence of gallstones,
trauma or alcohol abuse, or gastroin
testinal bleeding requiring transfusion
of more than two units of packed cells
in 24 hours.
Central nervous system failure was
a decreased level of consciousness
ranging from confusion to coma in
the absence of CNS infection or struc
tural abnormalities.
The initiating illness or insult is
defined as the single most important
life-threatening illness from which the
patient did not recover before the
onset of MOFS.
In our study, risk factors are classed
as those that might influence survival
of MOFS patients; they differ from
initiating factors. Some could not by
themselves cause MOFS (e.g., smok
ing, low serum albumin level) but
would have been present before its
onset; others occurred after the onset
of MOFS. For each patient the follow
ing potential risk factors were record
ed: age greater than 65 years, obesity,
malnutrition, diabetes mellitus, malig
nant disease, alcohol abuse, smoking,
immune suppression, shock, sepsis,
surgery, gastrointestinal bleeding and
pre-existing organ dysfunction.
We defined malnutrition as a
serum albumin level less than 25 g/L,
weight loss of more than 10% within
30 days or more than 20% within 6
months, weight more than 20% below
the ideal body weight or energy intake
of less than 4184 kJ/d for 7 days or
more.3
Criteria for immune suppression
included: continuous steroid therapy
for longer than 30 days, high-dose
steroid therapy of more than 15
mg/kg of methylprednisolone or its

Findings
Incidence
Of 1136 critically ill patients admit
ted consecutively to the two medicalsurgical intensive care units, 100
(8.8%) had MOFS. There were 67
males and 33 females ranging in age
from 6 to 84 years (mean 61.4 years).
There was no significant difference in
age between survivors and nonsurvi
vors. The average duration of stay in
the intensive care units was 13.4 days
(range from 1 to 78 days). Survivors
spent a mean of 20 days in the inten
sive care unit and nonsurvivors a
mean of 12 days (p < 0.0005). The
death rate, when there was failure of
three or more organ systems, was 78%
versus 12.8% in patients without
MOFS.
Initiating Illness or Insult
The primary insult or initiating
event for the MOFS was most com
monly sepsis, followed by surgery,
accidental injury and cardiogenic

shock (Table I). When serious sepsis
occurred with another insult it was
arbitrarily considered to be the initi
ating illness.
Time Sequences
There was no significant difference
in the time interval between the pri
mary insult and the onset of MOFS
between the survivors and nonsurvi
vors (4.4 ± 5.4 days versus 6.6 ± 9.9
days respectively) (p = 7.05). Patients
who died within 24 hours of the
primary insult were excluded from the
study.
The interval between primary in
sult and death was 26.5 ± 25.8 days
and 8.5 ± 6.3 days for the surgical
and nonsurgical groups respectively (p
<

0 . 001 ) .

In 45%, MOFS began within 24
hours of the initial insult; in 11% of
patients MOFS developed more than
2 weeks after the initial insult.
The interval between the primary
insult and death in both groups mani
fested a distinct trend. In thte nonsur
gical group, 38% died within 5 days
after which there was a gradual de
crease in the number of deaths. In the
surgical group there were two peaks:
early, within 5 days of the initial
insult, and late, after 2 weeks. This
includes 30% who died more than 4
weeks after their initial insult.
The majority of patients died with
in 5 days of the development of
MOFS. In the nonsurgical group there
were no deaths after 2 weeks.
Risk Factors
The frequency of potential risk fac
tors is shown in Table II. Shock,
sepsis, surgery, pre-existing organ dis
ease and age greater than 65 years
were most common, in decreasing
order of frequency. Comparison of
survivors and nonsurvivors using x2
analysis showed that malnutrition and
malignant disease were more common
in nonsurvivors (p < 0.05).
Episodes of hypotension were doc-

T a b le 1— P rim a ry In s u lt
N o s u rg e ry , n o . (% )

S u rg e ry , n o . (% )

N o n s u rv iv o rs

S u rv iv o rs

1 7)

(n = 3 5 )

(n = 5 )

11 (2 6 )

5 (2 9 )

1 7 (4 9 )

1 (2 0 )

34

1 8 (4 2 )

5 (2 9 )

0

0

23

N o n s u rv iv o rs
In s u lt

(n = 4 3 )

S epsis
S u rge ry

S u rv iv o rs
(n =

T ra u m a

4

(9)

7 (4 1 )

1

M y o c a rd ia l in fa rc tio n o r h e a rt fa ilu re

2

(5)

0

9 (2 6 )

(3)

T o ta ls

0

12

1 (2 0 )

12

G a s tro in te s tin a l b le e d in g

3

(7)

0

4 (1 1 )

1 (2 0 )

8

H y p o v o le m ic s h o c k

3

(7)

0

0

1 (2 0 )

4

0

1

1 (2 0 )

2

(2)

0

0

0

1

R e s p ira to ry fa ilu re

0

P a n c re a titis

1

M a lig n a n t d isease

0

VOLUME 31, NO. 3 MAY 1988/THE CANADIAN JOURNAL OF SURGERY

(3)
(3)

0

1

0

1
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umented in 90% of patients, making it
the most common risk factor for mul
tiorgan failure. Septic and cardiogenic
shock were the most frequent causes
of hypotension, but hypotensive peri
ods occurred before the development
of MOFS in only 76% of patients.

50%. The two most common locations
of the septic process were bronchopul
monary and intra-abdominal (Table
III). Many patients had more than
one focus or more than one episode of
sepsis.

When intra-abdominal sepsis was
combined with MOFS the death rate
was 84%, and it was 78% (p > 0.05) in
patients who did not have intra
abdominal sepsis. Twenty-five pa
tients with MOFS had intra-abdomi
nal abscesses; all were drained, 22
operatively and 3 percutaneously. De
spite adequate surgical intervention
only four of these patients survived.

who had surgery during the course of
MOFS, it was for “cure” (e.g., drain
age of abscess) in 26 and for other
indications in 18. Comparing the sur
gical and nonsurgical groups by x2
analysis, we found that surgery during
the course of MOFS either for “cure”
or other indications had neither an
adverse nor beneficial effect on out
come. We could not determine the
effect of surgery on outcome in the
patients for whom surgery was indi
cated, because surgical treatment was
never withheld; thus, there was no
control group. Our impressions were
that in surviving patients who had
surgery for “cure”, the intervention
tended to be early in the course of the
syndrome.

Blood Cultures and MOFS

Number o f Organ Systems Failing

Twenty-two of 35 nonsurvivors in
the nonsurgical group had positive
blood cultures; none of the survivors
had positive blood cultures (p <
0.0005 [x2 analysis]). However, in the
surgical group, positive blood cultures
were not necessarily associated with
poor survival.

By entrance criteria, all patients
had failure of more than two organ
systems. Most patients had failure of
four to six organ systems (mean 4.36
for survivors and 5.03 for nonsurvi
vors) (p < 0.05) (Table IV). Cardio
vascular and renal failure were more
common in nonsurvivors than in sur
vivors (p < 0.05).
The most common systems to fail
were the central nervous, cardiovascu
lar and respiratory systems (Table
IV). The respiratory system was most

Intra-abdominal Sepsis With MOFS

Pre-existing Organ Dysfunction
Pre-existing organ dysfunction was
present in 60 of the 100 patients and
the affected organ system was first to
fail in the course of MOFS in 47% of
these cases.
Sepsis
Although sepsis has been widely
implicated as the major cause of
MOFS,2'5-7 we found that in only 34
patients was it the initiating event or
cause of multiorgan failure. To be
considered as the cause of MOFS,
sepsis had to occur before the onset of
any organ failure. In 78% of patients,
sepsis occurred before or during the
course o f multiorgan failure, its fre
quency being similar in both surgical
and nonsurgical groups.
Of 44 surgical patients who had
sepsis, only 22 had the complication
before the onset of MOFS. Thus, even
in the surgery group sepsis cannot be
implicated as a cause in more than

Surgery in MOFS
The role of surgery in treatment of
MOFS was examined. Of 44 patients

T a b le II— P o te n tia l R isk F a c to rs fo r M u ltio rg a n Failure S y n d ro m e (M O F S )
S u rg e ry , no. (% )

N o s u rg e ry , n o. (%)
N o n s u rv iv o rs ,

N o n s u rv iv o rs
R isk fa c to r
Age
O b e s ity
M a ln u tr itio n
D ia b e te s m e llitu s
M a lig n a n t d ise a se

S u rv iv o rs

(n = 4 3 )

(n =

S u rv iv o rs ,

N o n s u rv iv o rs

S u rv iv o rs

n o. (% )

n o. (% )

(n = 3 5 )

(n = 5)

(n = 7 8 )

(n = 2 2 )

T o ta ls
54

1 7)

22

8

20

4

4 2 (5 4 )

1 2 (5 5 )

9

3

6

1

1 5 (1 9 )

4 (1 8 )

19

19

4

17

1

3 6 (4 6 )

5 (2 3 )

41*

9

1

4

0

1 3 (1 7 )

1

(5)

14

12

1

8

0

2 2 (2 8 )

1

(5)

23*

A lc o h o l a b u s e

11

3

13

2

2 4 (3 1 )

5 (2 3 )

29

S m o k in g

16

4

12

1

2 8 (3 6 )

5 (2 3 )

33

Im m u n e s u p p re s s io n
S h o ck

6

0

4

0

1 0 (1 3 )

38

15

34

3

7 2 (9 2 )

(0)

10

1 8 (8 2 )

0

90

S e p sis

33

14

26

5

5 9 (7 6 )

1 9 (8 6 )

78

S u rg e ry

43

17

0

0

4 3 (5 5 )

1 7 (7 7 )

60

24

8

23

5

4 7 (6 0 )

1 3 (5 9 )

60

3

1

4

1

P re -e x is tin g o rg a n
d ise a se
G a s tro in te s tin a l
b le e d in g

7

(9)

2

(9)

9

* p < 0 .0 5 s u rv iv o rs v e rs u s n o n s u rv iv o rs .

T a b le III— F o c i o f S e p s is
S u rg e ry , no. (% )
'lo n s u rv iv o rs
F o cu s

(n = 4 3 )

N o s u rg e ry , n o . (% )

S u rv iv o rs
(n =

N o n s u rv iv o rs

S u rv iv o rs

1 7)

(n = 3 5 )

(n = 5)

11 (3 1 )

P u lm o n a ry

1 0 (2 3 )

4 (2 4 )

A b d o m in a l

18 (4 2 )

4 (2 4 )

3

(9)

T o ta ls

3 (6 0 )

28

0

25

0

14

B lo o d s tre a m

5 (1 2 )

1

C e n tra l lin e s

3

(7)

3 (1 8 )

3

(9)

0

9

S o ft tis s u e /w o u n d s

3

(7 )

2 (1 2 )

4 (1 1 )

0

9

G e n ito u rin a ry

0

3 (1 8 )

1

4 (8 0 )

8

174

(6)

10 (2 9 )

(3)
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frequently the first to fail but was
followed closely by the other two.
The overall death rate associated
with MOFS in patients with more
than two organ system failures was
78.0% (Table V), compared with
12.8% for patients in the intensive
care unit without MOFS.

ease. We did not find a single cause or
abnormal state that was common to
all patients with multiorgan failure;
hypotension came closest as it preced
ed the syndrome in 78% of cases. It
seems clear that multiorgan failure
may be initiated by a wide range of
illnesses or injuries.

Discussion

Sepsis

One would not expect multiorgan
failure to be a feature of untreated
injury or infection, and it was not
described in the past when available
treatment for sepsis and injury was
minimal. Modern treatment prolongs
critical illness and is likely a permis
sive factor that allows time for multi
organ failure to occur. However, in
terventions such as operation, anes
thetics and analgesics, intubations, re
straints and invasive monitoring, may
have a causative role.
Tilney and colleagues8 first de
scribed multiple organ failure follow
ing treatment of patients who had
ruptured abdominal aortic aneurysms.
Since then, MOFS has been associat
ed with intra-abdominal infections,
accidental trauma and surgical proce
dures.25 Most authors have described
multiorgan failure occurring second
ary to one of these initiating factors.
To achieve a broader view, we studied
multiorgan failure in all admissions to
two medical-surgical intensive care
units. In this setting, the initiating
factors are multiple and include sep
sis, accidental trauma, surgical trau
ma, myocardial infarction, hypovo
lemic shock, primary respiratory fail
ure, pancreatitis and malignant dis

Whereas Fry and colleagues5 found
that 95% of patients with MOFS after
emergency laparotomy had sepsis,
Faist and colleagues4 found only 56%.
In our series, sepsis was identified in
78 patients but was the initiating
event in only 34. None the less, clini
cal observation suggests that sepsis
occurring during MOFS contributes
to its progression.
Intra-abdominal sepsis is particu
larly devastating. It was associated
with a death rate of 84% in patients
with MOFS, despite appropriate sur
gical intervention. This high rate has
been noted by others.9*10 Indeed, Fry
and colleagues11 found that organ fail
ure was one of the determinants of
death in patients with intra-abdomi
nal abscess.
Sepsis and Surgical Intervention
Some6*7*10 have suggested that unex
plained development or worsening of
organ failure is due to intra-abdomi
nal sepsis, which may or may not be
evident from clinical signs and local
ization studies. These authors suggest
that “blind” or non-directed laparoto
my in such patients may uncover pus
and therefore improve survival. In the

Table IV— Number of Organ Systems Failing and Associated Death Rates
No. of systems
failing

Nonsurvivors
(n = 78)

Survivors
(n = 22)

Total no.

Death
rate, %

3
4
5
6
7

5
24
19
24
6

6
5
9
1
1

11
29
28
25
7

45
83
68
96
86

5.03

4.36

Mean

series of Ferraris,9 laparotomy in pa
tients with MOFS was associated with
a 52% death rate. Other studies report
much higher death rates. When nondirected laparotomy was performed as
a potentially curative procedure,
death rates were as high as 80% and
100%.10*12 The mortality is also high if
no intra-abdominal cause for MOFS
is found. Death rates of this magni
tude make it difficult to justify blind
laparotomy in MOFS. In our series,
even when surgery was clearly indicat
ed (laparotomy in this group), direct
ed and positive, the death rate was
84%. We concluded therefore that al
though laparotomy is reasonable as a
directed procedure, it is hard to justi
fy as a non-directed procedure. Oth
ers13 have reached the same conclu
sion.
Pre-existing Organ Disease
Pre-existing organ disease may be a
risk factor for multiorgan failure.
Eiseman and associates14 found that
23 of 42 MOFS patients had pre
existing organ disease and that the
diseased organ subsequently failed
during the course of multiorgan fail
ure. In our series, 60 patients had
pre-existing organ disease and in 28
the diseased organ was the first to fail.
However, in 10% of the patients, the
diseased organ was not involved in
subsequent organ failure.
Etiology of MOFS
There has been much speculation
about the underlying etiology of mul
tiorgan failure. Some considered that
sepsis was the predominant factor
while others have implicated shock.
Certainly both are associated with the
syndrome. In our series, all patients
had either sepsis or shock before the
onset of organ failure. Goris and col
leagues15 have suggested that the basic
feature common to all patients with
MOFS is severe inflammation. They
suggest that toxic oxygen radicals re
leased by phagocytes which have been

Table V-— Organ Systems That Failed
Surgery, no. (%)
Organ system
Cardiovascular
Pulmonary
Renal
Hepatic
Blood
Central nervous
Gastrointestinal

No surgery, no. (%)

Nonsurvivors
(n = 43)

Survivors
(n = 17)

Nonsurvivors
(n = 35)

Survivors
(n = 5)

39
39
35
27
23
35
20

10
13
8
13
10
14
12

31
29
28
23
22
34
7

4
4
3
1
1
3
0

Nonsurvivors,
no. (%)
(n = 78)
70
68
63
50
45
69
27

(90)
(87)
(81)
(64)
(58)
(88)
(35)

Survivors,
no. (%)
(n = 22)

Totals

14(64)
17(77)
11 (50)
14(64)
11 (50)
17(77)
12(55)

84*
85
74*
64
56
86
39

*p < 0.05 survivors versus nonsurvivors.
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stimulated as a result o f tissue trau
ma, burns, endotoxin and other
agents are responsible for the picture
of generalized severe inflammation
and remote organ failure. Richards
and colleagues16 have suggested that
fibronectin deficiency is associated
with multiorgan failure.
Conclusions
Multiorgan failure is common
(8.8% incidence) in medical-surgical
intensive care units. Its etiology is
multifactorial. Sepsis and shock are
the most prominent features but are
not always present. The death rate in
patients with failure of three or more
organ systems is 78% compared with
12.8% in critically ill patients without
multiorgan failure. Current methods
o f treatment are inadequate. Surgical
intervention is associated with a very
high mortality even when pus is found
and drained. It is difficult to justify
use of blind or non-directed laparoto
my.
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ACTION
In vitro studies demonstrate that the bacteri
cidal action of cefoxitin, a cephamycin derived
fromcephamycin C, results from the inhibition
of bacterial cell wall synthesis. Evidence
suggests that the m ethoxy group in the
7a position is responsible for the resistance of
cefoxitin to degradation by bacterial betalactamases.
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TREATMENT

The treatment of the following infections when
due to susceptible organisms:
1 - In tra -a b d o m in a l in fe c tio n s such as
peritonitis and intra-abdominal abscess
2 - G y n e c o lo g ic a l in fe c tio n s such as
endometritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratla marcescens and
Serratia spp.)
5 - Lower respiratory tract infections
6 - Bone and jo in t infections caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies
should be performed to determine the sus
ceptibility of the causative organism(s) to
MEFOXIN*. Therapy may be started while
awaiting the results of these tests, however,
modification of the treatment may be required
once these results become available.
O rganism s p a rtic u la rly a p p ro p ria te for
therapy with MEFOXIN* are:
Gram positive

Staphylococci, penicillinase producing and
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactamase producing
and non-producing strains)

E. coli
Klebsiella species (including K. pneumoniae)
Proteus, indole positive and negative
Haemophilus influenzae
Providencia species
Anaerobes

Bacteroides fragilis
MEFOXIN* may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
MEFOXIN* is not active against Pseudomonas,
most strains of enterococci, many strains of
Enterobacter cloacae,
and m ethicillinre s is ta n t s ta p h y lo c o c c i and L is te ria
monocytogenes.
Clinical experience has demonstrated that
MEFOXIN* can be administered to patients
w h o are a lso re c e iv in g c a rb e n ic illin ,
gentamicin, tobram ycin, or amikacin (see
PRECAUTIONS and ADMINISTRATION).
Intravenous Administration

The intravenous route is preferable for
patients with bacteremia, bacterial septicemia,
or other severe or life-threatening infections,
or for patients who may be poor risks because
of lowered resistance resulting from such
d e b ilita tin g c o n d itio n s as m alnu tritio n ,
trauma, surgery, diabetes, heart failure, or
malignancy, particularly if shock is present or
impending.
PROPHYLACTIC USE

MEFOXIN* may be administered perioperatively (preoperatively, intraoperatively and
postoperatively) to patients undergoing
vaginal or abdominal hysterectomy and ab
dominal surgery when there is a significant
risk of postoperative infection or where the
occurrence o f postoperative infection is
considered to be especially serious.
In patients undergoing cesarean section, intra
operative (after clamping the umbilical cord)

and postoperative use ot MEFOXIN* may
reduce the incidence of surgery related post
operative infections.
Effective prophylactic use depends on the
time of administration. MEFOXIN* usually
should be given one-half to one hour before
the operation. Prophylactic administration
should usually be stopped within 12 hours. It
has been generally reported that continuing
a d m in istra tio n of any a n tib io tic beyond
24 hours fo llo w in g surgery increases the
possibility of adverse reactions but, in the
m ajority of surgical procedures, does not
reduce the incidence of subsequent infection.
If signs of postsurgical infection should
appear, specimens for culture should be
obtained for identification of the causative
organism(s) so that appropriate therapy may
be instituted.

CONTRAINDICATIONS
MEFOXIN* is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.

WARNINGS
Before therapy with MEFOXIN* is instituted,
careful inquiry should be made to determine
whether the patient has had previous hyper
sensitivity reactions to MEFOXIN*, cephalo
sporins, penicillins orotherdrugs. MEFOXIN*
should be given with caution to penicillinsensitive patients.
There is some clinical and laboratory evidence
o f p a rtia l c r o s s -a lle rg e n ic ity between
cephamycins and the other beta-lactam anti
b io tics, p e n ic illin s and cephalosporins.
Severe reactions (including anaphylaxis) have
been re p o rte d w ith m ost b e ta-la cta m
antibiotics.
Pseudomembranous colitis has been reported
with virtually all antibiotics. This colitis can
range from mild to life threatening in severity.
Antibiotics should therefore be prescribed
with caution in individuals with a history of
gastrointestinal disease, particularly colitis. It
is important to consider a diagnosis of pseudo
membranous colitis in patients who develop
diarrhea in association with antibiotic use.
While studies indicate that a toxin produced
by Clostridium difficile is one primary cause of
antibiotic-associated colitis, other causes
should also be considered.
Any patient who has demonstrated some form
of allergy, particularly todrugs, should receive
antibiotics including MEFOXIN* with caution.
If an allergic reaction to MEFOXIN* occurs,
administration of the drug should be discon
tinued. Serious hypersensitivity reactions may
require treatment with epinephrine and other
emergency measures.

PRECAUTIONS
The total daily dosage should be reduced
when MEFOXIN* is administered to patients
w ith transient or persistent reduction of
urinary output due to renal insufficiency (see
DOSAGE AND ADMINISTRATION) because
high and prolonged serum antibiotic con
centrations can occur from usual doses.
In patients treated with MEFOXIN* a false
positive reaction to glucose in the urine may
occur with Benedict’s or Fehling's solutions
but not with the use of specific glucose
oxidase methods.
Using the Jaffe Method, falsely high creatinine
values in serum may occur if serum concen
trations of cefoxitin exceed 100 ,ug/mL Serum
samples from patients treated with MEFOXIN"
should not be analyzed for creatinine if with
drawn within two hours of drug administration.
Increased nephrotoxicity has been reported
fo llo w in g co n co m ita n t adm inistration of
cephalosporins and aminoglycoside antibiotics.
The safety of MEFOXIN* in the treatment of
infections during pregnancy has not been
e s ta b lis h e d . If th e a d m in is tra tio n of

MEFOXIN' to pregnant patients is considered
necessary, its use requires that the anticipated
benefits be weighed against possible hazards
to the fetus. Reproductive and teratogenic
studies have been performed in mice and rats
and have revealed no evidence of impaired
fertility or harm to the fetus due to MEFOXIN*.
Cefoxitin has been observed in the milk of
nursing mothers receiving the drug.
Prolonged use of MEFOXIN* may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient's condition
is essential and if superinfection occurs
during therapy, appropriate measures should
be taken. Should an organism become
resistant during antibiotic therapy, another
antibiotic should be substituted.
In children 3 months of age or older, higher
doses of MEFOXIN* (100m g/kg /d a y and
above) have been a sso cia te d w ith an
increased incidence of eo sin o ph ilia and
elevated SGOT.

ADVERSE REACTIONS
MEFOXIN* is generally well tolerated. Adverse
re a ctio n s rare ly req u ire d ce ssa tio n of
treatment and usually have been mild and
transient.
Local Reactions
Thrombophlebitis has occurred with intra
venous administration. Some degree of pain
and tenderness is usually experienced after
in tra m u s c u la r in je c tio n s u s in g w ater.
Induration has occasionally been reported.
Allergic
M aculopapular rash, u rtica ria , pruritus,
eosinophilia, feverand other allergic reactions
have been noted.
Gastrointestinal
Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vomiting have been reported
rarely.
Blood
Transient eosinophilia, leukopenia, neutropenia,
hemolytic anemia, and throm bocytopenia
have been reported. Some individuals, particu
la rly those w ith azotemia, may develop
positive direct Coombs tests during therapy
with MEFOXIN*.
Liver Function
Transient elevations in SGOT, SGPT, serum
LDFI, and serum alkaline phosphatase have
been reported.
Kidney
Elevations in serum creatinine and/or blood
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failure
has been rep o rte d rare ly. T he role of
MEFOXIN* in changes in renal function tests
is d iffic u lt to assess, since fa cto rs pre
disposing to prerenal azotemia or to impaired
renal function have often been present.

TREATMENT OF OVERDOSE
Other than general supportive treatment, no
specific antidote is known. MEFOXIN* can be
eliminated by dialysis in patients with renal
insufficiency.

DOSAGE AND ADMINISTRATION
MEFOXIN* may be administered intravenously
or in tra m u scu la rly when required. (See
complete monograph on ADMINISTRATION
and RECONSTITUTION.)
TREATMENT DOSAGE
Adults
The usual adult dosage is 1 g or 2 g of
MEFOXIN* every 6 to 8 hours. Dosage and
route of administration should be determined
by severity of infection, susceptibility of the
causative organisms, and condition of the
patient. The usual adult dosages are shown in
the Table below.

Usual Adult Dosage
Type of
infection

Daily
Dosage

Frequency
and Route

Uncomplicated
forms* of infections such as
pneumonia,
urinary tract
infection, soft
tissue infection

3-4 g

1 g every 6-8 h
i.V. or I.M.

Moderately
severe or severe
infections

6-8 g

1 g every 4 h
or
2 g every 6-8 h I.V.

Infections
commonly
needing antibiotics in higher
dosage (e.g. gas
gangrene)

12 g

2 g every 4 h
or
3 g every 6 h I.V.

’ Including patients in whom bacteremia is
absent or unlikely
Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infections should be maintained
for at least 10 days to guard against the risk of
rheumatic fever or glom erulonephritis. In
staphylococcal and other infections involving
a collection of pus, surgical drainage should
be carried out where indicated.
Adults with Impaired Renal Function
MEFOXIN* may be used in patients with
reduced renal function but a reduced dosage
should be employed and it is advisable to
monitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given.
After a loading dose, the following recommen
dations for maintenance dosage may be used
as a guide:

pected, an appropriate antibiotic should be
used.
A t present there is in s u ffic ie n t data to
recommend a specific dosage for children
with impaired renal function. However, if the
administration of MEFOXIN* is deemed to be
essential the dosage should be m odified
consistent w ith the recom m endations fo r
adults (see Table above).
PROPHYLACTIC USE
For prophylactic use, a three-dose regimen of
MEFOXIN* is recommended as follows:
Vaginal or abdominal hysterectomy and
abdominal surgery
2 g administered intram uscularly or intra
venously just prior to surgery (approximately
one-half to one hour before initial incision).
The second and third 2g; doses should be
administered at 2-6 hour intervals after the
initial dose.
Cesarean Section
The first dose of 2g should be administered
intravenously as soon as the umbilical cord
has been clamped. The second and third
2 g doses should be given intravenously or
intramuscularly four hours and eight hours
after the first dose.

AVAILABILITY
MEFOXIN* is supplied as sterile powder in
boxes of 10 vials:
3356 Ca - 1 g cefoxitin as sodium salt
3357 Ca - 2 g cefoxitin as sodium salt
Storage
MEFOXIN* in the dry state should be stored
below 30° C.

PRODUCT MONOGRAPH AVAILABLE
ON REQUEST

*®Trademark
RENAL
FUNCTION

Mild
impairment
Moderate
impairment
Severe
impairment
Essentially
no function

CREATININE
CLEARANCE
mL/min

DOSE

FREQUENCY

50-30

1-2 g

every 8-12 h

29-10

1-2 g

every 12-24 h

9-5

0.5-1 g

every 12-24 h

<5

0.5-1 g

every 24-48 h

(425-a,6,87x)

In the patient undergoing hemodialysis, the
loading dose of 1 - 2g should be given after
each hemodialysis, and the maintenance dose
should be given as indicated in the Table
above.
Neonates (Including Premature Infants),
Infants and Children (See WARNINGS for
Neonates under ADMINISTRATION in the
complete monograph.)
Premature Infants
with Body Weights
Above 1500 g

20-40 mg/kg every 12 h I.V.

Neonates

20-40 mg/kg every 12 h I.V.
01 week of age
20-40 mg/kg every 8 h I.V.
1-4 weeks of age
Infants

1 month to 2 years
of age

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

Children

20-40 mg/kg every 6 h or
every 8 h I.M. or I.V.

In severe infections, the total daily dosage in
infants and children may be increased to
200mg/kg, but not to exceed 12 g per day.
MEFOXIN* is not recom m ended fo r the
therapy of meningitis. If meningitis is sus
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Lipomas of the Colon: a Clinicopathologic Review
The authors review their experience
with lipomas of the colon at St. Boni
face General Hospital in Winnipeg,
Man., during the period 1974 to 1985,
and compare their clinicopathologic
evaluation with that reported in the
literature.
Among 1 5 patients (average age
6 6 .7 years), the majority of whom
were women, 17 lipomas were found;
all were submucosal. One-third of the
lesions were symptomatic. The most
frequent symptoms were abdominal
pain, rectal bleeding and a change in
bowel habit. Only one patient had mul
tiple lesions. The right colon was most
frequently affected.
Five patients underwent major co
lonic resection either because the di
agnosis was confused with carcinoma
or because of intussusception. Only
one patient was treated by colotomy
and polypectomy.
Although most lipomas are small
and asymptomatic, tumours larger
than 2 cm tend to produce complica
tions or be confused with carcinoma.

Les auteurs font etat de leur pratique
dans le traitement des lipomes du
colon a I'Hopital general de St-Boniface, a Winnipeg, Manitoba, entre
1 9 7 4 et 1 985. Ms comparent leur eval
uation clinico-pathologique avec celle
qui est decrite dans la presse medicate.
Dix-sept lipomes, tous sousmuqueux, ont ete retrouves chez 15 pa
tients (age moyen 6 6 .7 ans), de sexe
feminin surtout. Le tiers des lesions
etait symptomatique. Douleur abdominale, saignement rectal et modification
du transit intestinal representaient les
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symptomes les plus frequents. Un seul
patient avait des lesions multiples. Le
colon droit etait le plus frequemment
affecte.
Cinq patients ont subi une resection
colique importante, soit parce que le
diagnostic laissait croire a un carcinome, soit a cause d'une intussuscep
tion. Un seul patient fut traite par
colotomie et polypectomie.
Meme si la plupart des lipomes sont
petits et asymptomatiques, les tumeurs de plus de 2 cm tendent a
causer des complications ou a etre
confondues avec un carcinome.

Lipomas of the colon are uncommon.
Their clinical importance arises from
the difficulty in differentiating them
from carcinoma and a tendency for
them to produce complications when
they are large enough to be symptom
atic. As a result, patients have under
gone major surgical procedures for a
benign condition. This paper reviews
our experience at St. Boniface Gener
al Hospital in Winnipeg with lipomas
of the colon encountered during the
period 1974 to 1985 and compares
our clinicopathologic evaluation with
that found in the literature.
Patients

The study involved all patients with
a pathological diagnosis of lipoma of
the colon whether symptomatic or
found incidentally in surgical speci
mens or at autopsy.
Findings

appendiceal lumen causing appendici
tis.
The diameter of 14 lipomas mea
sured ranged from 0.8 cm to 5.5 cm
(mean 2.2 cm). Four of the five caus
ing symptoms were larger than 2 cm;
the fifth, whose size was not reported,
was the lesion causing appendiceal
obstruction. In the two cases of intus
susception, the lipomas were larger
than 4 cm.
All tumours reported in this series
were submucosal and composed of
adult-type fatty tissue with no sarco
matous change. Multiple lesions
(three in the cecum) were found in
only one patient. Lipomas occurred
more frequently in the right colon,
with the cecum and ascending colon
each accounting for 29.4% of the to
tal. There were associated colonic car
cinomas in six patients, pancreatic
carcinoma in one and ovarian cancer
in another.
Five of the lesions were seen on
barium enema study as filling defects.
All were larger than 2 cm and none
was diagnosed as a lipoma. The two
causing intussusception were diag
nosed correctly on barium enema ex
amination.
Two patients underwent colono
scopy; the lesion was noted but not
recognized as a lipoma. Biopsy speci
mens appeared normal. In one patient
with a rectosigmoid carcinoma an as
sociated lipoma (2 X 1.5 cm) was not
mentioned on the sigmoidoscopy re
port.
In this series, only one patient un
derwent colotomy and excision of a
lesion in the ascending colon, diag
nosed as a lipoma by palpation at
laparotomy. Three patients had either
sigmoid resection or right hemicolec
tomy because the barium enema study
showed a filling defect presumed to be
carcinoma. The two with intussuscep
tion required bowel resection.

We found 17 lipomas in 15 patients
(9 women and 6 men) aged from 43 to
81 years (mean 66.7 years). Ten pa
tients were over 60 years of age. Five
patients were symptomatic; the most
frequent symptoms were abdominal
pain, rectal bleeding and change in Discussion
bowel habit. Of those with symptoms,
40% presented with intussusception. Lipomas of the colon, although in
In one case a lipoma obstructed the frequent, are second only to adenomaVOLUME 31, NO. 3 MAY 1988 / THE CANADIAN JOURNAL OF SURGERY

tous polyps as the most frequent be
nign bowel tumours.1'2 The true inci
dence has not been established but is
reported in autopsy series to vary
between 0.035% and 4.4% (Table
I ) . 1,3,4 M ost reported cases are associ
ated with complications requiring sur
gery.4 The etiology and pathogenesis
are not known.5 Approximately 65%
o f lipomas o f the gastrointestinal tract
are in the colon.5-7
As in this series, many authors12'5'6'8

(Table II). This distribution is the
reverse o f both carcinoma and adeno
matous polyps.11-13 It has been stated
that 90% o f these lesions are sub
mucosal and 10% subserosal.4'7'14
Available data indicate, however, that
submucosal lesions are found in
95.6% o f cases (Table III). The aver
age size is 3.25 cm (Table III). Multi
ple lesions, which are found mostly in
the right colon and are submucosal,
occur in 15% of cases (Table III).

have reported a 1.5 to 2-fold increase
in occurrence in women, but this
preponderance is less marked on re
view o f all available series. Women
are affected in 53.6% and men in
46.4% o f cases (Table I). Most lipo
mas occur in the fifth to seventh
decades, the average age being 63.3
years (Table I), a time when differen
tiation from carcinoma is critical.
Colonic lipomas occur most often
in the right colon (40% to 68%)1'5'7'9'10
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Typically, lipomas are localized en
capsulated lesions, either sessile or

pedunculated, composed of adult-type
fat cells414 (Figs. 1 to 3). Although
they frequently undergo ulceration,
necrosis, inflammation or cystic de
generation, there is little tendency to
become malignant. Castro and
Stearns5 knew of one unreported case
of liposarcoma complicating a lipoma.
Snover15 reported two cases of pseudosarcomatous atypia secondary to
ulceration and stressed the impor
tance of recognizing such changes as
reactive.
Reported series indicate that 47%
of patients with lipomas are symp
tomatic and 53% asymptomatic (Ta
ble IV). Symptoms are directly related
to size712 and caused by tumours mea
suring 2 cm or more in diameter.3-5-6-12-16 The most frequent symp
toms are abdominal pain 68%, change
in bowel habit 64% and rectal bleed
ing 44% (Table IV); they can be attri
buted to protrusion of the mass into
the bowel lumen, due to colonic
motor activity and contraction of the
muscularis mucosae, causing luminal
obstruction or forming the leading

FIG. 1 — Submucosal lipoma of ileocecal
valve, measuring 5.5 X 5.0 X 3.5 cm caused
cecocolic intussusception with rectal bleed
ing and large-bowel obstruction.

FIG. 2 — Cross-section of lesion in Fig.

FIG. 3 — Submucosal lipoma of sigmoid
colon (3 cm in diameter) caused altered
bowel habits.

FIG. 4 — Submucosal lipoma of colon
causing intussusception with large- and
small-bowel obstruction (arrows).

point for an intussusception. Second
ary traumatic inflammatory changes
result in necrosis, ulceration and he
morrhage. Robertson and colleagues17
reported a case of spontaneous expul
sion of a tumour presumably follow
ing this sequence of events.
Rectal bleeding secondary to lipo
ma is usually slow, leading to chronic
iron deficiency anemia, and may
occur even when the mucosa appears
intact.6 D ’Javid8 reported that the in
cidence of bleeding increased distally
in the bowel as stools became hard,
dry and abrasive. Several cases of
life-threatening hemorrhage have
been reported.5-8-19
Lipomas are the most frequent
cause of intussusception in adults.7-12-20
Mayo and colleagues16 estimated that
50% of clinical lipomas present as an
intussusception. However, we found
lower values of 0% to 40% with an
average of 17.7% (Table IV). Most
palpable masses are produced by an
intussusception.4-8 Figure 4 shows the
appearance at barium enema exam
ination of a lipoma of the colon caus
ing intussusception and subsequent
bowel obstruction.
Less frequent complications of lipo
mas include protrusion from the
anus,21 rectal prolapse and appen
diceal obstruction.4
Barium enema is the most frequent
examination performed (Table V).
Here the lesion may be seen as a
smooth, sharply demarcated in
traluminal filling defect. The adjacent
bowel wall is normally distensible and
contractile with intact mucosa.22 The
most characteristic diagnostic finding
is that, unlike other tumours, the
shape of the filling defect is not cons
tant.11-23 It is round or ovoid during
the filling phase but assumes a dis
tinctly elongated configuration during
evacuation (squeeze sign).13-22 Barium
enema studies may not always be
diagnostic of lipoma but are necessary
to rule out carcinoma. Loludice and
Lang24 reported a case of a colonic

Table IV— Symptoms and Signs of Colonic Lipomas and Correlation With Size

Series
Long and colleagues, 194914
D'Javid, I9 6 0 8
Haller and Roberts, 1964’
Wychulis and colleagues, 19642
Castro and Stearns, 19726
De Beer and Shinya, 197525
Jaworski, 1980'°
Michowitz and colleagues, 198518
Present study
Average

180

Symptoms, %
Size of symptomatic
r,
lesions, no./total no.
,,
Asymptomatic, %
cnange -------------------------------Symptomatic, ------_ ----------------- Abdominal Rectal
Intusin bowel
Not
%
Autopsy Incidental
pain
bleeding ijusception
habit
> 2 cm < 2 cm specified
75.8
—

15
56.7
26.6
32
100
36.4
33.3
47

24.2
—

—

55

30
43.3

20

53.3
68
0
63.6

6.7

60.0
53.0

80.6
75.5
100
55.3
66.7
71.4
50.0
50
60
67.7

35.5
49.6
33.3
44.7
33.3
42.8
50.0
62.5
40
43.5

32.2
33.0
0
7.9
25.0
0
16.7
4.5
40

83.9
50.3
100
63.1
33.3
57.1
83.3
62.5
40

17.7

63.7

3/3

0/3

0/3

9/12

2/12

1/12

0/5

1/5

6/6
4/5
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Table V - Radiologic Diagnosis by Barium Enema
No. of
lesions seen

Diagnosis
of lipoma

Size if
seen, cm

Long and colleagues, 1 9 4 9 1'1

28

—

Haller and Roberts, 1 9 6 4 1

18

W ychulis and colleagues, 19642
Castro and Stearns, 19726
De Beer and Shinya, 197526
Jaworski, 19 80’°
M ichow itz and colleagues, 198518
Present study

34
15
7
4
8
5

1 positive
2 likely
4 suspicious
of lipoma
4
None

Series

lipoma producing an apple-core de
fect on barium x-ray study and simu
lating carcinoma. Lesions less than 2
cm in diameter are not usually visi
ble.1 Since the fatty lucency of a
lipoma cannot be appreciated on bari
um studies, a water enema using low
kilovoltage x-rays was advocated but
has fallen out o f favour due to the
difficulty o f the technique.
Endoscopy has proven to be of
some value in the diagnosis when the
typical appearance is that o f a smooth
wide-based polyp, orange red at the
tip due to blood vessels coursing over
the surface, progressing to a yellow
colour at the base. Several techniques
may aid in the diagnosis: the pillow or
cushion sign,25 the tenting sign25 and
the naked fat sign pathognomonic of
lipoma.20
Computed tomography is consid
ered highly successful in the diagnosis
o f lipomas. Megibow and colleagues26
and Heiken and colleagues27 reported
six cases in which a diagnosis of
lipoma by enhanced computed to
mography was made by demonstrat
ing a filling defect with negative atten
uation numbers indicating fat. Four
o f these cases were confirmed at en
doscopy or surgery. In addition, Ho
and associates28 reported on a patient
who had simultaneous lipoma and
adenomatous polyps; computed to
mography permitted their differentia
tion by appearance and attenuation
number.

—

None
5 /8 positive
None

All > 2
—
—
—

—
—
All > 2

The management o f colonic lipo
mas is primarily surgical but those
discovered at endoscopy may be re
moved by electrocautery snare.1222 Al
though some12-23 advocate conserva
tive treatment, most2-5'6'19'29 agree that
surgical intervention is indicated in
suspected or proven lipoma, not only
to provide absolute differentiation
from carcinoma but to prevent com
plications that may necessitate more
extensive surgical procedures later.
D e fin itiv e ly diagnosed lipom as
should be treated by colotomy and
excision; large tumours, multiple tu
mours or intussusception need seg
mental resection and end-to-end anas
tomosis.
We thank Drs. G.P. Sharma and A.
Molgat and Mr. P. Shoenut for their assis
tance in the preparation of this manu
script.
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Early Results With the J-Pouch Procedure in Children
Mucosal proctectomy with J-pouch
construction and ileostomy were per
formed on eight patients (age range
from 4 to 18 years), five with ulcer
ative colitis and three with familial
polyposis coli.
Complications of the first stage in
cluded transient neuropraxia of the lat
eral popliteal nerves, partial dehis
cence of the ileoanal anastomosis and
prolapse of the loop ileostomy.
The ileostomy was closed 2 to 7
months after initial surgery and was
associated with four further complica
tions: enterocutaneous fistula at the
ileostomy site, early and late bowel
obstruction and pouchitis. Stool fre
quency decreased as the length of
follow-up increased: 3 to 4 stools daily
for three children at 2 years postoperatively compared with 4 to 10 stools
daily in all children 1 month after sur
gery.
Functional results were satisfactory
and all patients preferred the J pouch
to an ileostomy.

Une proctectomie muqueuse avec
construction d'un sac en J et ileostomie ont ete pratiquees chez huit pa
tients (ages de 4 a 18 ans), dont cinq
malades souffrant de colite ulcereuse
et trois de polypose colique.
Les complications de la premiere
etape operatoire comprennent une
neuropraxie transitoire des nerfs poplites lateraux, une dehiscence partiel de
I'anastomose ileo-anale et un prolap
sus de I'anse de l'ileostomie.
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L'ileostomie fut refermee de 2 a 7
mois apres la chirurgie initiate et cette
intervention fut rattachee a quatre
nouvelles complications: une fistule
entero-cutanee au point d'ileostomie,
des obstructions intestinales immedia
te et retardee et une infection de la
poche d'ileostomie. La frequence des
selles a diminue avec la duree de la
periode de surveillance: 3 a 4 selles
quotidiennes chez trois enfants 2 ans
apres I'operation, comparativement a
4 a 10 selles quotidiennes chez tous
les enfants apres 1 mois.
Les resultats fonctionnels ont ete
satisfaisants. Tous les patients ont
prefere le sac en J a l'ileostomie.

Recently there has been renewed in
terest in restorative proctocolectomy
with ileoanal anastomosis to treat ul
cerative colitis and familial polyposis
coli. In theory, this procedure can
eliminate all the diseased colonic mu
cosa, preserve normal anorectal func
tion and avoid the need for a perma
nent ileostomy. The operation may be
performed with a straight ileoanal
anastomosis without an internal reser
voir pouch12 or with a reservoir con
structed from terminal ileum. The
pouch may be in the shape of a J as
described by Utsunomiya and col
leagues,3 an S as described by Parks
and associates4 or two, separate, par
allel limbs of ileum as described by
Ferrari and Fonkalsrud.5 This report
describes the use of the J pouch in
children. I chose the J pouch because
it was simple to construct, seemed to
result in less diarrhea than the straight
ileoanal anastomosis and allowed
spontaneous evacuation of stool,
which is not always possible with the
S pouch.4
Patients and Methods

Eight consecutive children (five
boys and three girls) were operated on
over a 2-year period, beginning in
June 1983. Five had ulcerative colitis
and three had familial polyposis coli.

The J pouch was constructed at a
mean age of 11 years (range from 4 to
18 years) and in all cases was done in
two stages. The first stage consisted of
mucosal proctectomy, construction of
the J pouch, endorectal pull-through,
ileoanal anastomosis and proximal di
verting ileostomy. The ileostomy was
closed at a second procedure a few
months later. All patients with ulcer
ative colitis had undergone a previous
subtotal colectomy and Brooke ileos
tomy. Patients with familial polyposis
coli underwent abdominal colectomy
at the time of the restorative proc
tocolectomy and had not had a previ
ous ileostomy.
Operative Procedure

For the first stage, broad-spectrum
antibiotics (usually ampicillin, clin
damycin and gentamicin) were pre
scribed, beginning 1 hour before sur
gery and continuing for 5 to 7 days.
No attempt was made to reduce the
rectal inflammation in patients with
ulcerative colitis.
In the first two cases, the children
were placed in Lloyd-Davies stirrups
on the operating table from the onset
whereas the last six were left supine
until the mucosal dissection and con
struction of the J pouch were com
pleted. They were then placed in the
lithotomy position, in Lloyd-Davies
stirrups, for the pull-through and
ileoanal anastomosis.
The abdomen was opened through
a long midline incision and the rec
tosigmoid mobilized down to the level
of the peritoneal reflection. From the
abdominal approach, the outer layers
of the rectum were then divided cir
cumferentially down to the mucosa
with a scalpel, and the mucosa was
stripped from the muscle cuff to the
dentate line. No other dissection was
necessary within the pelvis. The rectal
muscle cuff was left intact from the
peritoneal reflection to the level of the
internal anal sphincter.
The ileostomy was taken down and
a point 10 to 20 cm from the terminal
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ileum chosen for the apex of the
pouch. The small-bowel mesentery
was mobilized to allow this point to
come at least 2 or 3 cm below the
symphysis pubis. The J pouch was
constructed according to the method
of Utsunomiya and colleagues,3 the
two limbs being 10 to 20 cm in length,
depending on the size of the patient.
A quarter-inch Penrose drain was
placed through the mesentery and
around the apex of the J and pulled
through the anus to position the
pouch for ileoanal anastomosis. In the
first two patients a GIA stapler was
used to construct the pouch; in the
last six it was constructed by hand,
using two layers (outer interrupted,
inner continuous) of 3-0 Vicryl su
tures. The latter method is almost as
fast as the stapler, eliminates the po
tential for leaks between the staple
lines and allows more accurate appo
sition of the antimesenteric borders of
the two limbs of the J.
The patient was then placed in the
Lloyd-Davies stirrups and the rectal
mucosa everted and excised at the
dentate line from below, as in a Soave
procedure for Hirschsprung’s disease.6
Special care was taken to remove all
of the rectal mucosa. The J pouch was
then pulled through the rectal muscle
cuff making sure that there was no
rotation. The apex of the pouch was
opened and the ileoanal anastomosis
made at the dentate line with a single
layer of interrupted 3-0 Vicryl su
tures, taking fairly large tissue bites
on both sides. Three stitches were
placed in each quadrant of the anasto
mosis.
The muscle cuff was divided by
electrocautery in the posterior midline
to the level of the coccyx and allowed
to slip down to the floor of the pelvis
to prevent the cuff from limiting Jpouch distension. No attempt was
made to stitch the muscle cuff around
the pouch. Two flat Jackson-Pratt
drains were placed deep in the pelvis
beside the pouch and brought out
through a separate stab incision in the
left lower quadrant; none were
brought through the perineum. All
drains were removed in 2 to 4 days or
when they had stopped draining.
A proximal loop ileostomy was
brought out in the right lower quad
rant and anchored to the skin with
interrupted 3-0 Vicryl sutures. A strut
left through the mesentery to prevent
retraction of the stoma was removed
5 to 7 days later.
The first rectal examination was
performed 3 to 4 weeks after opera
tion at which time the ileoanal anasto
mosis was inspected and palpated. If
healing was satisfactory, a contrast

roentgenogram of the pouch was ob
tained to detect any leaks.
No attempt was made to dilate the
pouch with either a balloon or instilla
tions through the ileostomy. No
sphincter exercises were used.
The patients were readmitted for
closure of the ileostomy an average of
4 months (range 2 to 7 months) after
proctocolectomy, when both clinical
examination of the anastomosis and
radiologic examination of the pouch
indicated complete healing. At opera
tion, the pouch was inspected endoscopically using a flexible sigmoido
scope. If the pouch was intact and the
mucosa was healthy, the ileostomy
was closed in a standard fashion.
No special diets or dietary restric
tions were applied. No antidiarrheal
medications were given for the first
10 to 14 days. Thereafter, loperamide
and bulk-forming agents were used as
required. The patients were reassessed
clinically 1, 3, 6 and 12 months after
ileostomy closure. Their functional
status was determined by number of
stools, fecal incontinence, need to use
perineal pads or diapers, ability to
distinguish feces from gas and need
for medications. After the first year,
the patients were reassessed every 12
months by flexible sigmoidoscopy and
by evaluation of function.
Results
All patients underwent closure of
their ileostomies, were satisfied with
the results of the procedure and were
functioning normally (Table I). One
works full-time as a bricklayer’s help
er and seven are in school.
Complications
There were no intrapelvic leaks,
abscesses or other septic complica
tions; however, major problems were
common. The first two patients, who
were in the lithotomy position
throughout the operation, suffered
transient neuropraxias involving the

lateral popliteal nerves of both legs.
They h a v e since fully recovered. Al
though th e legs were well padded, this
complication was probably due to the
unusually long time (about 6 hours)
spent in the stirrups. None of the
remaining six had any neurologic
problems.
One child had partial dehiscence of
the ileoanal anastomosis which was
visible on perineal inspection. This
healed slowly by secondary intention,
and the ileostomy was successfully
closed 4 m onths later.
The ileostomy was too proximal in
one child, who needed several admis
sions because of dehydration due to
high ileostomy losses. The problem
resolved after closure of the ileosto
my. In one patient the loop ileostomy
prolapsed, necessitating reoperation.
In another, an enterocutaneous fistula
developed at the site of the ileostomy
closure, b u t it healed spontaneously.
After closure of the ileostomy one
child suffered a partial obstruction in
the afferent loop to the pouch necessi
tating reoperation. The bowel was di
vided longitudinally where the affer
ent loop entered the pouch and was
closed transversely in the manner of a
Heineke-Mikulicz pyloroplasty. This
closure was protected by reconstruct
ing the loop ileostomy. Nine months
later, the ileostomy was reclosed and
the child now has good function.
There were two major late compli
cations. One child had an adhesive
small-bowel obstruction, which neces
sitated enterolysis, the other had mild
weight loss and minor rectal bleeding
due to pouchitis. In the latter there
was marked friability and redness of
the pouch mucosa on endoscopy. Bi
opsy of the mucosa showed a nonspe
cific inflammation, but cultures of the
stool grew normal fecal flora. The
patient responded well to a course of
metronidazole taken orally.
Function
In general, the functional results

Table 1— Patient Summary

Patient
no.

Age,
yr

Sex

1

15
18
12
4
10
12
11
7

M
M
F
M
F
M
M
F

2
3
4
5
6
7
8
Mean
± SEM

Indications for colectomy
Chronic
Familial
Familial
Chronic
Chronic
Chronic
Familial
Chronic

11 ± 2
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ulcerative colitis
polyposis coli
polyposis coli
ulcerative colitis
ulcerative colitis
ulcerative colitis
polyposis coli
ulcerative colitis

Colectomy
to J pouch
interval, mo

J pouch to
ileostomy
closure
interval, mo

10
—
—
18
18
9
—
8

2
7
2
6
4
3
2
4

13 ± 2

4 ± 1
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were excellent. After the first-stage
operation most patients experienced
discharge of mucus through the anus,
which was difficult to control. One
passed stool per rectum before closure
of the ileostomy, presumably because
of spillover past the loop.
All patients were able to defecate
spontaneously and distinguish feces
from gas. None required rectal intu
bations or irrigations. Stool frequency
and continence are summarized in
Tables II and III. The two patients
who required diapers at night were
the youngest in the series. One had
ulcerative colitis at 1 year of age and
underwent colectomy a year later, be
fore being toilet trained. He is now
continent during the day but still
wears a diaper at night. The second,
who also had ulcerative colitis, was
aged 7 years at the time of her pullthrough. She is continent during the
day but wears a diaper at night be
cause of occasional gross fecal incon
tinence.

surgeons experienced in performing
the Soave procedure for Hirsch
sprung’s disease will likely find it
easier to do the endorectal dissection
from above.
The morbidity was high in this
series, but most of the complications
were either self-limiting or easily cor
rected. Pouchitis may be the most
serious complication of all. Its true
incidence, cause and natural history
are unknown; it can be insidious. The
one patient who had this complica
tion was only mildly symptomatic
with slight weight loss and rectal
bleeding. He did not have diarrhea,
but the degree of inflammation of the
pouch mucosa was extreme. Pouchitis
may go undetected unless routine en
doscopic examination is performed.
Most reports on restorative proc
tocolectomy have indicated that stool
frequency decreases markedly with
time. This was not obvious in our
series. In fact, the initial daily stool
frequency 1 month after closure of the
ileostomy averaged only 6 (range from
4 to 10). However, with time there
was a gradual improvement in the
rectal urgency and less need for antidiarrheal medication. These patients
pass stools about as frequently as
patients with ileostomy empty their
appliance. In a follow-up study of 675
patients who had undergone proc
tocolectomy and Brooke ileostomy at
the Mayo Clinic, Pemberton and col
leagues9 found that most patients
emptied their appliances four to eight
times daily (median six times).
The children and their parents pre
ferred the functional results of the
J-pouch procedure to the previous
ileostomy although the results appear
to be a little disappointing since most
patients had some night-time soiling
and two wore pads or diapers at night
after 6 months. However, the soiling

Discussion
Although these initial results are
satisfactory, there are several obvious
drawbacks to widespread adoption of
the J-pouch procedure. The morbidity
is high, the functional results are less
than perfect and the long-term results
unknown.
One technical point is of interest.
Others7 have preferred to remove the
entire rectal wall down to the level of
the levator ani muscles and to remove
the distal rectal mucosa using the
perineal approach. This is quicker
and may allow the pouch to distend
more easily in the pelvis. However,
the extracolonic dissection carries
with it the risk of injuring the pelvic
autonomic nerves, as described by
Neal and colleagues.8 Most pediatric

Table II— Mean Stool Frequency During Follow-up Period

was minor except in the two youngest
patients, already mentioned, who re
quired toilet training after ileostomy
closure.
The initial choice of the J pouch
was supported by the fact that stool
frequency did seem to be lower than
reported for the straight ileoanal anas
tomosis without an internal pouch.2
This was also noted by the Mayo
Clinic group.10 They concluded that
this was because there is decreased
peristalsis and greater degree of com
pliance to distension with the pouch
than with the straight ileoanal anasto
mosis.11
All patients in the present series
were able to empty their pouch spon
taneously and none required intuba
tion for evacuation, as has been re
ported with the S pouch.4

* ±

A ,

4

This paper was prepared with the assis
tance of the Medical Publications Depart
ment, The Hospital for Sick Children,
Toronto, Ont.
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PRIMAXIN* I.V. offers management
advantages over combination therapy
that includes an aminoglycoside
G enerally well tolerated safety profile
sim ilar to cefazolin’
□ 1723 patients, including the severely ill, have received therapy in clinical trials.
The incidence of the most common adverse experience (nausea) was no greater
than 2%.
0 Avoids the potential nephrotoxicity or ototoxicity experienced with
aminoglycosides.
□ Avoids the potential hypoprothrombinemia and clinical bleeding experienced
with cephalosporins with MTTf side chain.
□ Avoids the potential disulfiram-like effect experienced with metronidazole and
cephalosporins with MTT side chain.

Convenience of a single agent
The broadest spectrum single
agent antibiotic representing
a transformation of parenteral
antibiotic therapy
5. Calandra G.B., Ricci F.M., Wang C., Brown K.R.: Safety and
tolerance comparison of imipenem/cilastatin to cephalothin and
cefazolin, J Antimicrob Chemother 12 (suppl D): 125-131,1983.
+ Certain antibiotics which possess, as part of their molecular structure, the l-methyl-5-thiotetrazole (MTT)
group have been associated with hypoprothrombinemia (and in some cases, clinical bleeding) and with
a disulfiram-like effect.
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PRIMAXIN*

•
•

(imipenem and cilastatin sodium
for injection)

•
•
•

Antibiotic
-r

CNS adverse experiences such as myoclonic
activity, confusional states, or seizures have
been reported with PRIMAXIN' especially when
recommended dosages based on renal function
and body weight were exceeded. These exper
iences have occurred most commonly in patients
with CNS disorders (e.g., brain lesions or
history of seizures) and/or who have compro
mised renal function. However, there were rare
reports In which there was no recognized or
documented underlying CNS disorder. Close
adherence to recommended dosage schedules
is urged, especially in patients with known factors
that predispose to seizures.

4

ACTION
Imipenem exerts a bactericidal action by inhibiting
-v cell wall synthesis in aerobic and anaerobic gram
positive and gram-negative bacteria.

•*

P R IM A X IN * con sists o f tw o co m p o n e n ts :
(1) im ipenem , a derivative of thienam ycin, a
carbapenem antibiotic; and (2) cilastatin sodium, a
specific inhibitor of dehydropeptidase-l a renal
enzym e w hich m etabolizes and in a c tiv a te s
imipenem. Cilastatin blocks the metabolism of
imipenem in the kidney, so that concom itant
administration of imipenem and cilastatin allows
antibacterial levels of imipenem to be attained in the
urine.

’

Inhibition of cell-wall synthesis is achieved in gram
negative bacteria by the binding of imipenem to
penicillin binding proteins (PBPs). In the case of
E s c h e r ic h ia c o li and s e le c te d s tra in s o f
Pseudomonas aeruginosa, imipenem has been
shown to have highest affinity for PBP-2, PBP-1a
and PBP-1b, with lower activity against PBP-3. The
preferential binding of imipenem on PBP-2 and
PBP-1 b leads to direct conversion of the individual
cell to a spheroplast resulting in rapid lysis and cell
♦ death without filament formation. When imipenem
is removed prior to complete killing of gramt
negative species, the remaining viable cells show a
measurable lag, termed a “ post-antibiotic effect”
(PAE), prior to resumption of new growth.

INDICATIONS AND CLINICAL USE
PRIMAXIN* (imipenem and cilastatin sodium for
injection) may be indicated in the treatment of
serious infections when caused by sensitive strains
4 of bacteria. Where considered necessary, therapy
may be initiated on the basis of clinical judgment
before results of sensitivity testings are available.
"" Continuation of therapy should be reevaluated on
the basis of bacteriological findings and of the
patient's clinical condition.
Imipenem is active in vitro against a wide range of
gram -positive and gram-negative aerobic and
anaerobic bacteria, including most strains which
„ are beta-lactam ase producing. Patients have
y responded while under treatment with PRIMAXIN*
for single or mixed infections of the following body
■ systems, when they were associated with a number
of pathogenic species and strains of the genera
listed:

-<
,
■

1.
2.
3.
4.
5.
6.

Lower Respiratory Tract Infections
Urinary Tract Infections
Intra-Abdominal Infections
Gynecological Infections
Septicemia
E ndocarditis caused by S taphylococcus
aureus
7. Bone and Joint Infections
8. Skin Structure Infections

Gram-positive Aerobes

•
•
•
•**•

Listeria monocytogenes
Nocardia asteroides
Staphylococcus (excluding many strains
which are methicillin resistant)
• Streptococcus (excluding S. faecium)

Gram-negative Aerobes

•
•
•
•
•
•
•
•

Acinetobacter
Citrobacter
Enterobacter
Escherichia coli
Haemophilus influenzae
Haemophilus parainftuenzae
Klebsiella
Morganella morganii

Neisseria
Proteus (indole positive and indole negative
strains)
Providencia
Pseudomonas aeruginosa
Serratia marcescens

Gram-positive Anaerobes

•
•
•

Clostridium (excluding C. diflicile)
Peptococcus
Peptostreptoccus

Gram-negative Anaerobes

•
•

Bacteroides fragilis
Bacteroides (non-fragilis)

CONTRAINDICATIONS
PRIMAXIN* (imipenem and cilastatin sodium for
injection) is contraindicated in patients who have
shown hypersensitivity to either component of this
product.

WARNINGS
PRIMAXIN* (imipenem and cilastatin sodium for
in je c tio n ) SHOULD BE ADMINISTERED WITH
CAUTION TO ANY PATIENT WHO HAS DEMONS
TRATED SOME FORM OF ALLERGY, PARTICULARLY
TO STRUCTURALLY-RELATED DRUGS. IF AN
ALLERGIC REACTION TO PRIMAXIN* OCCURS,
DISCONTINUE THE DRUG. SERIOUS HYPER
S E N S IT IV IT Y R EAC TIO N S MAY REQUIRE
E P IN E P H R IN E AND OTHER EMERGENCY
MEASURES.
Pseudomembranous colitis

Pseudomembranous colitis has been reported with
the use of PRIMAXIN*. Therefore it is important to
consider this diagnosis in patients who develop
diarrhea during or after therapy. This colitis may
range from mild to life threatening in severity.
Mild cases of pseudomembranous colitis may
respond to drug discontinuance alone. In more
s e v e re case s, m a n a g e m e n t m ay in c lu d e
s ig m o id o s c o p y , a p p ro p ria te b a c te rio lo g ic a l
studies, fluid, electrolyte and protein supple
mentation, and the use of a drug such as oral
vancomycin, as indicated. Other causes of colitis
should also be considered.

PRECAUTIONS

and death) at doses equivalent to the average
human dose in pregnant rabbits and cynomolgus
monkeys that is not seen in non-pregnant animals in
these or other species. Inotherstudies, PRIMAXIN*
was well tolerated in equivalent or higher doses (up
to 11 times the average human dose) in pregnant
rats and mice (see REPRODUCTION STUDIES
under TOXICOLOGY in the complete m onograph).
Nursing Mothers

It is not known whether PRIMAXIN* is excreted in
milk. If the use of PRIMAXIN* is deemed essential,
the patient should stop nursing.
Pediatric Use

Efficacy and tolerability in infants under the age of
3 months have not yet been established; therefore,
PRIMAXIN* is not recommended in the pediatric
age group below the age of 3 months.
Drug Interactions

C oncomitant administration of PRIMAXIN* and
probenecid results in only minimal increases in
plasma levels of imipenem and plasma half-life. It is
not recommended that probenecid be given with
PRIMAXIN*.
PRIMAXIN* should not be mixed with or physically
added to other antibiotics. PRIMAXIN* has been
administered concomitantly with some antibiotics,
such as aminoglycosides.
There is no evidence to suggest that association of
PRIMAXIN* with any other beta-lactam antibiotics
has any therapeutic advantage.

ADVERSE REACTIONS
PRIMAXIN* (imipenem and cilastatin sodium for
injection) is generally well tolerated. The following
adverse reactions were reported on 1,723 patients
treated in clinical trials. Many of these patients were
severely ill and had multiple background diseases
and physiological impairments, making it d ifficu lt to
determ ine causal re lationship of adverse ex
periences to therapy with PRIMAXIN*.
Local Adverse Reactions

Adverse local clinical reactions that were reported
as possibly, probably or definitely related to therapy
with PRIMAXIN* were:

General

Prolonged use of PRIMAXIN* (imipenem and
cila sta tin sodium fo r injection) may result in
overgrow th of resistant organisms. Repeated
evaluation of the patient’s condition is essential. If
superinfection occurs during therapy, appropriate
measures should be taken.
CNS adverse experiences such as m yoclonic
activity, confusionarstates, or seizures have been
reported with PRIMAXIN* especially when recom
mended dosages based on renal function and body
weight were exceeded. These experiences have
occurred most commonly in patients with CNS
disorders (e.g., brain lesions or history of seizures)
an d/or who have compromised renal function.
However, there were rare reports in which there was
no recognized or documented underlying CNS
disorder. Close adherenceto recommended dosage
schedules is urged especially in patients w ith
known factors that predispose to seizures (see
D O S A G E AN D A D M IN IS T R A T IO N ). A n t i
convulsant therapy should be continued in patients
with a known seizure disorder. If focal tremors,
myoclonus, or seizures occur, patients should be
evaluated ne urologically and placed on a n ti
convulsant therapy if not already instituted. If CNS
symptoms continue, the dosage of PRIMAXIN*
should be decreased or discontinued.

Incidence (%)

Phlebitis/thrombophlebitis
Infused vein pain
Vein induration
Infused vein infection

1.7
0.6
0.2
0.1

Systemic Adverse Reactions

Adverse clinical reactions that were reported as
p o s s ib ly , p ro b a b ly , o r d e fin ite ly re la te d to
PRIMAXIN* were:
Incidence (%)
Gastrointestinal

nausea
diarrhea
vomiting
tongue papillar hypertrophy
pseudomembranous colitis
(see WARNINGS)
hemorrhagic colitis
gastroenteritis
abdominal pain
glossitis
heartburn
pharyngeal pain
increased salivation

2.0
1.7
1.6
0.2
0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1

Use in Patients with Impaired Renal Function

Dosage in patients with impaired renal function is
based on the severity of infection but the maximum
daily dose varies with the degree of renal functional
im p a irm e n t (see DOSAGE AND A D M IN IS 
TR A TIO N - Dosage in P atients w ith Renal
Insufficiency).
Use in Pregnancy

CNS

fever
dizziness
seizures
(see PRECAUTIONS)
somnolence
confusion
myoclonus
vertigo
headache
encephalopathy
paresthesia

The use of PRIMAXIN* in pregnant women has not
been studied, therefore, PRIMAXIN* should be used
during pregnancy only if clearly needed. Use of this
drug in women of childbearing potential requires
that the anticipated benefits be weighed against
possible hazards.

Special Senses

Reproduction studies with bolus I.V. doses suggest
an apparent intolerance to PRIMAXIN* (including
emesis, inappetence, body weight loss, diarrhea

transient hearing loss in
patients with impaired hearing
tinnitus

0.4
0.3
0.2
0.2
0.2
0.1
0.1
0.1
<0.1
<0.1

<0.1
<0.1

Respiratory
dyspnea
hyperventilation
thoracic spine pain
Cardiovascular
hypotension
palpitations
tachycardia

0.4
0.1
<0.1

Renal
oliguria/anuria
polyuria

<0.1
<0.1

Skin
rash
pruritus
urticaria
skin texture changes
candidiasis
erythema multiforme
facial edema
flushing
cyanosis
hyperhidrosis
pruritus vulvae

0.9
0.3
0.2
0.1
0.1
<0.1
<0.1
<0.1
<0.1
<0.1
<0.1

Body as a whole
polyarthralgia
asthenia/weakness

Dosage in Infants and Children

TABLE 1
0.1
<0.1
<0.1

<0.1
<0.1

Adverse Laboratory Changes
Adverse laboratory changes, without regard to drug
relationship, that were reported during clinical trials
were:
Hepatic: Increased SGPT.SGOT, alkaline phospha
tase, bilirubin and LDH.
Hemic: Increased eosinophils, positive Coombs
test, decreased WBC and neutrophils, increased
W BC, increased platelets, decreased platelets,
decreased hemoglobin and hematocrit, increased
monocytes, abnormal prothrombin time, increased
lymphocytes, increased basophils.

ADULT DOSAGE OF PRIMAXIN*
I.V . Adm inistration
Severity
of in fectio n

Dose
(m g o f im ip en em )

Mild

Dosage
Interval

D a ily
D o se

250 mg

6h

1.0 g

Moderate

500 mg

8h

1.5 g

Severe (fully
susceptible)

500 mg

6h

2.0 g

CAUTION: CONTENTS OF VIALS NOT FOR
DIRECT INFUSION.

1000 mg
1000 mg

8h
6h

3.0 g
4.0 g

Each reconstituted 250 mg or 500 mg dose should A
be given by intravenous infusion over twenty to
th irty minutes. Each 1000 mg dose should be
infused over 40 to 60 minutes. In patients who
develop nausea during the infusion, the rate of
infusion may be slowed.

Severe* infections
due to less
susceptible
organisms
or life threatening
conditions

x Primarily some strains of Ps. aeruginosa.

Urinalysis: Presence of urine protein, urine red
blood cells, urine white blood cells, urine casts,
urine bilirubin, and urine urobilinogen.

TREATMENT OF OVERDOSAGE
There are no data available on overdosage.
PRIMAXIN* (imipenem and cilastatin sodium for
injection) is cleared by hemodialysis.

DOSAGE AND ADMINISTRATION
The dosage recommendations for PRIMAXIN*
(im ipenem and cilastatin sodium for injection)
represent the quantity of imipenem to be ad
ministered by I.V. infusion only. An equivalent
am ount of cilastatin is also present in the solution.

Administration

RECONSTITUTION

The maximum daily dose should not exceed 4 g or
50 mg/kg, which ever is less.

Contents of the 13 mL vials must be suspended and
transferred to 100 mL of an appropriate infusion
solution.

Dosage in Patients with Renal Insufficiency

A suggested procedure is to transfer approximately
10 mL from the 100 mL of the appropriate infusion
solution to the vial (see list of diluents under
COMPATIBILITY AND STABILITY). Shake well.
Return the resulting 10 mL of suspension to the
remaining 90 mL of the infusion solution.

P a tie n ts w ith c r e a tin in e c le a r a n c e s o f
<5 mL/m in/1.73m 2 (<0.08 mL/s/1.73m2) should
not receive PRIMAXIN* unless hemodialysis is
instituted within 48 hours. Both imipenem and
cilastatin are cleared from the circulation during
h e m o d ia ly s is . The p a tie n t s h o u ld re ce ive
PRIMAXIN* after hemodialysis and at 12 hour
intervals timed from the end of that hemodialysis
session. Dialysis patients, especially those with
background CNS disease, should be carefully
m o n ito re d ; fo r p a tie n ts on h e m o d ia ly s is ,
PRIMAXIN* is recommended only when the benefit
outw eighs the potential risk of seizures (see
PRECAUTIONS). Currently, there are inadequate
data to recommend the use of PRIMAXIN* in
patients undergoing peritoneal dialysis.
TABLE 2
MAXIMUM DOSAGE OF PRIMAXIN*
IN RELATION TO RENAL FUNCTION

Electrolytes: Decreased serum sodium, increased
potassium, increased chloride.
Renal: Increased BUN, creatinine.

The recommended total daily dosage of PRIMAXIN*
in children and infants 3 months of age and older is
60 to 100 mg/kg of body weight divided into 4 equal
doses given at six hour intervals. The higher
dosages should be used for infants and young “
children. The total daily dosage should not exceed
2 g ra m s. C lin ic a l data are in s u ffic ie n t to
recommend an optimum dose for infants and
children with impaired renal function.

RENAL
FU NC TIO N

M ild
im p airm e nt

M oderate
im p airm e nt

Severe*
im p airm e nt

C R EA TIN IN E
CLEARANCE
m L/m in/1.73 m 2
(m L/»/1.73 m2)

3 1 -7 0
(0 .5 2 -1 .1 7 )

2 1 -3 0
(0.35 - 0.50)

0 -2 0
(0 -0 .3 3 )

DOSE

DOSAGE
INTERVAL

M A X IM U M
TO T A L
DAILY
D O SA G E

(g)

(h)

(9)

0.5

6 -8

1 .5 -2

0.5

8 -1 2

1 - 1 .5

0.25 - 0.5

12

0 .5 -1 .0 **

P a tie nts w ith c re a tin in e clearance of 6 to
20 mL/min/1.73 m* (0.1 -0.3 mL/s/1.73 irp) should
be treated with 250 mg (or 3.5 mg/kg whichever is
lower) every 12 hours for most pathogens. When
the 500 mg dose is used in these patients, there may
be an increased risk of seizures.
xx The highest dose is only recommended fo r
infectio n s due to less susceptible organism s
primarily some strains of Ps. aeruginosa.

The dosage of PRIMAXIN* should be determined by
the severity of the infection, renal function, body
weight, the antibiotic susceptibility of the causative
organism(s) and the condition of the patient. Doses
cited are based on body weight of 70 kilos.

When only the serum creatinine level is available,
the following formula (based on sex, weight, and
age of the patient) may be used to convert this value
into creatinine clearance (mL/min). The serum
creatinine should represent a steady state of renal
function.

The median duration of treatment with PRIMAXIN*
in clinical trials for infections of the various body
system s ranged from 6 to 10 days except for
endocarditis and bone and joint infections for which
the median duration of treatment was 4 weeks.

Males:

Weight (kg) x (140 - age)
72 x serum creatinine (mg/100 mL)

Females:

0.85 x above value.

Dosage in Adults

When using the International System of units (SI),
the estimated creatinine clearance (mL/s) in males
can be calculated as follows:

The recommended daily dose is 1 to 2 g adminis
tered in equally divided doses every 6 to 8 hours
(see Table 1).

(lean body weight, kg) x (140 - age, years) x 1.4736

Dosage in Elderly Patients

and in females the estimated creatinine clearance
(mL/s) is:

(72) x (serum creatinine concentration, pmol/L)

Repeat, using 10 mL of the diluted suspension, to
ensure complete transfer of the contents of the vial
to the infusion solution.
CAUTION: CONTENTS OF VIALS NOT FOR
DIRECT INFUSION.

COMPATIBILITY AND STABILITY
List of diluents
0.9% Sodium Chloride Injection
5% or 10% Dextrose Injection
5% Dextrose Injection w ith 0.02% sodium
bicarbonate solution
5% D extrose and 0.9% Sodium C hlo rid e
Injection
*
5% Dextrose Injection with 0.225% or 0.45%
saline solution
NORMOSOL-M in D5-W
5% Dextrose Injection with 0.15% potassium
chloride solution
Mannitol 2.5%, 5% and 10%
Reconstituted solutions
Solutions of PRIMAXIN* range from colourless to
yellow. Variations of colour within this range do not t>
affect the potency of the product.
PRIMAXIN*, as supplied in vials and reconstituted
as above maintains satisfactory potency for four
hours at room temperature and for 24 hours under
refrigeration (4°C). PRIMAXIN* has been found to
be stable in 0.9% Sodium Chloride Injection for
10 hours at room temperature and 48 hours under
refrigeration.

DOSAGE FORMS
AVAILABILITY
PRIMAXIN* is supplied as a sterile powder mixture
in vials containing imipenem anhydrous and
cilastatin sodium as follows:
3514 Ca - 250 mg imipenem equivalent and 250 mg
cilastatin equivalent in vials.
3516 Ca - 500 mg imipenem equivalent and 500 mg
cilastatin equivalent in vials.
STORAGE
The dry powder should be stored at a temperature
below 30° C.

FULL PRODUCT MONOGRAPH
AVAILABLE ON REQUEST
(318-a,7,87)
*®Trademark
MEMBER

The recommended dosageof PRIMAXIN* in elderly
patients with normal renal function is the same as
given fo r adults above. Renal status of elderly
p a tie n ts may not be accurately portrayed by
measurement of BUN or creatinine alone. Deter
m ination of creatinine clearance is suggested to
provide guidance for dosing in such patients.

(lean body weight, kg) x (140 - age, years) x 1.2526
(72) x (serum creatinine concentration, pmol/L)
PRIMAXIN" is cleared by hemodialysis. After each
dialysis session the dosage schedule should be
restarted.
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Effects of Immobilization and Continuous Passive Motion
on Postoperative Muscle Atrophy in Mature Rabbits
The effects of continuous passive mo
tion and cast immobilization on muscle
atrophy were compared 3 weeks after
bilateral arthrotomies on 10 mature
New Zealand rabbits. The gastrocne
mius, rectus femoris and tibialis ante
rior muscles were excised and
weighed, and the dry weights of the
gastrocnemius were also determined.
The protein concentration and crosssectional areas of types I and II muscle
fibres in the rectus femoris and tibialis
anterior muscles were measured.
Compared with the results in rabbits
treated by cast immobilization, contin
uous passive motion significantly (p <
0.05) reduced muscle atrophy as de
termined from the w et and dry
weights of the gastrocnemius mus
cles, the protein content in the tibialis
anterior muscles and the cross-sec
tional areas of the type II fibres in the
rectus femoris muscles.
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On a compare chez 10 lapins de Nouvelle Zelande adultes, les effets de la
mobilite articulaire passive continue et
ceux de I'immobilisation par platrage
sur I'atrophie musculaire, 3 semaines
apres une arthrotomie bilaterale. Les
gastrocnemiens, le muscle droit anterieur de la cuisse et le muscle jambier anterieur furent excises et peses;
on a aussi determine le poids sec des
gastrocnemiens. Lateneuren proteine
et les aires transversales occupees par
les fibres musculaires de type I et II
des muscles droits anterieurs de la
cuisse et jambiers anterieurs ont aussi
ete mesurees. Comparativement a
I'immobilisation par un platre, la mobi
lite articulaire passive continue a diminue significativement (p < 0.05) I'atrophie musculaire du lapin, tel que le
demontrent les poids frais et secs des
gastrocnemiens, la teneur en proteine
des muscles jambiers anterieurs et les
aires transversales des fibres de type II
dans les muscles droits anterieurs de
la cuisse.

The time-honoured practice of immo
bilizing limbs after injuries and opera
tions leads to joint stiffness and atro
phy of the muscles,1-6 with the result
that extended periods of rehabilita
tion are often necessary for the limb
to regain normal function. Altered
function of a muscle (due to immobi
lization) affects not only its size and
strength, but also its histologic and
biochemical characteristics.37-10 Atro
phy of a muscle is characterized by an
immediate and exponential decrease
in its wet weight, total protein con
tent7 and the cross-sectional area of
its fibres.3*511’12 The reduction in wet
weight is paralleled by a proportion
ate reduction in dry weight6 and pro
tein content.6*13 The beneficial effects
of continuous passive motion (CPM)
on articular cartilage and periarticular
tissues, and on the regeneration of
articular cartilage have recently been
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demonstrated in animals.14-26 As a
result of these experimental investiga
tions, the concept of CPM has been
applied to the care of humans with a
variety of disorders and injuries of
synovial joints.25*27*28
We designed a study to compare
the effects of CPM and cast immobili
zation on muscle atrophy postoperatively.
Materials and Methods
U nder general inhalation anesthesia
(halothane, nitrous oxide and oxy
gen), medial arthrotomies were per
formed on both knee joints of 10
adult male New Zealand rabbits, each
weighing between 3.3 and 3.7 kg.
After dislocation, then reduction of
the patellae, the capsular incisions
were closed with continuous 4-0 Vic
ryl sutures and the skin with continu
ous subcuticular 4-0 stainless steel
sutures.
One of the two limbs was randomly
selected to be immobilized in a longleg plaster cast with the knee held in
80° of flexion and the ankle in 50° of
plantar flexion. The rabbit was then
placed in the CPM apparatus so that
the other limb could be moved pas
sively and continuously for the dura
tion of the experiment, as described
previously.20*29 After 3 weeks of such
treatment the animals were sedated,
then killed by an intravenous over
dose of sodium pentobarbital.
The animals were weighed and the
ranges of motion of the ankle and
knee joints measured, at least twice,
using a goniometer (the median value
was used). The tibialis anterior and
rectus femoris muscles were dissected
free. Anticipating that the cross-sec
tional areas of the muscle fibres
would vary with the degree of short
ening or lengthening of each muscle,
we controlled this variation by hold
ing the knee and hip joints in 90° of
flexion and the ankle joints in 30° of
185

plantar flexion before we took muscle
samples. Furthermore, the length of
muscle to be excised was kept cons
tant by fixing the ends of each sample
in a specially designed clamp (Fig. 1)
before excision. One sample was ob
tained from the anterior region of the
rectus femoris muscle and one from
the medial region of the tibialis ante
rior. While still held in the clamps,
each sample was immersed in a bath
of isopentane, “snap frozen” in liquid
nitrogen, then weighed.
In a cryostate at -25°C, transverse
sections, 10 pm thick, were cut from
the muscle samples then stained for
myofibrillar adenosine triphosphatase
activity (preincubation pH 9.4) ac
cording to the methods of Padykula
and Herman30 as modified by Guth
and Samaha.31 Using a Bausch and
Lomb digital image analyser (System
Omnicon 3000; Bausch and Lx>mb,
Rochester, NY) connected to a micro
scope, we measured the cross-section
al areas of the type I and type II
muscle fibres in a randomly selected
group of 50 fibres for each type. The
remaining parts of the rectus femoris
and tibialis anterior and the whole
gastrocnemius muscles were carefully
excised and blotted dry, and the fat
and connective tissue were removed.
The wet weight of each specimen was
obtained and the samples were then
stored on dry ice. For dry weights, the
gastrocnemius muscles were diced
and dried in an oven at 72°C for 120
hours before weighing.
The protein concentration in a 25to 30-mg sample taken from the prox
imal aspects of each of the tibialis
anterior and rectus femoris muscles
was determined according to the
method of Lowry and colleagues,32
using bovine serum albumin as a stan
dard. Protein levels were measured
within 12 hours after the animals had
been killed. Since it is necessary to
dessicate the whole muscle to obtain
its dry weight, this procedure or the
combination of protein concentration
and muscle fibre size, but not both,
could be determined in any one mus
cle.
The data were analysed using the
paired /-test, with differences being
accepted as significant at a probability
level of p < 0.05.

Range of motion in both the ankle
and knee joints was significantly re
duced in the limbs treated by cast
immobilization, compared with those
receiving CPM (Fig. 2).
Wet and Dry Weights
The mean wet weights (± one stan
dard deviation) of the gastrocnemius
muscles were 7.58 =t 1.37 g in the cast
limbs compared with 9.61 ± 1.97 g in
the CPM limbs (p < 0.05) (Fig. 3).
The wet weights of rectus femoris
muscles in the cast limbs (8.02 ±
0.028 g) were lower than those in the
CPM limbs (8.30 ± 1.07 g), but this
difference was not statistically signifi
cant. The wet weights of the tibialis
anterior muscles were equal in the
cast (4.28 ± 0.76 g) and CPM (4.28 ±
0.96 g) groups. The dry weights of the
gastrocnemius muscles were signifi
cantly (p < 0.05) lower in the cast
limbs than in the CPM limbs (1.85 ±
0.34 g versus 2.33 ± 0.50 g) (Fig. 4).

The protein concentration, ex
pressed as a percentage of the wet
weight of the muscle (grams of protein
per gram of muscle), in the tibialis
anterior was significantly (p < 0.05)
lower in the cast group (17.95% ±
1.69%) than in the CPM group
(19.64% ± 2.41%). There was no sig
nificant difference between the pro-

FIG. 3 — Wet weights of gastrocnemius
muscles 3 weeks postoperatively (nine rab
bits). Values are mean ± one SD. * =
significantly different (p < 0.05).

FIG. 1 — Specially designed muscle
clamp consisting of two straight hemostats
held fixed distance apart by clamp consist
ing of two metal plates. Ends of muscle
sample to be excised were fixed in clamps
before excision and held in position during
histochemical fixation.

FIG. 4 — Dry weights of gastrocnemius
muscles 3 weeks postoperatively (nine rab
bits). Values are mean ± one SD. * =
significantly different (p < 0.05).

Table I— Cross-Sectional Areas of Muscle Fibres in Nine Rabbits*
Rectus femoris

Gross Findings
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FIG. 2 — Range of motion of ankle and
knee joints 3 weeks postoperatively for nine
rabbits. Values are mean ± one standard
deviation. * = significantly different (p <
0.05).

Protein Concentration

Results

One animal with a dislocated patel
la was excluded from the analysis.
Each animal lost an average of 16% of
its original body weight during the
experiment.

tein concentration in the rectus femo
ris of the cast (19.47% ± 1.24%) and
the CPM (20.21% ± 1.49%) groups.

Tibialis anterior

Group

Type 1

Type Ilf

Type 1

Type II

Cast
CPM

3593 ± 1280
3966 ± 1348

2910 ± 555
3795 ± 629

4237 ± 862
3460 ± 450

3253 ± 608
2750 ± 526

•Values are expressed as the mean ± one SD (in pm2),
t p < 0.05.
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Histochemical Findings
The cross-sectional areas of the
muscle fibres are listed in Table I.
The average cross-sectional areas of
both type I and type II fibres in the
rectus femoris muscles of the casted
limbs were lower than those in the
CPM-treated limbs, although the dif
ference was only statistically signifi
cant for the type II fibres. Interesting
ly, this pattern appeared to be re
versed in the tibialis anterior muscles
although these differences were not
statistically significant (Table I).
Discussion

Our experiment demonstrated that
gastrocnemius muscles undergo a sig
nificantly greater loss of wet and dry
weight in limbs that are immobilized
postoperatively than do those treated
by CPM. Moreover, the cross-section
al areas of the type II fibres in the
rectus femoris muscles in the cast
group were significantly smaller than
those in the CPM group.
Normally, the protein concentra
tion in a muscle is not affected by
moderate systemic weight loss.613
However, the protein concentrations
in the tibialis anterior muscles were
significantly lower in the cast group
than in the CPM group, even though
the wet weights of these muscles were
equal in both groups. Consequently,
the total protein content (protein con
centration X wet weight of the mus
cle) was significantly lower in the
tibialis anterior muscles from the
limbs treated by cast immobilization
than in those from the limbs treated
by CPM. This could be interpreted to
mean that the muscles were edema
tous, but this would conflict with the
observation that the cross-sectional
areas of both the type I and type II
fibres were slightly, but not signifi
cantly, greater in the immobilized ti
bialis anterior muscles than in the
CPM-treated muscles. The latter ob
servation is consistent with the phe
nomenon of transient hypertrophy,
described in muscles that have been
immobilized in a position of light
stretch.7'33
A factor that might have affected
the results for the tibialis anterior
muscles was that during immobiliza
tion these muscles were held under
tension. The length of a muscle during
immobilization, relative to its resting
length, influences the amount of atro
phy that will occur. When a muscle is
immobilized in a state of relaxation,
atrophy will occur in a matter of
days.7-33 However, when a muscle is
immobilized in a state of tension, the

atrophic changes are preceded by a
period of transient hypertrophy.7*33
This was illustrated in 1957 by Fergu
son and colleagues,4 who demonstrat
ed marked hypertrophy of the tibialis
anterior muscle after 3 weeks of cast
immobilization with the muscle under
tension.
Many authors5'81213 have related
the histochemical changes in crosssectional areas (or diameters) of the
muscle fibres to the other parameters
of muscle atrophy, but apparently
they gave no consideration to the
dependence of these measurements on
the length of the muscle at the time of
excision and histochemical fixation.
We believe that the cross-sectional
area or diameter of a muscle fibre
should increase if a muscle is allowed
to shorten before, or after, excision of
the specimen. Therefore, in our study,
the joints were held in a similar posi
tion in all animals and a specially
designed clamp was used to standard
ize the length of each muscle sample
before excision and to maintain this
length during histochemical fixation.
A relatively greater degree of atro
phy was observed in the type II than
the type I fibres of the rectus femoris
muscles. Although the explanation for
this observation is not clear, oth
e r s , 12,13 have shown that changes in
size with atrophy or hypertrophy de
pend on many factors and may differ
for the two fibre types.
Conclusions

Our investigation has demonstrated
that, with respect to wet and dry
muscle weight, protein content and
histochemical muscle fibre size,
atrophic changes in muscles from
three major compartments of rabbits’
limbs subjected to an operative proce
dure can be substantially reduced by
using continuous passive motion rath
er than cast immobilization.
Although we cannot extrapolate
these findings directly to other clinical
situations in which a joint has been
injured or inflamed, this conclusion
might also be valid for nonoperative
abnormalities of synovial joints. For
example, CPM has been shown to
have a protective effect on articular
cartilage in septic arthritis,22 and to
enhance the clearance of synovial ef
fusions and hemarthroses14-15 and the
healing of articular cartilage de
fects.19'20'22 These are conditions fre
quently treated by rheumatologists
and orthopedic surgeons, and for
which the prescribed treatment tradi
tionally has included resting or splint
ing the affected joints. The prevention
of muscle atrophy is a goal to be
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considered not only in patients post
operatively, but also in those suffering
from acute inflammatory conditions
that limit active motion of joints.
We thank Mr. Ajai Kumar for technical
assistance.
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Colonoscopy in the Follow-up of Patients With Colorectal
Carcinoma
In an effort to determine the value
of colonoscopy in the follow-up of
patients who have undergone resec
tion for colorectal carcinoma, the au
thors evaluated prospectively 100 con
secutive patients who, during follow
up after resection for colorectal can
cer, had normal findings on barium
enema examination and also under
went colonoscopy. The follow-up from
operation to colonoscopy ranged from
8 months to 1 5 years (average 2.6
years). Tw o recurrent and two meta
chronous carcinomas were detected.
In addition, 25 polyps (3 benign) were
removed from 22 patients. Twelve of
the malignant polyps were less than 1
cm in dimension, the other 10 were
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Canadian Society for Clinical Investiga
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Physicians ana Surgeons o f Canada,
Toronto, Ont., Sept. 24, 1986

larger. Colonoscopy is considered valu
able in this setting for earlier detection
and removal of recurrent and meta
chronous carcinomas and potentially
premalignant lesions.
En vue de determiner I'interet de la
colonoscopie dans I'examen de controle des patients qui ont subi la resec
tion d'un carcinome colorectal, on
a evalue de facon prospective 100
patients qui, en cours de surveillance
de post-cure, presentaient des resultats normaux au lavement baryte et
qui ont aussi subi une colonoscopie. La
periode ecoulee entre I'operation et la
colonoscopie a varie entre 8 mois et
15 ans (moyenne 2.6 ans). Deux recidives et deux carcinomes metachrones
ont ete deceles. De plus, 25 polypes (3
benins) ont ete reseques chez 22
patients. Douze des polypes malins
avaient une taille inferieure a 1 cm; les
10 autres etaient plus gros. Dans un
tel contexte, la colonoscopie fut utile
puisqu'elle permit la detection de recidives et de carcinomes metachrones,
et que plusieurs lesions premalignes
ont ete decelees et resequees.
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It is an established fact that patients
who have undergone resection of a
colorectal carcinoma run an increased
risk o f development of a metachro

nous carcinoma, polyp or anastomotic
recurrence.1-3 The degree of follow-up
after resection is controversial. Propo
nents o f intensive follow-up state4-5
that should a recurrent or metachro
nous lesion be detected when a pa
tient is asymptomatic, the probability
of cure by repeat resection will be
increased, since the newly detected
lesion will be at a more favourable
stage6 than if the patient were symp
tomatic. Opponents710 argue that in
tensive follow-up is not worth the
effort and expense, since up to 62%'1
o f new lesions will be detected when
the patient presents with symptoms
between scheduled follow-up sessions.
Among those favouring intensive
scrutiny, the method by which it is
carried out is under discussion. Some
suggest colonoscopy in all cases, with
or without barium enema examina
tion because it enables the detection
o f anastomotic recurrences, metachro
nous carcinomas or new polyps,
which can be removed. Colonoscopy
permits the detection o f lesions that
may have been missed on barium
enema study and can more accurately
evaluate the nature o f suspicious nar
rowings in the bowel.
The purpose of this prospective
study was to determine if colonoscopy
was o f value in the follow-up o f pa
tients who had undergone resection
for colorectal carcinoma.
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Patients and Methods

The study comprised 100 consecu
tive asymptomatic patients (57 men,
43 women) who had undergone resec
tion for colorectal carcinoma. They
ranged in age from 35 to 82 years
(average 63 years). The locations of
the primary carcinomas are listed in
Table I and the Dukes’ staging in
Table II.
Scheduled follow-up examinations
carried out were as follows: proctosig
moidoscopy, presence of carcinoembryonic antigen, liver function tests
and complete blood counts every 3
months for the first 2 years postoperatively, then every 6 months for anoth
er 3 years and annually thereafter;
chest x-ray every 6 months for 5 years
and single-contrast barium enema an
nually. Subsequently, at varying times
postoperatively the patients under
went colonoscopy. Patients with posi
tive findings on barium enema were
excluded from the study, since it was
our intent to see if by colonoscopy we
were able to pick up lesions that were
missed on barium enema examina
tion.
A metachronous carcinoma was de
fined as that occurring more than 1
year after the initial resection.
Results

The colonoscopy was performed
Table 1— Location of Primary Carcinomas
Location

No. of patients
44
30
6
5
10
5

Rectum
Sigmoid colon
Descending colon
Transverse colon
Ascending colon
Cecum

from 8 months to 15 years after initial
resection (mean 2.6 years). The exam
ination was completed to the cecum
in 94% of cases; in the remaining 6%
it was considered incomplete because
of technical difficulties, patient intol
erance or poor bowel preparation.
Colonoscopic findings included two
anastomotic recurrences, both of
which occurred 1 year after right he
micolectomy. Metachronous car
cinomas were detected in two pa
tients, in the ascending colon and
cecum, 1 year after sigmoid and low
anterior resections respectively.
Twenty-five polyps were found in 22
patients; 3 polyps were benign.
Twelve of the malignant polyps were
found to be less than 1 cm in dimen
sion and 10 were larger than 1 cm.
The histologic variety of each polyp is
listed in Table III and the location in
Fig. 1.
Discussion

After “curative” resection for colo
rectal carcinoma the goal of follow
up should be the detection of anas
tomotic recurrences or metachronous
lesions at a time when further treat
ment for cure may be possible.
Whereas it was generally believed
that 75% of colorectal carcinomas
could be detected with rigid or flexi
ble sigmoidoscopy,12 a recent shift in
the distribution of large-bowel cancer
has been observed.1314 In our study,
nearly 75% of primary carcinomas
were in the left colon and malignant
lesions that developed after resection
were predominantly right sided. Thus,
had the traditional methods of follow
up been used, 86% of neoplastic le
sions, two metachronous carcinomas

Table II-— Dukes' Staging of Primary
Carcinoma
Stage

No. of patients
36
37
27

A
B
C

Table III— Histologic Type of Polyps Found at
Colonoscopy
Size, cm
Histologic type
Tubular adenoma
Tubulovillous adenoma
Villous adenoma
Hyperplastic

< 1 cm > 1 cm
8
4
—
3

*1 polyp with carcinoma in situ.

2
5*
3

FIG. 1 — Location of polyps found at
colonoscopy. Circles = less than I cm in
dimension, squares = more than 1 cm,
triangles = benign polyps. FFS = extent of
flexible sigmoidoscopy.
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and two anastomotic recurrences
would have gone undetected until,
presumably, symptoms developed.
Buhler and colleagues4 noted that
repeat resections for cure were possi
ble in 66% of patients who were
asymptomatic at the time the recur
rent lesion was detected, but in symp
tomatic patients the lesion was usual
ly unresectable. Since many reports
have documented that most recur
rences occur within the first 2 years
after resection of the primary le
sion,1015 it seems reasonable to con
centrate follow-up efforts during this
period. Those opposed to intensive
follow-up71115 state that the poor
reoperation rate for cure, ranging
from 7% to 20%, negates the cost and
effort applied.
Although follow-up aimed at de
tecting recurrent disease has met with
little success, it has been suggested
that intensive scrutiny would be more
productively directed toward the de
tection of metachronous polyps and
carcinomas. There is considerable evi
dence that patients who have had a
previous colorectal carcinoma are at
risk for metachronous neoplasms
since their entire colorectal mucosa
seems to be unstable and potentially
malignant,16 the so-called “terrain
preparee” . It is also accepted that
many, if not most, colorectal car
cinomas develop from an adenoma
tous polyp.1718
Although a metachronous lesion is
defined as one occurring after resec
tion of the primary carcinoma, some
authorities6 require a 2-year interval
before a lesion would be classified as
such. Thus, the metachronous neo
plasms in our series would be consid
ered as missed synchronous lesions,
present at the time of the original
resection, and one would be com
pelled to conclude that barium enema
examination failed to detect these le
sions, since all patients had the exam
ination before resection. A similar
point has been expressed by oth
ers.6'19'20 This would justify colonos
copy preoperatively to clear the colon
of all other neoplastic elements. In
one report21 preoperative colonoscopy
identified 55% of synchronous neo
plasms that were undetected on bari
um enema examination. Indeed, it
may alter the extent of resection in
some patients.21 24
That the entire colon must be eval
uated is not in dispute, rather it is the
method by which evaluation is ac
complished that is controversial. Two
methods are currently available: bari
um enema and colonoscopy. Both
have their limitations.
Although some may take issue with
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our use of single-contrast barium
enema examination, there is evidence
that both single- and double-contrast
examinations have almost identical
sensitivities for detecting polyps larg
er than 1 cm in diameter.25 Double
contrast barium enema is, however,
superior in detecting smaller neo
plasms (less than 1 cm) and polyps in
general, regardless o f size.25 Single
contrast barium enema examination
allows diagnosis of most malignant
lesions.25 It is the examination most
commonly performed, being less cost
ly, less time-consuming and better
tolerated in elderly patients than the
double-contrast technique.25
The prevalence o f carcinoma in
small adenomatous polyps is negligi
ble as illustrated by Ott and col
leagues26 in a review o f 2344 adeno
mas; they recorded a rate o f invasive
malignant disease of 0.09%. The ques
tion then arises whether it is necessary
to detect polyps less than 1 cm in size.
The general consensus appears to be
that detection o f diminutive adeno
mas in patients over 70 years old is
less crucial because o f a limited life
span. However, a recent study27 re
vealed a 15% incidence o f invasive
carcinoma in polyps less than 1 cm in
size; thus, miniature polyps may be of
importance in younger patients. It
must be pointed out that this high
incidence o f carcinoma in small pol
yps has not been reported by others,
and the reason for the discrepancy is
unclear.
Colonoscopy, although hailed as
the best diagnostic tool available to
evaluate the entire colon,28 is not
infallible. It, too, has several “blind
spots” where lesions may be over
looked. For polypoid lesions it is asso
ciated with a false-negative rate of
12%,29 similar to that of double-con
trast barium enema examination.30 It
may also fail to detect carcinoma in
10% o f cases.29 The procedure is not
without complications. Perforation
rates o f 0.1% to 0.6% and bleeding
rates o f 2.2% to 4.7% have been re
ported.29 Inability to reach the cecum
ranges from 9% to 37%,2-3'22'31'32 a
serious limitation in view o f the re
cently observed right-sided shift of
neoplasia. It is also more costly, seda
tion is often necessary and the com
plication rate is higher than for the
barium enema study.25 However, it is
superior in enabling direct inspection
o f the mucosa, thus having a false
positive rate of zero.30 It can detect
the so-called diminutive polyp, biopsy
and destroy it using the cautery biop
sy forceps. Although it can confirm
the suspicion of anastomotic recur
rence, the problem is now believed to
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begin extraluminally, before reaching
the mucosa, a fact that is better appre
ciated on barium enema examina
tion.33 Taken together, barium enema
and colonoscopy have a combined
sensitivity approaching 100%.30
Although many studies have com
pared the efficacy o f both procedures,
they are not directly comparable;
some have been conducted prospec
tively, others are retrospective. Peri
ods of follow-up vary, and generally
the conclusions reached are biased,
depending on whether the author is
an endoscopist or radiologist.
We believe that colonoscopy plays
a valuable role in the follow-up of
patients after resection for colorectal
carcinoma, but we share the view of
others34-35 that the two examinations
are complementary and that one
should not be done to the exclusion of
the other.
Another point needing clarification
is the timing and frequency o f colono
scopy. An apparent consensus is that
it should be performed preoperatively
since it enables synchronous polyps to
be removed, neoplasms to be identi
fied and modification o f the planned
operative procedure in 5% to 16% of
cases.22-24 Should obstruction, perfora
tion or other mitigating circumstances
prevent its performance preoperative
ly, then it should be done within the
first 3 to 6 months after resection.
Postoperative follow-up should be
most intense in the first 2 years; the
frequency o f colonoscopy in this peri
od is debatable. Despite the many
suggestions on the subject in the liter
ature, there is little conclusive evi
dence justifying the cost and risk of
performing colonoscopy more often
than annually during the initial 2
years after colorectal resection. This
question can only be answered defini
tively by a long-term prospective
study.
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Demographic and Medical Characteristics of Adult Head
Injuries in a Canadian Setting
The frequency of head injury is sub
stantial and the problem is associated
with a correspondingly high cost to
society. Approximately 50 000 pa
tients are discharged from Canadian
hospitals annually with a diagnosis of
either skull fracture or intracranial
injury.1 It has been estimated that
there are between 20 000 and 30 000
serious head injuries in Canada each
year.2 In 1983, over 3400 deaths were
attributed to such injuries.3
Although the exact economic costs
of head injury to Canadian society are
not known, statistics from the United
States give some idea of their poten
tial magnitude. In 1974, the total
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graphiques et medicates des patients
head injury in the US were estimated
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studies have investigated adult head
injuries in Canadian settings. Klonoff
and Thompson5 reviewed the inci
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This study provides demographic and
medical information about patients ad
mitted with head injuries to Sunnybrook Medical Centre, Toronto, Ont.,
in 1978 and in 1982. Data are pre
sented about patient age and sex, type
and cause of accident, length of stay,
extracranial complications, severity of
head injury, frequency of use of vari
ous neurodiagnostic techniques and
type of discharge placement. The
costs of hospitalization for such pa
tients, both in the Sunnybrook Medical
Centre and for Canada as a whole, are
estimated.

epidemiology of head injuries among
patients admitted to the Trauma Unit
at Sunnybrook Medical Centre from
Apr. 1, 1981 to Dec. 31, 1982. Over
two-thirds of the patients admitted
were classified as head injured. Over
80% of these injuries were the result
of motor vehicle accidents or pede
strian-motor vehicle accidents. In this
study also there were more than twice
as many men as women. Nelson’s
patients were younger than those in
Klonoffs study, with over 70% being
less than 41 years old. The death rate
was greatest in those over the age of
60 years; in that group one of every
four patients admitted with head inju
ries died.
Parkinson and associates7 studied
3000 consecutive patients with head
injury admitted to the Health Sci
ences Centre in Winnipeg. Unlike the
previous studies, children were in
cluded. Again there was a predomi
nance of males and younger patients.
Their sample also showed almost as
many falls (873) as traffic-related in
juries (988), a finding that is probably
attributable to the inclusion of chil
dren. In their setting, 35% of the head
injuries were sustained in fights or
assaults compared with 12.9% in the
study of Klonoff and Thompson5 and
1.5% in that of Nelson and col
leagues.6
One striking aspect of the existing
epidemiologic literature has been the
lack of a consistent definition of head
injury across the studies. Klonoff and
Thompson5 did not specifically define
their criteria for head injury but did
include patients with injuries to the
scalp alone, while both Nelson and
colleagues6 and Parkinson and associ
ates7 excluded these injuries. Parkin
son’s group also did not define clearly
their criteria for calling patients head
injured. These two studies included
only patients who were hospitalized,
but Klonoff and Thompson5 also in191

eluded patients seen only in the emer
gency department. Nelson’s group in
cluded only those patients who had
either computed tomographic evi
dence of brain lesion, loss of con
sciousness or post-traumatic amnesia,
and their sample included only pa
tients who were admitted to the Trau
ma Unit; other head-injury admis
sions to Sunnybrook Medical Centre
were not included.
The absence of common diagnostic
criteria makes it difficult to compare
the results from these different
studies. One possible way to assure
greater diagnostic consistency across
settings would be to use the Interna
tional Classification of Diseases
(ICD-9).8 While there are some prob
lems classifying head injuries by this
system,910 it at least provides some
basis for consistency of definition
across settings.
A second problem with previous
Canadian studies has been a lack of
information about the severity of the
injury. Different criteria have been
used and, in some cases, scant atten
tion has been paid to the issue of
severity. The Glasgow Coma Scale
(GCS)9 has gained increasing accep
tance as a quantitative index of the
severity of head injury. Providing
GCS scores would permit researchers
Table I— ICD-9 Diagnoses of Patients
Included in Present Study

to compare severity of injuries across
samples.
Bearing in mind the limitations of
the existing literature, we designed a
study to provide data on a sample of
head-injured individuals whose diag
noses were based on ICD-9 criteria,
with severity documented (where pos
sible) by GCS scores.
Method

We reviewed the charts of patients
who had been discharged (or died)
with a diagnosis of closed head injury
in either 1978 or 1982 at Sunnybrook
Medical Centre in Toronto. Time of
discharge was used because medical
charts at this institution are coded
and filed on the basis of date of
discharge. Two different years were
chosen in the hope that this approach
would provide some estimate of the
stability of the findings over time.
Between 1978 and 1982, two major
changes occurred in the evaluation of
head-injured patients treated at our
hospital. First, the hospital did not
acquire its first computed tomography
scanner until September 1978. Before
then, computed tomograms were ob
tained at other hospitals, so fewer
computed tomograms were available
for 1978. Second, GCS scores were
not routinely obtained on patients
admitted in 1978, but this practice
had changed by 1982.

Fractures
800 Fracture skull - vault
801 Fracture skull - base
803 Fracture skull - not specified
Intracranial injury (excluding those with skull
fracture)
850 Concussion
851 Cerebral laceration and contusion
852 Hemorrhage - subarachnoid, subdu
ral, extradural
853 Hemorrhage - other and unspecified,
intracranial
854 Head injury - not specified

Table III— Type of Accident
Type

1978

1982

76
15
4
16
15
84
7
2

120
21
4
17
10
85
10
1

Motor vehicle
Pedestrian
Bicycle
Sports
Interpersonal violence
Fall
Hit by falling object
Unknown

Table II— Distribution of Patients by Age, Sex and Year of Discharge
1978*

1982

Age, yr

Males

Females

Males

Females

1 1 -1 9
20 - 29
3 0 -3 9
4 0 -4 9
50 - 59
60 - 69
7 0 -7 9
80 - 89
90 +

40
36
18
12
14
14
3
7
3

11
7
9
9
13
6
9
7
0

37
53
19
27
22
12
9
3
1

11
21
15
8
8
9
8
4
1

71

183

Totals
Mean age
SD

147
36.7
21.7

47.7
21.9

*1 patient missing because his age was not recorded.

192

36.6
18.6

85
42.4
22.1

Patients

Patients were included in the study
only if their discharge diagnoses in
cluded one of the ICD diagnoses list
ed in Table I. Patients with fractures
of the facial bones and those with
superficial facial and scalp lacerations
were excluded because they would not
likely have brain dysfunction and our
primary interest was in patients with
potential brain injury. Using the
ICD-9 criteria shown in Table I, we
identified 219 cases for 1978 and 268
for 1982. There were an additional 19
charts for the 2 years that either could
not be located or had a questionable
diagnosis of head injury.
Findings

Data on patient age and sex by year
of discharge are presented in Table II.
The head-injured patients were rela
tively young, with a tendency for
males to be younger than females.
The mean age of the patients for 1978
and 1982 was 40.3 and 38.4 years
respectively.
With respect to the type of acci
dent, approximately 43% of the cases
involved some form of motor vehicle
accident (including bicycles) in 1978
(Table III). In 1982, this figure was
54%. In both years, the second most
frequent cause of accident was a fall.
Almost all the head injuries were of
the closed type, 96.3% in 1978 and
98.1% in 1982. The death rate was
13% in 1978 and 15% in 1982.
Data on length of stay are present
ed in Table IV. In both years, over
half of the patients were discharged
within 2 weeks of admission.
The frequency of associated extra
cranial complications was high (Table
V). Over 90% of the patients sus
tained multiple injuries. The number
of patients who were admitted
through the Trauma Unit increased
from 63 (28.7% of the 1978 sample)
to 122 (45.5% of the 1982 sample)
between the study years.
Table IV - -Length of Hospital Stay
Stay, d

1978

1982

1
2
3
4
5
6
7
8-14
15-28
29-56
57 - 84
> 84

62
19
6
7
12
5
6
38
24
24
8
8

38
20
10
8
14
6
8
50
49
37
17
11
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Glasgow Coma Scale scores for
1982 are presented in Table VI. Using
a cut-off score of 13 and above, we
could classify approximately 50% of
these injuries as mild. However, there
was a large number (71) for whom
complete scores could not be obTable V— System Involved for Extracranial
Complications
System
Musculoskeletal
Respiratory
Cardiovascular
Central nervous
Gastrointestinal
Genitourinary
Integumentary

1978

1982

76
33
12
143
15
13
154

111
87
19
220
36
30
187

Table VI— Glasgow Coma Scale (GCS) at
Admission*
GCS

1982

3
4
5
6
7
8
9
10
11
12
13
14

6
3
2
7
1
2
7
5
6
17
33
100

‘ Glasgow Coma Scale scores were only
infrequently recorded in 1978 and are therefore not reported here. In 71 patients a
medical condition (e.g., intubation) precluded
scoring. In 8 the score was not recorded.

Table VII—Type of X-ray Procedure
Procedure
Skull x-ray
Brain scanning
Tomography
Computed tomography (at
Sunnybrook Medical
Centre)
Echoencephalography
Angiography
Cerebrospinal fluid flow study
Isotope cisternography
Fluoroscopy

1978

1982

192
22
7

131
2
10

21
9
31
0
2
2

206
0
6
4
0
0

tained. Since 73% of this group were
intubated, they were probably among
the more severely injured.
Table VII addresses changes in the
radiologic investigation of these pa
tients over the 2 years in question.
The impact of computed tomography
is particularly noteworthy. Only 21
scans were done in 1978 at our insti
tution, but by 1982 the number had
reached 206. Although the number of
patients increased between the 2
years, the only diagnostic procedures
that showed an increase were comput
ed tomography, tomography and
studies of cerebrospinal fluid flow.
Other data indicate that a higher per
centage of the patients underwent
monitoring of intracranial pressure in
1982 (18.6%) than in 1978 (1.4%).
An attempt was also made to deter
mine the percentage of head injuries
that might have been the result of
suicide attempts. Patients were classi
fied as such if the discharge summary
and some correlative piece of infor
mation, such as the social worker’s
notes, made- reference to this as a
factor. With these criteria, the inci
dence was 2.7% in 1978 and 1.1% in
1982. However, since this was not a
prospective study and since incidence
figures for suicide are often underesti
mated,11 our rates may be low.
Estimates were also made of the
use of alcohol at the time of the
accident. Patients were classified as
using alcohol if this was reported in
either the admission notes or dis
charge summary. If there was no such
reference, the patient was classified as
not using alcohol, even if there was a
documented history of alcohol abuse.
By these criteria, 24.6% of the 1978
patients and 17.5% of the 1982 pa
tients showed signs of alcohol use at
the time of their injury.
Table VIII presents information
about the discharge placement of pa
tients. In both years, the majority of
patients were discharged home, but
from 1978 to 1982, there was an
increase in the percentage of patients
admitted to rehabilitation institu
tions.
Discussion

Table VIII— Discharge Placement*
Placement
Home
Convalescent care
General hospital
Rehabilitation centre
Chronic care
Extended care

1978

1982

159
8
6
10
8
2

156
12
6
47
5
2

*ln 1978 there were 26 deaths and in 1982,
40.

Previous studies of the demograph
ic characteristics of head-injured pa
tients have found that victims are
predominantly young males. Our
study replicated these findings. In
both years, there were approximately
twice as many males as females and
approximately two-thirds of the pa
tients were under the age of 50 years.
Head injury was most commonly
caused by motor vehicle accidents.
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with the next most frequent cause
being falls. In contrast to findings
from some American studies, few in
juries resulted from violence.
The severity of injuries seen in the
present study is also similar to that
reported in other investigations. For
example, in one cooperative study of
Glasgow Coma Scale scores in hospi
tals in Galveston and Houston,12 it
was found that 53% of such injuries
fell in the mild range (that is, greater
than 12). In the present study, 49.6%
of the patients admitted in 1982 had
GCS scores in this range.
It is apparent that there are some
differences in the findings obtained
between the 2 years surveyed in this
study. There were more admissions to
hospital in 1982 and a higher percent
age of these admissions came through
the Trauma Unit. Lacking GCS scores
from 1978, one cannot conclude that
the injuries in 1978 were less severe
than those seen in 1982, but given the
increase in percentage (and number)
of Trauma Unit admissions, it is pos
sible that there has been some change
in the types of injuries sustained by
those admitted.
One of the clearest changes between
1978 and 1982 was the increase in
intracranial pressure monitoring. The
impact that computed tomography has
had on the use of other radiologic pro
cedures is also clearly demonstrated.
The death rates noted here indicate
that many of the patients were severe
ly injured. The percentage of deaths is
similar to that reported by Nelson and
colleagues6 (16%) and Klonoff and
Thompson5 (13.6%). Parkinson and
associates7 reported a rate of 4.4%,
but their sample contained a high
incidence of interpersonal violence
and may, therefore, not have com
prised injuries as severe as in other
settings.
This study also suggests that the
average person admitted to our hospi
tal with cerebral injury is likely to
have involvement of some other body
system. In both years about 70% of
the patients had at least one body
system other than the central nervous
system involved. While some of these
injuries may have been minor (such
as skin abrasions and lacerations),
others were not. Recently, there has
been substantial research on the psy
chosocial problems associated with
head injury. While the effects of head
injury should not be underestimated,
these problems may be a function not
just of the head injury but also of all
the other injuries sustained. Indeed,
there is some evidence that the psy
chosocial sequelae in trauma patients
with and without head injury do not
193

differ,13 suggesting that head injury
does not have a unique psychosocial
impact.
This study also provides a basis for
estimating some of the economic im
pact of head injury. In 1978, the
estimated average cost of a day’s stay
in our hospital (exclusive of physi
cian’s fees and direct bills to the
provincial health plan) was $215.
(This represents the average cost to
the hospital of a day’s stay by the
average patient. The average cost of
care for head-injured patients may be
higher.) By 1982 this figure had risen
to $320/d. Thus, the direct costs of
hospitalization for head-injured pa
tients in this hospital were approxi
mately $767 000 for the year 1978.
The estimated costs for 1982 had
risen to $2.1 million or, alternatively,
approximately $7836 per patient. Sta
tistics Canada figures for 1980-19811
give an average length of hospital stay
of approximately 8.3 days (versus
24.5 days in our setting) for the aver
age patient over the age of 15 years
with either a skull fracture or a head
injury. If the annual Canadian inci
dence of 50 000 patients a year is
multiplied by 8.3 days, and the result
ing figure is multiplied by a cost of
$320/d, then the hospital cost of head
injury would be $132.8 million. This
figure, of course, excludes physician’s
and surgeon’s fees, post-hospital care
and income loss.

While the current study gives some
idea of various demographic charac
teristics as well as of the medical and
surgical treatment of head-injured pa
tients, there is clearly a need for
further research on this topic. For
example, there is a need for replica
tion in other Canadian settings to
determine more precisely how much
variation there is across settings in the
type and severity of such injuries.
This is one area in which the use of
standardized diagnostic criteria (such
as the ICD-9) and standardized crit
eria for severity (such as the GCS) can
be useful. Our study also suggests that
there have been some changes, even
over the relatively brief period of the
present study, in the ways in which
head injury is investigated and treat
ed. It is therefore important to have
regular reviews of the care of headinjured people in Canada.
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SESAP V Critique
ITEM 112

Overwhelming postsplenectomy sepsis (OPSI), recognized since 1952, highlights the importance of preserving the
spleen for prevention of OPSI. Progression from health to death frequently occurs in a matter of hours. Patients who
have had splenectomy should be informed about the importance of reporting even minor respiratory and other
infections promptly. Most fatal sepsis occurs in the first two years after splenectomy, but it has been reported many
years later.
Pneumococci have been isolated in approximately 50% of the cases. Polyvalent pneumococcal vaccine gives some
protection, but not all of the types of Pneumococci involved are included in the vaccine. Aggressive treatment of all
infections in these patients is therefore still necessary. The incidence of OPSI among trauma victims who have had
splenectomy is much lower than that among patients who have had the splenectomy for hematologic disease.
Although accessory spleens or the development of splenosis (autoimplantation of fragments of spleen) might
provide protection against OPSI, fatal sepsis has been reported after both.
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Preservation of the Spleen Using Human Fibrin Seal
B e ca u se of the sp le e n 's role in host
defence and the recognition of over
w h e lm in g p ost-sp le n e c to m y se psis,
the current aim of treatm ent for sp le 
nic injuries is to preserve th e spleen. A
n um ber of he m o static a g e n ts have
been used in an effort to control bleed
ing but have not proved satisfactory.
The authors report the re su lts of an
experim ent u sin g a tw o -co m p o n e n t fi
brin seal on injured rabbit spleens.
In fem ale rabbits a longitudinal lac
eration of the entire spleen w a s made.
After 2>/2 m in u tes of c o n tin u o u s h e m 
orrhaging, the sp le e n s w e re either not
treated (5 rabbits) or treated by sp le 
nectom y (5), suture repair (10) or fi
brin-seal repair (10). H e m o glo b in va l
ues w ere m easured preoperatively and
3 d ays postoperatively.
The greatest num ber of d eaths
w ithin 1 4 d a y s occurred in th e un
treated group. There w a s no difference
in death rate b etw een the treated
groups; sim ilarly, there w a s no differ
ence in blood lo ss or fall in hem oglobin
values. Fe w e r a d h e sio n s form e d in the
fibrin-seal group than in the others (p <
0.02). Histopathological exam ination
revealed a greater fibrinoblastic re
sp o n se in the sp le e n s treated w ith
fibrin seal than in the other groups.
The authors believe that fibrin seal
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is an effective and sa fe h e m o sta tic
a ge n t applicable to sp le n ic p a re n c h y 
m al injuries, and that it p rom ote s
w o u n d healing and s u p p r e s s e s a d h e 
sio n formation.

A ca u se du role im portant de la rate
d a n s les m e c a n ism e s de d e fe n se imm unitaire et p u isq u e Ton connaTt bien
le risque de se p sie fulm in an te postsplenectom ie, le traitem ent actuel d e s
le sion s splen iq u es v ise a co n se rve r la
rate. Q u e lq u e s a g e n ts h e m o sta tiq u e s
ont ete utilises pour tenter de juguler
I'h em orra gie m ais a u cu n ne s 'e s t
avere satisfaisant. Le s a u te u rs decrivent les resultats d 'u n e experience au
co u rs de la quelle un a d h e sif de fibrine
a d eux co n stitu a n ts fut utilise su r d e s
rates le se es de lapin.
C h ez d es lapines, une laceration
longitudinale fut pratiquee su r tou te la
longueur de la rate a I'a id e d 'u n sca lp e l
no. 10. A p re s 2 1/2 m in u te s d 'h e m o rra gie continue, la rate fut soit la isse e
s a n s traitem ent (5 lapines), traitee par
splenectom ie (5), reparee par su tu re
(10) ou reparee a I'a id e de l'a d h e s if de
fibrine (10). L 'h e m o glo b in e m ie fut m esu re e en preoperatoire et 3 jou rs a p re s
I'operation.
Le plus grand nom b re de d e c e s a
survenir au cours d e s 1 4 jours d 'o b se rvation fut enregistre au se in du gro u p e
non traite. On n 'a o b se rve a u cu n e d if
ference de taux de m ortalite entre les
gro u p e s traites. De m em e, il n 'y a eu
a u cu n e difference entre les traitem e n ts en ce qui con ce rn e la perte
sa n g u in e et la chute de I'h e m o g lo b inemie. L 'a d h e sif de fibrine a c a u se
m o in s d 'a d h e sio n s q u e les a u tre s traite m e n ts (p < 0.02). L 'e x a m e n h istop a thologique a revele une re p on se fibrinoblastique plus im portante d a n s les
rates traites avec l'a d h e sif de fibrine
que d an s les autres group es.
Les auteurs croient qu e l'a d h e sif de
fibrine est un he m o statiq u e su r et efficace qui se prete au traite m e n t du
parenchym e splenique en fa v o risa n t la
cicatrisation et en su p p rim a n t la for
m ation d 'ad h e sio n s.
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Historically, the treatment of choice
for the ruptured spleen has been sple
nectomy.1 However, with increasing
knowledge of the spleen’s role in host
defences and recognition of the entity
of overwhelming post-splenectomy
sepsis,2’3 enthusiasm for retaining
splenic tissue has become wide
spread.4-6
Procedures such as splenorrhaphy,
once discarded, are now accepted
methods for managing splenic trau
ma. However, splenic preservation
must be proven to be as safe as
splenectomy and to minimize the risk
of fulminant sepsis.
Attempts to salvage the spleen have
included the use of partial splenecto
my, splenic suture, splenic artery liga
tion, the application of hemostatic
agents and no treatment. In addition,
splenic autotransplantation has been
performed.
A variety of topical hemostatic
agents have been used to control sple
nic surface bleeding (e.g., Avitene,
Gelfoam) but these agents have not
been entirely satisfactory.7’8
This study examines the use of high
ly concentrated human fibrinogen as a
hemostatic agent in splenic injury.
Material and Methods
The two-component fibrin seal sim
ulates the physiologic process of
wound closure. Its mode of action is
based on the central function of fibrin
in blood coagulation, creating a he
mostatic clot.
The major ingredients of this twocomponent adhesive are fibrinogen
and thrombin solutions. The fibrino
gen solution contains fibrinogen, Fac
tor XIII, fibronectin, calcium plas
minogen and aprotinin. The thrombin
solution contains thrombin and calci
um chloride. When the two solutions
are mixed, fibrinogen is transformed
to fibrin monomers which aggregate
to form a gel. Concomitantly, throm
bin acts upon Factor XIII and, in the
presence of calcium, Factor X llla is
formed. This factor cross-links the
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fibrin monomers to form a highmolecular-weight polymer. Cross
links between the fibrin polymer and
the collagen of the tissue to which the
sealant was applied are also formed.
In the course of wound healing,
plasminogen activators convert plas
minogen to plasmin. The cross-linked
fibrin is lysed into fibrin degradation
products. This process is retarded by
the antifibrinolytic agent aprotinin.
Thirty female rabbits, each weigh
ing between 2.2 and 2.6 kg and fed a
water and pellet diet, were anesthe
tized with intravenous sodium thio
pental. Under sterile conditions, a
midline laparotomy was performed
on each rabbit and the spleen mobi
lized. A no. 10 scalpel blade was used
to create a longitudinal laceration
down the entire length of the spleen.
The spleen was then observed for 2V2
minutes, during which time the
wound did not stop hemorrhaging.
Animals were randomized into four
groups: splenectomy (5 rabbits), su
ture repair (10), fibrin-seal repair (10)
and no repair (5).
In the suture and fibrin-seal repair
groups, splenectomy was performed if
the repair failed to control the he
morrhage.
The abdominal incisions were
closed in two layers with 2-0 silk
sutures, and the animals were allowed
to recover in warm surroundings.
All blood losses were carefully mea
sured. Blood samples were obtained
preoperatively and on postoperative
day 3 for a complete blood count. The
animals were then explored again on
postoperative day 14 or within 24
hours of death. Careful note was
made of adhesion formation, and the
spleens were removed for histopathological examination.
Statistical analysis was performed
with Student’s paired t-test, analysis
of variance and Duncan’s multiple
range test.

Results

Of the animals that had no repair,
two (40%) died. None of the animals
that underwent splenectomy alone
died, but one that had suture repair
did. In the fibrin-seal group none
died, although one animal required
splenectomy because of a hilar vessel
injury (Fig. 1).
Blood loss for the animals that
underwent splenectomy or splenorr
haphy did not differ significantly (Fig.
2). Those that underwent splenectomy
lost an average of 6.8 ml compared
with 6.2 ml and 7.0 ml for those that
underwent suture repair and fibrinseal repair, respectively.
The decrease in hemoglobin con
centration did not differ significantly
between groups (Fig. 3); however, the
decrease within each group was sig
nificant (p < 0.05).
The platelet counts were also evalu
ated pre- and postoperatively. There
was no significant difference between
the splenectomy and the suture-repair
group, but between these two and the
fibrin-seal-repair groups, the change
was significant (p < 0.05) (Fig. 4).
At autopsy the rabbits that did not
undergo splenectomy or splenorrha
phy and survived 14 days all had
extensive adhesions. The animals that
died had blood within the peritoneal
cavity.
Adhesions formed in 60% of the
animals that had splenectomy and in
50% of those with suture repair but in
only 20% of those with fibrin-seal
repair (p = 0.02 compared with no
repair, splenectomy and suture repair)
(Fig. 5).
Histopathological examination of
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FIG. 3 — Change in hemoglobin level bygroup. ■ = splenectomy, O = suture, A =
fibrin seal.
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FIG. 4 — Change in platelet count by
group. ■ = splenectomy, O = suture, A =
fibrin seal.
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the spleens repaired with the fibrin
seal showed an intense inflammatory
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FIG. 1 — M ortality by group. Hatched
bars = alive, black bars = dead.
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FIG. 2 — Blood loss by group.

FIG. 5 — Adhesion formation by group.
Hatched bars = yes, black bars = no.
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The fibrin seal can be used as the
primary hemostatic agent, or as an
adjuvant in managing the traumatized
spleen, without increasing the periop
erative morbidity or mortality and
without increasing the incidence of
delayed hemorrhage.
Injuries to the hilar vessels of the
spleen are not amenable to conserva
Discussion
tive management and should be treat
Because of increasing recognition of ed by splenectomy. However, for sple
the spleen’s role in immunologic func nic parenchymal injuries, fibrin seal
tion, the principle of preservation is gives rapid and adequately hemostatic
now firmly implanted in surgical repair. For these injuries, sutures may
practice. The risks and benefits of not be required, thereby reducing fur
attempting splenic preservation, how ther trauma and maximizing the
ever, must be weighed against those of amount of viable tissue remaining.
Fibrin seal also has the theoretical
splenectomy.
In children, the incidence of sepsis advantage of being effective for a
after a normal spleen has been re pre-existing coagulopathy, because of
moved because of injury ranges up to the direct application of components
6% and the death rate up to 73%.9 of the coagulation system to the
There is little question that the bene wound.
Fibrin seal seems to evoke less
fits of splenic preservation outweigh
peritoneal inflammatory response
the risks.
In adults, though, the overall mor than other agents, as evidenced by the
tality of an isolated splenic injury lack of adhesion formation. Histologi
requiring splenectomy is less than cally, however, there is an intensive
0.5%, and the incidence of post inflammatory response with respect to
splenectomy sepsis is significantly less tissue reactivity. Fibrin seal evokes an
increased fibroblastic response in the
than that in children.10
Any attempt to preserve the spleen tissue-fibrin seal interface. There is
must yield results superior to the risks some evidence to suggest that fibrin
involved with splenectomy and de and Factor XIII stimulate fibroblast
growth within the injured organ, pro
layed post-splenectomy sepsis.
Approaches to preservation of a moting wound healing.14
The use of the fibrin seal, therefore,
damaged spleen include observation
appears
to be a safe and effective
without operation, reimplantation of
splenic tissue and splenic repair. The method for repairing splenic paren
nonoperative approach has been used chymal injuries. Maximum preserva
successfully in children, but the safety tion of splenic tissue is achieved with
of this method in adults is controver no increased risk of delayed hemorrh
sial. In one series,11 73% of patients age. Further studies of splenic func
initially managed nonoperatively later tion require evaluation.
required surgery.
We acknowledge the financial assis
When the spleen cannot be repaired tance of Immuno Canada for this project.
because it is too badly injured, splenic
reimplantation has been performed to References
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Citrucel,

METHYLCELLULOSE
Therapeutic Classification:
Bulk forming laxative.
Indications:
For the treatment and prevention of constipation.
Contraindications:
Known sensitivity to methylcellulose; internal
obstruction or fecal impaction.
Precautions:
Failure to consume adequate fluid can reduce
efficacy of the drug and even lead to obstruction.
Adverse Effects:
Rarely flatulence and abdominal discomforts.
Dosage and Administration:
Adults and children over 12 years: One or two
rounded teaspoonfuls thoroughly mixed in 240 mL
(8 oz.) of cold water or juice, 1 to 3 times a day or
as directed by a physician. Stir and drink promptly.
Each 6 g dose (one rounded teaspoonful) contains
1 g methylcellulose.
Children 6 to 12 years: One level teaspoonful
thoroughly mixed in 120 mL (4 oz.) cold water,
2 to 3 times a day or as directed by a physician.
Stir and drink promptly.
Each 3 g dose (one level teaspoonful) contains 0.5 g
methylcellulose.
Children under 6 years: Consult a physician.
Full amount of liquid should be ingested with each
dose. Continued use for 2 to 3 days may be needed
for adequate relief.
Supplied: 300 g Citrucel powder in wide-neck
plastic bottle.
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Dalacin® C Phosphate Sterile Solution

(clindamycin phosphate)

Antibiotic
Recommended Applications
Action: Clindamycin exerts its antibacterial effect by causing cessation of protein synthesis and also by
causing a reduction in the rate of synthesis of nucleic acids.
Indications: Dalacin C Phosphate (clindamycin phosphate) is indicated for the treatment of infections
where the oral route is not indicated or feasible.
Dalacin C Phosphate is indicated in the treatment of serious infections due to sensitive anaerobic
bacteria, such as Bacteroides species, peptostreptococcus, anaerobic streptococci, Clostridium
species and micro-aerophilicstreptococci.
Dalacin C Phosphate is also indicated in serious infections due to sensitive Gram-positive organisms
(staphylococci, including penicillinase-producing staphylococci, streptococci and pneumococci)
when the patient is intolerant of, or the organism resistant to other appropriate antibiotics.
Contraindications: The use of Dalacin C Phosphate (clindamycin phosphate) is contraindicated in
patients previously found to be hypersensitive to this compound, the parent compound, clindamycin, or
clindamycin palmitate. Although cross-sensitization with Lincocin® (iincomycin hydrochloride) has not
been demonstrated, it is recommended that Dalacin C Phosphate not be used in patients who have
demonstrated iincomycin sensitivity.
Until further clinical experience is obtained, Dalacin C Phosphate is not indicated in the newborn (in
fants below 30 days of age), or in pregnant women.
Warnings: Some cases of severe and persistent diarrhea have been reported during or after therapy
with Dalacin C Phosphate (clindamycin phosphate). This diarrhea has been occasionally associated with
blood and mucus in the stools and has at times resulted in acute colitis. When endoscopy has been
performed, some of these cases have shown pseudomembrane formation.
If significant diarrhea occurs during therapy, this drug should be discontinued or, if necessary, con
tinued only with close observation. Significant diarrhea occuring up to several weeks post-therapy
should be managed as if antibiotic-associated.
If colitis is suspected, endoscopy is recommended. Mild cases showing minimal mucosal changes
may respondtosimpledrugdiscontinuance.Moderatetoseverecases.includingthoseshowingulceration or pseudomembrane formation, should be managed with fluid, electrolyte, and protein
supplementation as indicated. Corticoid retention enemas and systemic corticoids may be of help in
persistent cases. Anticholinergics and antiperistaltic agents may worsen the condition. Otbercauses
of colitis should be considered.
Studies indicate a toxin(s) produced by Clostridia (especially Clostridium difficile) may be a principal
cause of clindamycin and other antibiotic-associated colitis. These studies also indicate that this
toxigenic Clostridium is usually sensitive in-vitro to vancomycin. When 125 mg to 500 mg of vanco
mycin were administered orally four times a day for 5 - 10 or more days, there was a rapid ob
served disappearance of the toxin from faecal samples and a coincidental recovery from the diarrhea.
It should be noted that serious relapses have occurred up to one month after apparently successful
treatment. A relatively prolonged period of continuing observation is therefore recommended.
Precautions: Dalacin C Phosphate (clindamycin phosphate), like any drug, should be prescribed with
caution in atopic individuals. Dalacin C Phosphate must be diluted for intravenous administration.
(See Dosage and Administration)
The use of antibiotics occasionally results in overgrowth of nonsusceptible organisms - particularly
yeasts. Should superinfections occur, appropriate measures should be taken as dictated by the
clinical situation.
As with all antibiotics, perform culture and sensitivity studies in conjunction with drug therapy.
Since abnormalities of liver function tests have been noted occasionally in animals and man, periodic
liver function tests should be performed during prolonged therapy. Blood counts should also be
monitored,during extended therapy.
Dalacin C Phosphate may be used in anuretic patients. Since the serum half-life of clindamycin in
patients with impaired hepatic function is greater than that found in normal patients, the dose of
Dalacin C Phosphate should be appropriately decreased. Hemodialysis and peritoneal dialysis are not
effective means of removing the compound from the blood. Periodic serum levels should be deter
mined in patients with severe hepatic and renal insufficiency.
Adverse Reactions: Local
(a) Intramuscular Injections: Of 404 patients treated with Dalacin C Phosphate (clindamycin
phosphate) intramuscularly (with a solution containing 150 mg/ml), six (1.5%) demonstrated local
reactions as follows: Two complained of pain at the injection site, two demonstrated induration at
the injection site and two developed sterile absesses.
(b) Intravenous Infusions: Of 192 patients treated with Dalacin C Phosphate by intravenous infusion,
14 (7.3%) demonstrated local reactions. Eleven patients developed superficial thrombophlebitis and
one patient developed both superficial and deep thrombophlebitis. The majority of these cases
developed in conjuctionwiththe useofindwelling I.V.cathetersand itisdifficulttoknowhowmuchthe
drug contributed to the irritation. Two patients developed localized erythema, swelling and pain at
the site of the infusion.
Systemic Side Effects: Twenty-eight patients of 596 treated with Dalacin C Phosphate (clindamycin
phosphate) by either the intramuscular or intravenous routes developed systemic side effects as follows:
Number of Patients
Rash......................................................................................................................................................... 7
Urticaria................................................................................................................................................... 1
Pruritus.................................................................................................................................................... 1
Fever, Leucocytosis............................................................................................................................... 1
Nausea, with or without vomiting.......................................................................................................... 1
Diarrhea (See also under 'Warnings").................................................................................................... 4
Hypotension............................................................................................................................................. 1
Hypertension........................................................................................................................................... 1
Shortness of Breath................................................................................................................................ t
Superinfection' ....................................................................................................................................... 4
Cardiac a rre s t" ..................................................................................................................................... 1
Bad or bitter taste in mouth.................................................................................................................... 5

Superinfection is a complication of antibiotic therapy in general and is not necessarily a true side
effect of clindamycin phosphate.
* * Due to underlying myocarditis in this patient.
Clinical and Laboratory Findings: Patients treated during clinical trials of Dalacin C Phosphate *”
(clindamycin phosphate) were followed with clinical laboratory tests, including complete hematology,
urinaiysisand liverand kidneyfunctiontests. Some of these tests were abnormal initially and returned*' ^
to normal during therapy with Dalacin C Phosphate, while others were normal initially and became
abnormal,during therapy. Overall evaluation of clinical laboratory values in these patients does not
indicate that Dalacin C Phosphate therapy has a toxic effect on the hematopoietic, hepatic or renal
systems. Transient elevations of serum transaminases have occured in some patients, but other liver ,4
function tests (alkaline phosphatase, serum bilirubin) have not shown any tendency to increase and
there have not been clinical signs of drug-induced hepatic toxicity.
Symptoms and Treatment of Overdosage: No cases of overdosage have been reported. No specific
antidote is known. Doses as high as 1200 mg every six hours (4800 mg/day) by infusion for five days1have been given without adverse effects.
»
DOSAGE AND ADMINISTRATION
Adults
^
Intramuscular Injection: 600 mg/day in 2 equal doses.
Moderately severe infections: 600 to 1200 mg/day in 2 or 3 equal doses.
Severe infections: 1200 to 2400 mg/day in 2,3 or 4 equal doses. Intramuscular injections of more than ^
600 mg into a single site are not recommended.
Intravenous Administration: Dalacin C Phosphate (clindamycin phosphate) must be diluted prior to"* '
I V. administration to a dilution of 300 mg in 50 mL of diluent (6mg/mL) or more, and infused in not less
than 10 minutes. Administration of morethan 1200mg inasingle 1 hourinfusion isnot recommended, yDalacin C Phosphate should not be injected intravenously undiluted as a bolus.
Moderately severe infections: 900 to 1800 mg/day by continuous drip or in 2 or 3 equal doses, each -4
infused over 20 minutes or longer.
Severe Infections: 1800 to 2700 mg/day by continuous drip or in 3 or 4 equal doses, each infused ovei20 minutes or longer. In life-threatening infections, doses of 2700 to 4800 mg/day by continuous drip or "
in 3 or 4 equal doses each infused over 20 minutes or longer may be given.
Dilution and infusion rates:
Dose
Diluent
Time
__
300 mg
50 mL
10 min.
600 mg
100 mL
20 min.
900 mg
150 mL
30 min.
*■
1200 mg
200 mL
45 min.
Alternatively, drug may be administered in the form of asingle rapid infusion of the first dose followed
by continuous I.V. infusion as follows:
To maintain serum
Rapid
Maintenance
clindamycin levels
infusion rate
infusion rate
* <*■
Above 4 mcg/mL
10mg/min. for 30 min.
0.75 mg/min.
Above 5 mcg/mL
15mg/min. for 30 min.
1.00mg/min.
N '
Above 6 mcg/mL
20mg/min.for30min.
1.25 mg/min.
4
Children: (Over one month of age)
Intramuscular injection: 10 to 15 mg/kg/day in 2,3 or 4 equal doses.
Moderately severe infections: 15 to 20 mg/kg/day in 3 or 4 equal doses.
+>
Severe infections: 20 to 30 mg/kg/day in 3 or 4 equal doses.
Intravenous Administration:
,
Moderately severe infections: 15 to 25 mg/kg/day by continuous drip or in 3 or 4 equal doses, each
infused over 20 minutes or longer.
Severe infections: It is recommended that children be given no less than 300 mg/day regardless of body *
weight. (Dilute Dalacin C Phosphate Sterile Solution in the same manner as for adults.)
Dilution and Compatibility:
4 mL (600 mg) Dalacin C Phosphate when diluted with 1000 mL of the following commonly used in
fusion solutions was found to be physically compatible and demonstrated no significant change in pH r
or antimicrobial potency over a period of 24 hours:
Sodium chloride injection
k
Dextrose 5% in water
M
Dextrose 5% in saline
Dextrose 5% in Ringer's Solution
Dextrose 5% in half-strength saline plus 40 mEq potassium chloride
u
Dextrose 2V2% in Lactated Ringer's Solution (Hartmann's Solution)

.

Dalacin C Phosphate was not stable when added to Dextrose 5% in water plus vitamins. Therefore it is
not recommended that Dalacin C Phosphate be mixed with any infusion solution containing B vitamins.
Supplied:
.
Dalacin C Phosphate contains the following per mL of sterile solution:
'
Clindamycin phosphate equivalentto clindamycin base 150 mg
Benzyl alcohol 5 mg
Disodium edetate 0.5 mg
Water for injection q.s.
When necessary the pH is adjusted with sodium hydroxide and/or hydrochloric acid to maintain a pH
range of 5.5 to 7.0.
tDalacin C Phosphate is available in 2 mL and 4 mL ampoules.
NOTE: Do not store below 15°C.
-4
Product Monograph available upon request.
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A Review of Intra-articular Knee Injuries in Racquet Sports
Diagnosed by Arthroscopy
Because of the recent rapid increase in
the number of knee injuries related to
racquet sports, the authors undertook
a retrospective study of such injuries
seen over a 5-year period at the Toron
to Western Hospital Sports Medicine
Institute. The 121 patients who pre
sented over the study period with a
racquet-sports-related knee injury re
quiring arthroscopy represented 30%
of all racquet-sports related injuries
seen during that period. The mean age
at presentation was 3 2.8 years and
two-thirds of the patients were men.
All the major racquet sports were rep
resented. In all, 213 lesions (7 bilater
al) were seen at 128 arthroscopies,
and 165 arthroscopic procedures were
performed. The most common lesion
was meniscal followed by chon
dromalacia patellae, anterior cruciate
ligament tears, chondral lesions and
pathologic plicae. Over 90% of the
patients returned to their chosen rac
quet sport within 3 months of the
arthroscopy and most were playing at
a similar performance level to that
before the initial injury.

Devant I'augmentation rapide et
recente du nombre de blessures du
genou reliees aux sports de raquettes,
les auteurs ont entrepris une etude
retrospective des blessures de ce type
qui ont ete vues au cours d'une periode de 5 ans au Toronto Western
Sports Medicine Institute. Les 121 pa
tients qui ont ete recus au cours de
cette periode souffrant d'une blessure
du genou reliee aux sports de raquet
tes et necessitant une arthroscopie
representaient 30% de toutes les bles-
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sures dues aux sports de raquettes
vues durant la meme periode. L'age
moyen etait de 3 2.8 ans et deux-tiers
des patients etaient des hommes.
Tous les principaux sports de raquet
tes etaient representes. Au total, 21 3
blessures (dont 7 bilaterales) ont ete
observees au cours de 128 arthrosco
pies, alors que 165 interventions arthroscopiques etaient pratiquees. Les
blessures les plus frequentes affectaient les menisques, suivies des
chondromalacies rotuliennes, des
dechirures du ligament croise anteroexterne du genou, des lesions du carti
lage et des replis pathologiques. Plus
de 90% des patients sont retournes a
leur sport de raquette prefere moins de
3 mois apres I'arthroscopie et la plupart jouait au meme niveau de com
petition qu'avant leur blessure.

Participation in racquet sports has
escalated rapidly over the past 10
years. The United States Squash Asso
ciation estimates that there are more
than 500 000 people playing squash in
that country, with the number in
creasing at a rate of more than 20%
annually.1 Racquetball is the fastest
growing racquet sport in North Amer
ica with more than 10 million people
now playing,2 and tennis is as popular
as ever. Despite this increase in par
ticipation and a concomitant increase
in the number of associated injuries,
there is little information in the litera
ture on the injury profile seen in
racquet sports.3 5 The literature that
does exist addresses the problems of
facial and upper extremity injuries
but virtually ignores the lower extrem
ity. Over the past year we have seen a
lot of injuries to the lower extremity,
especially to the knee, related to rac
quet sports. This prompted us to un
dertake a retrospective analysis of rac
quet-sports related injuries, with par
ticular attention to knee injuries re
quiring arthroscopy, seen over a
5-year period (1982 to 1987) at the
Toronto Western Hospital Sports
Medicine Institute.
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Patients and Methods
Of 404 racquet-sports related inju
ries seen, 222 (55%) involved a knee
joint and 121 (30%) knees required
arthroscopic evaluation based on the
history of the injury and the physical
findings. The injuries in these 121
patients were analysed by review of
the patient’s chart and by detailed
questionnaire with telephone follow
up to form an epidemiologic profile in
addition to accurate operative data.
All patients were contacted. Although
a formal follow-up might have provid
ed more information, this was not
possible for the majority of patients
because many were from out of town.
Average follow-up was 27.2 months
(range from 6 to 78 months). Several
patients were followed up for less
than 2 years, but since no strong
conclusions are to be made based on
the results of treatment, this should
not be considered a major weakness
of our study.
Findings
Two-thirds of the patients were
male, ranging in age from 14 to 68
years (mean 32.8 years). All patients
suffered an acute knee injury during
participation in a racquet sport. Al
though several of these patients par
ticipated in other sports and had pre
vious injuries, they were only consid
ered for this study if it was clear that
the injury was caused while playing a
racquet sport. Two-thirds were in
jured playing squash or tennis, the
remainder playing badminton or rac
quetball (Table I). Competition level
of the injured participants ranged
from recreational beginner to profes
sional, but over 90% of those injured
were of an advanced amateur level of
participation, playing at least twice a
week.
Warm-up
Pre-game preparation and surface
conditions were considered as possi199

ble factors in the injuries and were
therefore investigated in detail. In
over 60% of the patients the warm-up
procedure was inadequate; either
there was no warm-up at all or inade
quate time was given to stretching
exercises or rallying. Of the remain
der, 22 patients (18%) performed at
least 5 minutes of rallying and 25
(21%) engaged in a warm-up proce
dure that included at least 10 minutes
of slow, prolonged stretching followed
by at least 5 minutes of rallying before
competition. The surface played on
varied depending on the sport. The
condition of the playing surface was
normal in the majority of cases. How
ever, a small group of patients report
ed playing on either hard, slippery or
irregular surfaces.
Previous Injury
In response to questioning about
previous injuries, most patients re
ported none, but 22 had at least one
prior knee injury, including 14 meniscal tears, 9 medical collateral ligament
sprains, 7 cases of patellar tendinitis
and 2 anterior cruciate ligament tears.
Seventeen of the patients had suffered
ankle injuries in the past.
Mechanism o f Injury
Over 85% of the patients injured
their knee through a twisting mecha
nism, either by a fast turn for a
difficult shot, an improper landing
after playing a high overhead shot, or
as a result of fast stop or start (Table
II). Twisting places rotatory forces on
the knee joint and commonly leads to
intra-articular injuries. In a small
group of patients, direct contact with
a wall, the racquet or, on one occa
sion, a player, resulted in the injury to
the knee joint.
Symptoms
Time from injury to presentation
ranged from immediately to more
than 6 months (Table III). Almost
50% presented within 2 weeks and
over 90% within 3 months. In all
cases the patient’s symptoms at pre
sentation were referable to the injury
and were not simply exacerbations of
previous injuries. The most common
complaint upon presentation was of
knee pain (over 90%). Other symp
toms included intermittent swelling
(62%), a feeling of instability (27%)
and frank giving way (8%). These
symptoms, combined with the find
ings of joint line or patellofemoral
tenderness, joint effusion or ligamen
tous instability (demonstrated by an
200

terior drawer, Lachman and pivot
shift signs), led to the arthroscopic
evaluation.
Arthroscopy
Of the 121 patients, 114 underwent
a unilateral arthroscopy and 7 bilater
al - 128 arthroscopic examinations in
all. A total of 202 intra-articular le
sions were found, indicating that in
most cases more than one lesion was
present (Table IV).
Five major categories of lesions
were found at arthroscopy. The most
common was meniscal lesions (76
cases [60% of knees]). This preponder
ance is likely related to the mecha
nism of injury (i.e., twisting) reported
by most patients. The other categories
were chondromalacia patellae (32
cases [25% of knees]), anterior cruci
ate ligament injuries (28 cases [22% of
knees]), chondral lesions (26 cases
[20% of knees]) and pathologic pli
cae (15 cases [12% of knees]). Other
intra-articular lesions found included
osteoarthritis, loose bodies, fat-pad
contusions and traumatic synovitis.
Eleven arthroscopies revealed no intraarticular lesions. Thus, in over 90%
of knees subjected to arthroscopy, one
or more lesions were found, and in all
cases the condition correlated with
the patient’s clinical presentation.
Meniscal tears, the most common le
sion, can be classified by type (Table
V). Almost 50% of the meniscal tears
were of the oblique or flap type.
Vertical longitudinal tears, commonly
known as bucket handle tears, and
vertical transverse tears, commonly
known as radial tears, made up the
bulk of the rest. Medial meniscal tears
far outnumbered lateral tears, and the
posterior horn was the most common
site of injury within the meniscus.
These numbers correlate well with
those reported in the literature.6
From the data presented one might
consider the chronicity of the disease
process seen arthroscopically. As al
ready noted, most patients had more
than one lesion or diagnosis. In all
cases of potentially degenerative dis
ease (i.e., osteoarthritis or late-stage
chondromalacia), there was a more

acute problem as well (meniscal tear,
chondral lesion or fat-pad contusion).
It should also be remembered that the
patients all had injuries referable to a
racquet sport in the recent past to
account for their acute condition.
A wide variety of arthroscopic sur
gical procedures were performed to
treat these intra-articular lesions (Ta
ble VI). Of 165 procedures, there were
T a b le 1—-R a c q u e t S p o rts P articip a tio n
S p o rt

N o. (% )

Sq u a sh

4 3 (3 6 )

T e n n is

3 8 (3 1 )

B a d m in to n
R a c q u e tb a ll

2 5 (2 1 )
1 5 (1 2 )

T a b le II— M e ch a n ism o f Injury
M e c h a n ism

N o. {% )

T w is t in g
Im p ro p e r la n d in g

1 0 8 (8 9 )
40
61
4

F a s t tu rn in g
F a s t sto p
F a s t sta rt
D ire c t c o n ta c t
O pponent

3
6 (5)
1

W a ll
R acquet
O th e r

3
2
7 (6)

T a b le I I I - - T im e F ro m In ju ry to P re se n tatio n
T im e
0 -

N o. (% )
1 wk

1 - 2 wk
2 - 4 wk

3 8 (3 1 )
1 9 (1 6 )
2 9 (2 4 )

1 - 3 mo
3 - 6 mo

2 3 (1 9 )
8 (7)
4

> 6 mo

(3)

T a b le IV — A r th r o s c o p ic F in d in g s (2 0 2
L e sio n s)*
F in d in g s

N o. (% )

M e n isc a l le sio n s
C h o n d ro m a la c ia pa te lla e
A n te rio r c ru c ia te lig a m e n t le sio n s
C h o n d ra l le sio n s
P a t h o lo g ic p lic a

7 6 (3 8 )
3 2 (1 6 )
2 8 (1 4 )
2 6 (1 3 )

O ste o a rth ritis
M is c e lla n e o u s
(in c lu d in g lo o s e b o d ie s , fa t-p a d
c o n tu s io n s , s u b lu x a tin g patella)

15
7

(7)
(3)

18

(9)

‘ N o th in g fo u n d in 11 kn e e s.

T a b le V — T y p e o f M e n isc a l L e s io n s (n = 7 6 )
T y p e of lesion
O b liq u e (flap o r "p a rro t b e a k " )
V e r tic a l lo n gitu d in a l (b u c k e t handle)
V e r tic a l tra n s v e rs e (radial)
M u ltip le -p la n e (d e g e n e ra tiv e /co m p le x)
H o rizo ntal
M is c e lla n e o u s
(d isco id , h y p e rm o b ile , m e n isca l c y st)

M edial

La te ra l

T o ta l (% )

28
16
6
6
2

8
0
4
2
0

3 6 (4 7 )
16 (2 1 )
1 0 (1 3 )
8(11)
2 (3)

3

1

4

(5)
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61 soft-tissue resections, mainly to
meniscal lesions, 40 shavings of the
articular cartilage of the patella or the
femoral condyle and 33 lavage proce
dures. Trimming was considered to be
the minimal resection in treating
small meniscal tears. Debridement of
articular cartilage of the femoral con
dyle was performed on five occasions.
Only 11 knees required open opera
tive procedures, including reconstruc
tive procedures for anterior cruciate
ligament deficiency and open menis
cectomies for difficult posterior horn
tears to the lateral meniscus.
Other therapeutic modalities were
used in the pre- and post-arthroscopic
management period. Oral anti-inflam
matory agents have been shown to
reduce post-arthroscopy swelling and
pain, allowing earlier, more-effective
rehabilitation.7 Stretching exercises,
ice, frictional massage and electro
therapy were all used. In several pa
tients with anterior cruciate ligament
tears the knee was braced.
Return to Sport

Most patients (91%) returned to
their sport within 3 months of their
arthroscopy (range from 1 week to 6
months) and achieved a performance
level similar to that before injury
(Table VII). Patients with meniscal
lesions, chondral lesions or pathologic
plicae tended to return more quickly,
most within 3 months, whereas those
T a b le V I— A r th r o s c o p ic S u rg ic a l P ro ced u re s
(n =

165)

P ro c e d u re

N o. (%)

R e s e c tio n

61 (3 7 )

M e n is c a l

51
10

Plica
A r tic u la r c a rtila g e s h a v in g

4 0 (2 4 )

P a te lla

19

M e d ia l fe m o ra l c o n d y le

18

L a te ra l fe m o ra l c o n d y le

3

Lava g e

3 3 (2 0 )

T rim m in g

10

M e n is c a l

8

(6)

Fat pad

2

D e b rid e m e n t

8

(5)

C lo s e d la te ra l release

3

(2)

10

(6)

M is c e lla n e o u s

with chondromalacia patellae or ante
rior cruciate ligament injuries general
ly had a more prolonged recovery.
Eleven patients were unable to return
to their sport as a result of their
injury.
Discussion

In the past, emphasis has been
placed on facial and upper extremity
injuries in racquet sports. It is evident
from this study that a substantial
number of racquet sports injuries
occur in the lower extremities, partic
ularly knee joints. Over half the pa
tients with knee injuries underwent
arthroscopy and in 90% of those 121
people, gross intra-articular lesions
were found. The lesions seen were no
different from those seen in other
sports injuries, and the proportions of
lesions were similar to those in other
non-contact sports. Investigations
into the causes of the injuries identi
fied twisting as the major culprit, but
no strong conclusions can be made
with respect to causative or preven
tive factors. It is our opinion that a
proper warm-up, consisting of stretch
ing and rallying for an adequate
length of time, might reduce the num
ber of injuries seen. Prospective, wellcontrolled studies into these and other
potential preventive measures such as
shoe type and condition are needed,
so that appropriate recommendations
can be made to the ever-growing num
ber of racquet sports participants. The
increasing use of protective equip
ment to prevent eye injuries by
squash and racquetball players is in
dicative of the influence work such as
this can exert. It was reassuring that
over 90% of patients returned to their
sport and that 80% returned within 3
months and had regained their pre
injury performance level. Just as other
investigators have found in the past,8-9
we believe that the use of operative
arthroscopy, as opposed to more tra
ditional open techniques, played a
major role in the early and successful
return of our patients to their desired
activities.
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Muir and Barclay are joined by J.A.D.
Settle to produce the third edition of Burns
and Their Treatment. Comparison of this
edition with the first reveals that all of the
original chapter headings have been re
tained and some of the original informa
tion remains unchanged. Additions to the
section on outpatient treatment include
first aid and transport, and the last chapter
on administrative aspects of burns in
cludes design of a burn unit. Important
material on the management of a large
number of burns from a disaster is includ
ed, based on first-hand experience with the
Bradford football-stadium fire of 1985.
Burn shock and fluid resuscitation fills a
quarter of this book. Plasma administra
tion is advocated as the cornerstone of
initial resuscitation. This practice is no
longer common in North America but may
be so in the United Kingdom. The estima
ted volume requirement for the first 24
hours is close to that calculated by the
Brooke or Evan’s formula, with supple
mentation orally by water or intravenously
by 5% dextrose. The authors do not stress
the overall importance of measuring hour
ly urine output to regulate fluid replace
ment but attach equal importance to rest
lessness, colour, blood pressure, nausea
and hematocrit value. (They mention crys
talloid resuscitation methods and dismiss
these as of no greater benefit because
hematocrits in patients treated with crys
talloid solutions are still high at the end of
24 hours, a state one would expect in the
presence of extensive burns.)
Although they recommend the use of
plasma, the authors cite the cost and the
dangers of transmitting hepatitis and
AIDS. They advocate red blood cell ad
ministration for burns to 10% or more of
the body surface, although earlier they
state that patients with burns of up to 15%
of the body surface do not even require
fluids intravenously. For burns of more
than 25% of body surface area, they advo
cate red blood cell administration 4 to 8
hours and again 24 to 36 hours after
injury. Today, unless escharotomies have
been performed with excessive blood loss,
red blood cells would not normally be
administered until after 48 hours.
The book contains a curious mix of
detail and lack of detail. For instance,
morphine intravenously, 0.2 mg/kg body
weight, is advocated but no time interval is
given for repeat administration. There are
three sentences on how to insert a subcla
vian line for central venous pressure. Any
one who needs such instruction would
require much more detail. Use of Dextrane
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in the first 24 hours is now of only
historical interest but receives a full page,
while crystalloid resuscitation, including
hypertonic, advocated by Monafo and the
Parkland formula of Baxter, both receive
only brief mention.
Bums of the respiratory tract occupy
two pages including a half-page description
on how to do a tracheotomy, compared
with three pages devoted to treatment of
open wounds. No mention is made of the
diagnostic criteria for smoke inhalation,
including roles of patient history, bronchoscopic findings, blood gas levels, chest
x-ray findings and results of zenon wash
out, and no treatment principles are in
cluded. It is evident that, although smoke
inhalation is a major component in com
prehensive burn care, these authors regard
it as someone else’s problem.
The chapter on local treatment of the
burn wound is a mix of old and new
concepts and includes the only balanced
evaluation of different treatment philoso
phies such as early versus delayed excision.
The role of topical antibacterials is
touched on and the value of Sulfamylon in
penetrating infected wounds is stressed.
Today one would probably excise an in
fected wound. Surprisingly, the important
differentiation between bacterial coloniza
tion and invasive infection is not ad
dressed, and the value of a full-thickness
biopsy for histologic examination and
quantitative culture of the wound are miss
ing. The open and closed methods of
grafting are discussed, but practical infor
mation on the use of sutures, staples,
tie-over dressings and splints for grafting
across joints is not given.
The usual methods of storage and refrig
eration of grafts at 4°C is mentioned.
Storage at —4°C, providing 3 months of
viable autografts, is advocated. This meth
od has not become common and its inclu
sion is, I think, misleading. The accepted
pretreatment of skin with glycerol and
rapid freezing to -7 0 °C is included. For
limited donor sites, meshing nine to one is
advocated. This technique has not really
gained wide practical acceptance and other
methods of circumventing limited donor
sites are available. The text acknowledges
the existence of AIDS and other blood and
tissue-transmitted diseases but advocates
the archaic and dangerous practice of har
vesting extra skin from other burn patients
for a patient requiring homograft, without
first testing the donor burn patient for
AIDS and hepatitis. This practice is to be
condemned in 1987.
Escharotomy is buried in a section on
management of limb burns but really be
longs with initial management. No techni
cal details are included.
The shortcoming of this third edition is
its adherence to the original chapter head
ings and format, which reflect burn prob
lems at the time of initial publication in
1962. Thus, emphasis on plasma for initial

fluid resuscitation, sparse mention of the
complex problem of smoke inhalation in
jury and opinions on the role of excisional
surgery and topical antibacterial use,
which do not reflect present practice, date
this book. It would be interesting to know
how many of the treatment methods de
scribed are actually standard in British
hospitals today.
CHARLES F.T. SNELLING, MD. FRCSC

Director,
Burn Unit,
Vancouver General Hospital,
855 West 12th Avenue,
Vancouver, BC
V52 1M9

REOPERATIVE VASCULAR S U R 
GERY. Edited by Hugh H. Trout, III,
Joseph M. Giordano and Ralph G. DePalma. 392 pp. Illust. Marcel Dekker,
Inc., New York, 1987. $89.00 (US).
ISBN 0-8247-7723-9.

This book is one of a series on the science
and practice of surgery. Its editors are
from The George Washington University
Medical School in Washington, DC. The
authors are experienced surgeons who
present practical solutions to difficult
problems.
Vascular surgery has developed rapidly
in the past 35 years, so the number of
reoperations has also increased. Second
operations are more difficult due to scar
ring and limited options. Few surgeons
have extensive experience in this field.
Repeat operations on the vascular sys
tem are required by progression of athero
ma, myointimal hyperplasia, infection, re
jection of transplants or development of
false aneurysms. The management of prob
lems such as false aneurysms, infected
bifurcation grafts and occlusion of a bifur
cation graft are discussed in the book. Less
common problems such as failed in-situ
vein grafts and reoperations for inferior
vena caval obstruction or thoracic outlet
compression are also included. There is a
chapter on the role of myocardial revascu
larization for patients with peripheral vas
cular disease.
The book is attractively printed and has
excellent illustrations. It will be valuable
for vascular surgeons, for fellows in vascu
lar surgery and any surgeons performing
vascular procedures.
S.E. C a r r o l l , m d , f r c s c

Professor of surgery,
University of Western Ontario,
St. Joseph’s Hospital,
268 Grosvenor St.,
London, Ont.
N6A 4V2
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Further Remembrances of That Revered Anatomist,
Dr. J.C. Boileau Grant
From access to a d e taile d c u rric u lu m
vitae w ritte n by Dr. G rant w h e n he
w as about 75 years old, th e a u thor has
learned som e little -k n o w n fa c ts o f his
background and life.
His ancestors cam e fro m France
and had been ennobled. One predeces
sor w as a m ayor o f Paris. S everal of
his fa m ily decided to e m ig ra te to G reat
B ritain w ith th e H u gu eno t m ove m en t.
G rant gra du ated fro m th e U n iversity
o f Edinburgh in 1 9 0 8 in th e sam e class
as his fu tu re b ro th e r-in -la w , W illia m
Boyd.
W hen W o rld W a r I w a s declared, he
im m e d ia te ly volunte ered fo r th e army.
During service on th e W e s te rn Front,
he w a s m en tion ed in d isp a tch e s in
1 9 1 6 , w o n th e M ilita ry C ross in 1917
and a bar to th e M ilita ry C ross in
19 18 .
A t th e o u tb re a k o f W o rld W a r II,
G rant, w h o had been a pro fe sso r of
anatom y firs t in W in n ip e g and then in
T oronto fo r m any years, volunte ered
again fo r w a r service, b u t w a s rejected
as being to o valuable a te a c h e r to be
allow ed to en list.

A ya n t pu co n su lte r un c u rric u lu m vitae
de taille e c rit par le Dr G rant alors q u 'il
ava it environ 75 ans, I'a u te u r a appris
quelques fa its peu connus s u r ses an 
te ce d e n ts e t sa vie.
Ses ancetres, des gens q u i avaient
ete anoblis, ve n a ie n t de France. Un
d 'e n tre -e u x a v a it e te m aire de Paris.
Plusieurs m em b res de sa fa m ille
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ava ie n t decide d 'e m ig re r en GrandeB retagne lors du d e p la ce m e n t des H u
guenots.
G rant o b tin t son d ip lo m e en 1 9 0 8
de I'U n iv e rs ite d 'E d inb ourg . II e ta it de
la m em e p ro m o tio n que W illia m Boyd,
son fu tu r beau-frere.
A la de cla ra tio n de la P rem iere
Grande G uerre, il s ’ e st im m e d ia te m e n t
porte vo lo n ta ire a I'A rm e e . D u ran t son
service sur le fro n t o ccid e n ta l, son nom
fu t m e n tio n n e dans les depeches m ilita ire s en 191 6, il re m p o rta la croix
m ilita ire en 1 9 1 7 e t a jo u ta une b a rre t
te a sa croix en 1 9 1 8 .
Au d e cle n ch e m e n t de la Seconde
G uerre M on dia le, G rant, qui a v a it ete
pro fe sseu r d 'a n a to m ie a W in n ip e g
puis a T oron to p e nd an t plu sie u rs annees, se porta de nouveau volonta ire. II
fu t to u te fo is re je te , ses m e rite s de
pro fe sseu r e ta n t ju g e s tro p im p o rta n ts
pour lui p e rm e ttre de s'enro ler.

According to the Boileau family
tree, a John Boileau (fourth genera
tion after Etienne) was ennobled, by
King Charles V, and the nobility con
tinued for at least another nine gener
ations, the last of the titled members
of the family that remained in France
was a Charles Boileau (Dr. Grant’s
full Christian names were John
Charles Boileau).
Grant graduated in medicine from
the University of Edinburgh in 1908,
in the same class as Dr. William
Boyd. During the following year he
was for a term resident medical offi
cer at the Infirmary in Whitehaven,
Cumberland. From 1909 to 1911, he
was a fulltime demonstrator of anato
my in the University of Edinburgh,
under Professor Cunningham. He was
also a demonstrator of anatomy from
1911 to 1913 at the University of
Durham, Newcastle-on-Tyne, under
Professor R. Howden, who was the

Dr. J.C.B. Grant (Fig. 1) died in
August 1973 at the age of 87 years.
Twelve years before he had written a
detailed curriculum vitae, one copy of
which was given to his brother-in-law,
Dr. David Christie (Grant’s wife, Catriona, was a Christie, as was Enid, the
wife of Dr. William Boyd). Because I
had assisted in caring for him during
his final illness and knowing that I
had been an anatomy demonstrator
for Dr. Grant, Dr. Christie be
queathed the copy to me.
In an early paragraph of the curric
ulum vitae, written when he was 75
years of age, Grant states:
My mother was a direct descendant,
20th generation, of Etienne Boileau, who
was the first Mayor or Provost of Paris, in
the year 1255. Being of the Reformed
Church (Huguenots), some of the Boileaus
left France for England and Ireland in the
year 1685.
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FIG. I — Dr. J.C.B. Grant.
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editor of Gray’s Anatomy. He then
served as resident medical officer in
the ear, nose and throat department at
the Infirmary in Bristol from 1913 to
1914. In the meantime, he was locum
tenens numerous times in general
practice, to supplement his income.
In his curriculum vitae he titles war
service as “Period of the First War”:
War was declared by Great Britain on
Germany on 4 August, 1914. On the next
morning, I wrote to the War Office apply
ing for a commission in the R.A.M.C. and
this I did not receive until 2nd November,
1914. I was posted to a regiment of the
Rifle Brigade, stationed on the Island of

Sheppey. In February 1915, as medical
officer I helped to erect the first hospital,
18th general hospital near Le Touquet,
Paris Plage. On July 1915, I became medi
cal officer to the 1st Battalion Grenadier
Guards. On September 9th, 1917, I asked
to be transferred to the 9th Division, for
the reason that my remaining brother was
adjutant to a Battalion in that Division. I
was posted to the 8th Battalion Black
Watch (R.H.). On 6th September 1918, I
was transferred to 58th C.C.S. to do Ear,
Nose, and Throat work. On 17th October
1918, I was transferred to No. 10 Station
ary Hospital to continue that work. On
11th November 1918 came the Armistice.

Military Awards

The curriculum continues:
I was mentioned in Dispatches in Sep
tember 1916, received a Military Cross
(immediate award) in September 1917,
and a bar to the Military Cross (immediate
award) on August 19, 1918 (2nd army). In
April 1919, I was demobilised and re
turned to Anatomy and Newcastle-onTyne.

The exact deed of valour for the
mention in dispatches has not been
detailed, but was printed in The Lon
don Gazette, Jan. 4, 1917, and signed
by General Sir Douglas Haig, GCB,
Commander, the British Armies in
France, and dated Nov. 13, 1916 (Fig.
2 ).

The Military Cross is dated July 31,
1917, place of deed Boisinghe.

T./Capt. John Charles Boileau Grant,
M.B., R.A.M.C. For conspicuous gallantry
and devotion to duty during attack. Find

FIG. 3 — Grant demonstrating anatomy of skull to one of his students.
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ing that all his stretcher-bearers were occu
pied, he went forward dressed the cases
himself on the spot, sending them back as
opportunity arose and stretchers turned
up. By this gallant act of devotion he
undoubtedly expedited the evacuation of
the wounded from the shelled area.

This would have been awarded dur
ing the Third Battle of Ypres, during
an offensive under General Haig’s 5th
Army.
The bar to the Military Cross is
dated Apr. 19, 1918, place of deed
Meteren. This action would have oc
curred at the start of the last great
German offensive, led by General Ludendorf. The offensive continued
along the battle lines to the south as
far as Chateau Thierry and Rheims
for the remainder of the summer and
autumn, and then Germany capitulat
ed. It reads:
Bar to the Military Cross
T./Capt. John Charles Boileau Grant,
M.C., M B.. R.A.M.C.,
attd 8th Bn., R. Highrs.
For conspicuous gallantry and devotion to
duty. He attended to wounded men lying
in the open under heavy fire, and subse
quently for three days and nights, with
little rest, he was constantly out with
stretcher-bearers searching for and remov
ing the wounded. He was undoubtedly the
means of saving many lives, and his fine
example was of the greatest value at a very
trying time.

It has been stated that Dr. Grant,
with characteristic modesty about his
gallantry, did not collect his medals
from Buckingham Palace (Mrs. Grant
did it for him later).
When World War II was declared
in 1939, Dr. Grant was 53 years of
age and had been professor of anato
my at the University of Toronto since
1930. He went to enlist in the armed
forces, but because of an inguinal
hernia was rejected on medical
grounds.
He immediately consulted Dr. Gor
don Murray, who successfully operat
ed on the hernia. When he again tried
to enlist, he was told his contribution
as an anatomy professor was much
more important than as a garrison
medical officer (Watters N: Personal
communication, 1947).
Dr. Grant is remembered as a mag
nificent teacher (Fig. 3), quick of
thought and action. He could draw on
the blackboard, using coloured chalks,
with either hand or sometimes both
hands simultaneously. Lectures were a
demonstration of anatomical art, not
to be forgotten. At the end of an hour,
he would have filled four blackboards
with coloured anatomical drawings,
more an illustrator than an orator. ■
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HEAD OF DIVISION OF
SURGICAL RESEARCH
The Research Institute of the Hospital for Sick
Children, one of the largest and most active of its
kind in the world, is seeking a Researcher with a
Ph.D. and/or M.D. to head a surgical research
group. Current research interests include:
physiology of the microcirculation, transplantation,
surgical oncology, and wound healing with
emphasis on the musculoskeletal system. The
present research group consists of 2.5 full time
research scientists and eight part time
clinician/scientists. The research activities are
closely associated with well known surgical
divisions covering all specialties of pediatric
surgery. There is opportunity for modest growth of
the research group in the near-term and further
expansion in the future. Currently, approximately
4,000 sq. ft. of space is available as well as access
to experimental surgery animal facilities.
The successful applicant will be expected to
obtain extramural funding to conduct his/her own
research and encourage and develop the research
activities of others.
Salary and level of appointment negotiable.
Please send replies, no later than June 1,1988, to:
Dr. James D. Friesen, Director, Research
Institute.
S88-24
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THE HOSPITAL
FOR SICK CHILDREN
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“CCAB provides direct
assurance that consumer circulation
claims are valid”
Lowell Lunden, Manager, Marketing Services
The Quaker Oats Company of Canada Ltd.

•5

“We make heavy use of consumer advertising as well
as promotional techniques such as co-op coupon mail
ings. As we handle direct mail campaigns ourselves,
we were pleased when the Canadian Circulation Audit
Board expanded its services to audit the distribution of
direct mail coupons.”
Mr. Lunden is also enthusiastic about CCAB’s grow
ing coverage of consumer magazines and community
newspapers...“Just as many business-to-business
advertisers insist on using only CCAB audited
publications, so do consumer mar
keters gain from the high quality
data presented through the CCAB
Publisher’s Statement.” For
further information call Patrick
Sweeney at 416-487-2418.

mm
Comprehensive Circulation Data
for consumer, business
and farm media

RESEARCH ASSOCIATE
ORTHOPEDIC SURGERY
The Division of Orthopedic Surgery of the University of
Alberta is seeking a full time PhD researcher in mus
culoskeletal surgery, immediately available with a
background adaptable to either bio-materials, bio
mechanics, exercise physiology, neurophysiology or
functional electrical stimulation.
The appointment is for a minimum of three years.
Deadline for application is May 31,1988. Appointment
will be at the Associate Professor level. Salary com
mensurate with rank. (Range - $39,620 -$57,236).
Please send all correspondence to:
DR. M. MOREAU
ROOM 4A37
EDMONTON GENERAL HOSPITAL
111 STREET & JASPER AVENUE
EDMONTON, ALBERTA, CANADA
T5K0L4

The University of Alberta is an equal opportunity
employer, but in accordance with Canada employment
and immigration regulations, this advertisement is
directed to Canadian citizens and permanent re
sidents of Canada.
-S88-19

SURGEON-IN-CHIEF
TORONTO GENERAL AND TORONTO WESTERN
HOSPITALS
The Toronto Hospital represents a merger of Toronto
General Hospital and Toronto Western Hospital. The hospital
is seeking a Surgeon-in-Chief to be responsible for the
clinical and academic programs at both sites. The position is
supported through the University of Toronto by an endowed
chair which is located at the hospital.
The Surgeon-in-Chief will organize and lead strong clinical
and academic programs in all sub-specialties of surgery.
These programs are supported by over 800 beds, physician
offices and ambulatory practice space, and hospital based
research laboratories. The opportunity to creatively organize
the surgical programs between the two hospitals to achieve a
more productive clinical and academic environment is an im
portant responsibility of this position.
The successful candidate must qualify as Professor or
Associate Professor at the University of Toronto, must have a
proven track record in academic surgery, and demonstrated
leadership skills. Date of appointment open; closing date for
receipt of applications May 31, 1988. Interested candidates
should apply to:
Chairman
Surgeon-in-Chief Search Committee
c/o President’s Office
The Toronto Hospital
585 University Avenue
Toronto, Ontario
M5G 2C4
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CLASSIFIED ADVERTISING
GENERAL
SURGEON
The Red D eer R e g io n a l
Hospital Centre hasa vacan
cy fo r a G eneral Surgeon.
An interest in th o ra cic or
vascular surgery is an asset,
b ut not essential.
The Red D eer R eg ion al
Hospital C entre is a w e lle q u ip p e d , 400 bed in s ti
tu tio n , b u ilt in 1981, w ith
seven operating rooms plus
tw o others ‘ shelled in ' fo r
fu tu re expansion. It serves
Red Deer w ith a civic p o p u 
lation of 54,000 and a catchm entarea o f approxim ately
150,000.
Further in fo rm a tio n can be
obtained by contacting:

RH L

Chief of Staff Office
Red Deer Regional
Hospital Centre
P.O. Bag 5030
Red Deer, Alberta
T4N 6R2
Phone: (403) 343-4529

ADVERTISERS’ INDEX

OSHAWA GENERAL HOSPITAL

PLASTIC RECONSTRUCTIVE
AND HAND SURGEONS
The Oshawa General Hospital invites applications
for a position in plastic reconstructive and hand
surgery on the medical staff for 1988. Canadian
fellowship and certificate of specialty competence
is required.
The Oshawa General Hospital is a 650-bed regional
community hospital located 48 km east of Toronto.
Please contact:
Dr. D.G. Pierson,
Chairm an, D epartm ent of Surgery
Oshaw a General Hospital
2 4 A lm a St.,
Oshaw a, ON L1G 2 B 9
-S 8 8 -2 3

ORTHOPEDIC SURGEON: US - Excellent
opportunity to develop orthopedic surgery
program affiliated with modern, regional
hospital. Excellent guarantee plus full fringe
benefits. Beautiful rural area one hour from
Canadian metropolitan centre. Enjoy Ameri
ca's most scenic sailing waters. For further
information call: Lianne Harris, President,
New England Health Search. 63 Forest
Ave., Orono, Maine US 04 4 73 . Tel:
(207) 866 -5 6 8 0 or 8 6 6 -5 6 8 5 .
-S 8 8 -2 1

ACADEMIC APPOINTMENT: ON - Applica
tions are invited for a full-time position in the
Department of Urology at Queen's University.
The successful applicant will have responsibility
for teaching in an established postgraduate
program involving clinical practice and adminis
tration. There are excellent opportunities for
basic and clinical research. The applicant must
be able to conduct independent research. In
accordance with Canadian immigration require
ments, this advertisement is directed to Canadi
an citizens and permanent residents of Canada.
Candidates of either sex are equally encouraged
to apply. Please send curriculum vitae and the
names of three referees to the attention of:
Mrs. S. Perry, Administrative Assistant, De
partment of Urology, Queen's University.
Kingston, ON K7L 2V6.
-S88-22

See page 205for
Classified ad numbers S88-17,
S88-19, S88-24.

NOTICE OF CHANGE OF ADDRESS /
AVIS DE CHANGEMENT D’ADRESSE
To ensure that you continue to receive the Canadian Journal o f Surgery without
interruption, please fill in this form before you move.

Davis & Geek
Outside Back Cover

Merck Sharp & Dohme Canada
Mefoxin
Primaxin

PLASTIC SURGEON: ON — Applications are
invited for the position of plastic surgeon at The
Victoria Hospital Corporation, London, Ontario.
The applicant must be certified in plastic sur
gery by The Royal College of Physicians and
Surgeons of Canada and have a minimum of
one and preferably two years of post residency
training in some aspect of plastic surgery. The
position includes the management of a six bed
burn unit. The applicant must express a primary
interest in burn care. The position carries an
academic rank within the department of surgery
at the University of Western Ontario. As such,
the applicant must express an interest in ongo
ing basic research. The appointment is available
as of July 1, 1988. Send enquiries to: Dr. R.M.
McFarlane, Department of Surgery, Victoria
Hospital, 391 South St., London, ON N6A
4G5.
- S 8 8 -2 0
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